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Abstract 
 
Background: 
Breast milk is the principal source of nutrition during a critical period of immune 
programming - maternal and environmental exposures may influence breast milk 
composition and infant health. 
Objectives: 
To examine whether environmental and/or maternal factors influence levels of immune 
active components in colostrum and breast milk and identify associations between 
these factors and health outcomes. To examine if colostrum/breast milk immune 
composition can be grouped into specific 'lactotypes'. 
Methods: 
A prospective cohort study of mother/infant pairs in London, Moscow and 
Verona. Colostrum samples (days 0-6) and Mature Breast Milk (4-6 weeks) were 
analysed in duplicate using electrochemiluminescence, and the relationship between 
levels of immune active factors and maternal/environmental/infant factors was 
evaluated using mixed models. Lactotypes were identified using Principal Components 
Analysis. 
Results: 
Levels of immune active cytokines and growth factors in colostrum declined rapidly over 
time (r=-0.39 to -0.16; p<0.01). The effect of time could not be corrected using total 
protein or sodium as correction factors, due to different kinetics for each mediator 
measured. 
There were significant differences in colostrum and breast milk composition between 
countries, which could not be explained by the environmental and maternal factors 
examined. 
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Using PCA there were two clusters of mediators, suggesting that four human breast 
milk ‘lactotypes’ exist, based on immune composition. There was some evidence in 
support of a relationship between human milk mediator levels and/or lactotypes, and 
infant health outcomes. 
Conclusions: 
The data support an important role for breast milk cytokines, and especially growth 
factor, levels as determinants of infant health. Further work is needed to identify 
improved methods for analysing colostrum and mature milk composition, which account 
for time of collection and/or stage of lactation. 
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1 Introduction 
1.1  History of Infant feeding 
1.1.1 Primitive tribes 
Some barbarian tribes imposed a delay of several days before a mother could 
commence feeding her baby. Initiation of breastfeeding varied from tribe to tribe, with 
the average period for commencement being four days, though in some cases 
exceeding nine days. This reflected attitudes to the use of colostrum. This taboo is 
evident from the writings of 17th century English and French authors which had been 
passed on from Greek and Roman times. The duration of the breastfeeding period 
varied from one tribe to another but on average, mothers continued lactation for three to 
four years with the rare exception of King William Land (now known as a King William 
Island) where children were breast fed for up to 15 years. Mother may have been 
feeding two or more children of different ages at the same time under such 
circumstances (Wickes, 1953a). 
 
Other infant feeding practices which have evolved include wet nursing, bottle feeding, 
and formula use (Stevens et al., 2009). 
 
1.1.2 Wet nursing 
Wet nursing has been in use from as early as 2000 BC and has continued into  the 21st 
century (Stevens et al., 2009). In many cultures women of high rank employed wet 
nurses, indeed it was standard practice for the English royal family. However, in some 
cultures it was considered that “strangers milk” was harmful to the infant. Eskimos froze 
the infants of mothers that died in child birth rather than expose them to this kind of 
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danger. In contrast, some Arab communities passed suckling infants round many 
lactating women. 
 
In tribes associated with Eastern civilization, such as Java, grandmothers were 
expected to put the child to the breast whilst the mother worked. There is considerable 
doubt as to whether persistent sucking ever stimulated true lactation in this way, though 
there are several reputed instances which suggest that it is possible and there are even 
reports of fathers successfully suckling infants (Wickes, 1953a). 
 
In Israel, children were regarded as a blessing and breast feeding as a religious 
obligation. Evidence for the existence of wet nurses is noted in Exodus 2, 7, 
approximately one thousand years before Christ and clearly demonstrates the hire of 
wet nurses as a well organized procedure. It seems probable that the average duration 
for suckling was about three years (2 Maccabees 7, 27), though there is no mention of 
artificial feeding anywhere in the Talmud (Wickes, 1953a). 
 
In Homeric Greece (950 B.C.) wet nurses were in frequent demand, particularly by 
women of the higher classes. In these households, wet nurses  came to hold  positions 
of great responsibility with authority over the slaves and often with prolonged care of 
their charges up to adolescence (Wickes, 1953a). From approximately 100 AD through 
400 AD, medical authors such as Soranus of Ephesus, Galen of Pergamus, and 
Oreibasius listed the qualifications for a wet nurse (Radbill, 1981). For example, 
Soranus of Ephesus (98 AD to 117 AD) composed an obstetrical and gynecological 
treatise of 23 chapters that provided a model for infant feeding (Osborn, 1979). 
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In parts of Africa (e.g. Cameroon) it was customary for the women also to suckle, if 
required, domestic puppies and piglets. The converse of infants suckling animals has 
also been recognized since the time of Romulus and Remus, and was still practised in 
France in the 19th century where babies at L'Hopital des Enfants Assistes in Paris were 
regularly put to the teat of asses that were permanently housed in stalls adjoining the 
ward (Wickes, 1953a). 
 
1.1.3 Bottle feeding 
Despite wet nursing being a suitable option for mothers not able to breastfeed for 
various reasons other approaches existed in the ancient world (Osborn, 1979). Vessels 
of different size and shape have been used for feeding over many centuries and have 
been found by archaeologists in the graves of newborn infants (Weinberg, 1993, 
Stevens et al., 2009, Wickes, 1953a). These bottles were initially thought to be 
containers for filling oil lamps but casein found present after chemical analysis,  
suggested that animal milk had been in use in ancient times as an alternative to breast 
milk (Wickes, 1953a, Weinberg, 1993, Stevens et al., 2009).  Poorly made feeding 
bottles were in use from the Roman Era to Renaissance time with frequent adverse 
consequences due to hygiene issues. During the time of the Industrial Revolution, 
improved feeding bottles  were developed that were more hygienic (Wickes, 1953b). 
 
During the Middle Ages, feeding bottles were made from various materials: wood, 
ceramics, and interestingly, the most common type was a perforated cow’s horn 
(Stevens et al., 2009). In 17th and 18th century, feeding bottles were usually made of 
leather and wood. By the 1800s, many infant-feeding devices were made from lead and 
silver (Weinberg, 1993). 
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Given the lack of knowledge on milk storage, sterilization and infancy nutrition in earlier 
centuries,  it is surprising that infants survived  their first year of life.  Even as recent as 
the 19th century, more than one third of all artificially fed babies in 1870 were expected 
to die during the first year of life (Weinberg, 1993, Stevens et al., 2009). 
 
1.1.4 Formula feeding 
The first scientific comparison of human and animal milk was reported in the 18th 
century by Jean Charles Des-Essartz in his "Treatise of Physical Upbringing of Children 
in 1760" and provided analysis of  human, cow, sheep, ass, mare and goat milk 
composition. Based on the chemical composition of these milks, Des-Essartz concluded 
that human milk is the best source of infant nutrition (Stevens et al., 2009). There have 
been many attempts to create an artificial milk comparable or of ‘improved quality’ to 
human milk (Radbill, 1981). In 1865, Liebig’s formula made of cow’s milk, wheat and 
malt flour, and potassium bicarbonate was marketed widely and was considered as a 
perfect infant food (Radbill, 1981). More formulas started to appear after the marketing 
of Liebig’s infant food and the invention of evaporated milk resulted in 27 patented 
brands of infant feeds  by 1883 (Radbill, 1981, Fomon, 2001). 
 
These dietary products for babies were produced in powdered form and consisted of 
carbohydrates such as sugars, starches, and dextrins added to cow's milk (Stevens et 
al., 2009). These formulas were lacking important nutrients, such as protein, vitamins, 
and minerals but their gradual addition over time improved formula nutritional qualities 
(Radbill, 1981, Fomon, 2001). 
 
Artificial formulas in the 19th century were known to be a cause of many summertime 
infant deaths (Wickes, 1953b) due to “spoilage of milk left in bottles” (Weinberg, 1993) 
CHAPTER 1: INTRODUCTION 
 
22 
 
and were explained by germ contamination (Stevens et al., 2009). As a consequence of 
"germ theory" developed in early 20th century, the aim became  to purify formula milk of 
pathogenic bacteria. First attempts to produce non cow's milk formulas to address the 
needs of children allergic to cow's milk protein began in 1920 when soy based products 
became available to the public (Stevens et al., 2009). 
 
Very active and aggressive marketing of formula milk caused a global decline in 
breastfeeding worldwide, especially in developing countries (Stevens et al., 2009). With 
direct advertising to the public, formula industry companies created a tension between 
themselves and physicians. The American Academy of Pediatrics released a statement 
listing reasons for the organization’s opposition to advertising infant formulas to the 
general public. It stated that advertisements had a negative impact on breastfeeding 
practices, interfered with physicians’ advice on infant feeding, led to confusion amongst 
parents purchasing formula milk and increased the cost of feeding an infant (Greer and 
Apple, 1991). 
 
The World Health Organisation (WHO) recommends exclusive breastfeeding for at least 
6 months in all infants (WHO, 2001). However this is only achieved for 35% of infants 
worldwide and 19% in Europe (WHO, 2009b). The effect of the WHO recommendations 
on risk of allergy development has been investigated in several observational studies 
since a link between milk feeding and eczema was originally made by Grulee and 
Sanford (Grulee and Sanford, 1936). It is important to highlight that in many studies 
authors used various definitions of exclusive breastfeeding, and these are not always 
consistent with the WHO definition. According to WHO "Exclusive breastfeeding means 
that the infant receives only breast milk. No other liquids or solids are given – not even 
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water – with the exception of oral rehydration solution, or drops/syrups of vitamins, 
minerals or medicines"(WHO, 2009a). 
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1.2 Stages of human lactation 
There are three stages in human lactation that are currently identified and explained by 
changes in specific components of the breast milk (e.g. whey proteins, lactose). These 
compositional changes seem to match the changing physiological needs of the infant, 
and can be stratified into colostrum, transitional milk and mature milk. Unfortunately 
there is no alignment in the precise definition of the terms mentioned above. According 
to various sources, colostrum is the special milk that is secreted in the first 2–3 days 
(WHO, 2009a) or 1–5 days (Darragh and Lönnerdal, 2011) after delivery; transitional 
milk is usually produced 7-14 (WHO, 2009a) 5–21 (Darragh and Lönnerdal, 2011) days 
postpartum; and mature milk after two weeks (WHO, 2009a) or >21 days (Darragh and 
Lönnerdal, 2011) post-partum. 
 
It is known that so-called colostrum contains higher levels of protein and lower lactose 
content in comparison with mature milk. The specific gravity of colostrum is 1.040 
compared with 1.060 for mature milk, and the mean energy content of colostrum is also 
lower at 67 kcal 100 ml-1 compared with mature milk, which supplies 75 kcal 100 ml-1 of 
energy. Fat and ash composition of colostrum and mature milk do not differ significantly 
(Darragh and Lönnerdal, 2011). At the same time colostrum is particularly rich in 
immunological components such as secretory IgA, lactoferrin, a variety of growth factors 
and cells (Kobata et al., 2008, Pang and Hartmann, 2007). 
 
Lack of unified definitions of milk during different stages of lactation leads to variability in 
results in compositional studies. Due to a lack of agreement on current definitions which 
are empirical rather than evidence based, this highlights the need for a consensus. 
 
CHAPTER 1: INTRODUCTION 
 
25 
 
1.3 Breastfeeding and GI and allergy outcomes 
BM is the optimal source of nutrition for a newborn, and an important factor helping the 
newborn adapt to the extra-uterine environment. Human milk provides the developing 
infant with a range of bioactive factors influencing  immune system maturation, physical 
and cognitive development and the infant intestinal microbiome (Borsutzky et al., 2004). 
At the time of birth, the infant intestinal immune system is relatively mature compared 
with other parts of the immune system, and therefore able to actively respond to signals 
from antigens and other immune constituents in BM (Jones et al., 2002a). 
 
We know that the infant’s immune system  is influenced by maternal immunity via BM 
(Orlando, 1995), in addition to other routes (Billington, 1992). It has been shown in a 
number of studies that BM can affect intestinal immunity and may have long-term health 
consequences (such as influence on blood pressure, type 2 diabetes and intelligence 
quotient in later life) (Penttila et al., 2003, Ogawa et al., 2004, Nguyen et al., 2007, 
Horta B, 2007, Horta and Victora, 2013). Moreover, breastfeeding during introduction of 
gluten into the infant diet may reduce the risk of celiac disease, suggesting important 
interactions between BM components, dietary antigens and the gut associated lymphoid 
tissue (GALT) (Akobeng et al., 2006). This protective effect on celiac disease remains 
unclear as studies have produced conflicting evidence (Vriezinga et al., 2014). 
Non-human milk feeds during infancy are known to increase the risk of infectious 
diarrhoea, due to of the lack of exposure to pathogen-specific sIgA in human milk 
(Newburg et al., 2004, Morrow et al., 2004, Kramer and Kakuma, 2012)  As cow milk 
derived formulae also increase the risk of respiratory infections (Bachrach et al., 2003), 
this suggests that human milk has a broader effect on infant immune development than 
that achieved by sIgA supplementation to the gastrointestinal tract. In the early 20th 
century Clifford et al. were among the first to show that artificial milk use was associated 
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with a higher incidence of eczema in comparison with exclusive or partial breastfeeding 
(Gazzinelli et al., 1994). More recent data suggest that this may be due to the absence 
of prebiotic in the artificial milk used at that time (Gruber et al., 2010). 
WHO and UNICEF proposed the Global Strategy for infant and young child feeding in 
2002 (WHO/UNICEF, 2003). The main goal of this document was to focus world 
attention on the influence of various feeding approaches on infants’ development, 
health, morbidity and mortality. 
As mentioned above, the World Health Organisation (WHO) recommends exclusive 
breast feeding for at least 6 months in all infants (WHO, 2001). To what extent the WHO 
recommendation delays introduction of non-milk food sources at a critical period where 
tolerance induction may be important beyond 4 months of  age and thereby affects the 
risk  of  allergy development is uncertain (Tomicic et al., 2010). 
 
1.3.1 Evidence that mode of infant milk feeding changes allergy risk 
One of the first attempts to systematise present evidence on the breast feeding 
protective effect on the development of allergic diseases was performed by Gdalevich et 
al. in the beginning of 21-st century. This led to the production of two meta-analyses. 
One of them was focused on the breast feeding protective effect on bronchial asthma 
development in children (Gdalevich et al., 2001b) and the second one addressed the 
protective effect of breast feeding on the development of atopic dermatitis in children 
(Gdalevich et al., 2001a). In the first meta-analysis they analyzed relevant papers from 
MEDLINE database which had been published in English between 1966 and 1999. Out 
of 177 papers (these included 41 studies, which varied in designs) there were 
completely different outcomes, from a protective effect to even a positive association 
between breast feeding and atopy. Twelve prospective studies have been included into 
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meta-analysis (a total of 8183 subjects) to support the preventive effect of exclusive 
breast feeding on the development of asthma. Systematic review of observational 
studies has shown a protective effect of exclusive breast feeding (as defined by WHO) 
for at least 3 months on the development of asthma, at least for children with a positive 
family history of asthma or atopy [OR = 0.52, 95% CI 0.35 - 0.79] (Gdalevich et al., 
2001b). The outcomes of the second meta-analyses done by the same group of authors 
on the protective effect of breast feeding on atopic dermatitis also supported their 
theory. Authors included 18 prospective studies into meta-analysis (a total 4158 
subjects) and found a protective effect against atopic dermatitis in children with a family 
history of atopy [OR = 0.58, 95% CI 0.41 - 0.92] (Gdalevich et al., 2001a). 
In 2003, van Odjik et al. provided a comprehensive but non-systematic review on the 
mode of early feeding in infancy and its influence on future atopy development. Of 132 
studies reviewed only 56 were regarded as qualitatively acceptable. Studies were 
divided into one or more of the four following categories: studies of breast feeding and 
atopic manifestations in cross-sectional populations; studies of breast feeding and 
atopic manifestations in children with atopic heredity; studies of formula feeding and 
atopic manifestations in children with atopic heredity and studies of cow’s milk exposure 
and development of atopic manifestations. For the purpose of my thesis I will focus on 
the data from the first two groups. Results supported the conclusion that breastfeeding 
protects against development of allergic disease, especially among children with an 
atopic heredity. Authors found that exclusive breastfeeding reduced the risk of asthma 
and any breast feeding decreased the risk of recurrent wheezing and development of 
atopic dermatitis. Furthermore, the  protective effects increased with the duration of 
breast feeding, up to at least 4 months and persisted at least for the first decade of life 
(van Odijk et al., 2003). 
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Two of 3 large cohort studies published subsequent to these systematic reviews, 
showed breastfeeding protective effects on wheeze in general [RR = 0.67, 95% CI 0.48 
- 0.96, p=0.021] and in the first 3 years of life [OR = 0.80, 95% CI 0.70 - 0.90] and 
eczema [OR = 0.64, 95% CI 0.45 - 0.90] but one study, from Denmark (COPSAC birth 
cohort) on 321 exclusively breastfed babies (eczema was diagnosed in 122 (38%), in 
contrast found that exclusive breastfeeding increased the risk of eczema development 
[RR = 2.09, 95% CI 1.15 - 3.80, p=0.016] adjusting for demographics, filaggrin variants, 
parents eczema, and pets at home. Elliott et al. using data from ALSPAC study 
highlighted that the protective effect on wheeze did not extend at ages 7-8 years [OR = 
0.98, 95% CI 0.79 - 1.22] (Laubereau et al., 2004, Giwercman et al., 2010, Elliott et al., 
2008). 
 
Ip and co-authors produced a meta-analyses of 18 prospective studies done in 
developed countries, assessing atopic diseases development as an outcome, dividing 
groups into infants breastfed for more than 3 months with a family history of atopy [OR 
= 0.58, 95% CI 0.41 - 0.92] in comparison to those who were exclusively breastfed for 
less than 3 months (Ip et al., 2007) and  [OR = 0.84, 95% CI 0.59 - 1.19] infants without 
a family history of atopy respectively (Ip et al., 2007). They reported that in children 
without a family history of asthma breastfeeding for more than 3 months was associated 
with reduced risk of asthma compared to infants without 3 months of exclusive 
breastfeeding [OR = 0.73, 95% CI 0.59 - 0.92]. 
 
Yang et al. failed to find a protective effect of exclusive breastfeeding for at least 3 
months against eczema development [OR = 0.89, 95% CI 0.76 - 1.04), and for study 
populations with atopic heredity [OR=0.78, 95% CI 0.58 - 1.05] (Yang et al., 2009). 
However, there was a protective breastfeeding effect on eczema development when 
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analysis was restricted to the studies comparing breastfeeding with conventional 
formula feeding  (OR 0.70, 95% CI 0.50–0.99). Authors highlight that their results 
should be interpreted with caution due to substantial heterogeneity across studies (χ2 = 
83.6, d.f. = 26; p < 0.001). 
 
Another meta-analysis did not provide strong evidence that breast feeding is protective 
against wheezing illness in children aged 5 years and over. The authors stated that any 
breast feeding slightly lowered the odds of wheeze [OR = 0.92, 0.86 - 0.98] but slightly 
increased the odds of asthma defined by specific criteria [OR = 1.10,  95% CI 1.00 - 
1.22] (Brew et al., 2011).  
 
A recent meta-analysis by Dogaru et al. adds more evidence to support breastfeeding 
protective effect on wheezing [OR = 0.78, 95% CI 0.74 - 0.84] during the first two years 
of life (Dogaru et al., 2014).  
 
None of the studies included in these systematic reviews were controlled trials and 
therefore, they have a significant risk of confounding. The large randomized control trial 
of a breastfeeding support programme from Kramer et al. did not show a protective 
effect of prolonged and exclusive breast feeding against  asthma and showed an 
increased risk of inhalant sensitisation at age 7, but did find reduced risk of early 
eczema [OR = 0.54, 95% CI 0.31 - 0.95]  (Kramer et al., 2001). 
 
The Cochrane review done by Kramer  did not show any evidence that  exclusive 
breastfeeding for six months reduced risk of allergic disease, compared with lesser 
durations of exclusive breastfeeding (Kramer and Kakuma, 2012). In addition exclusive 
breastfeeding for six months did not have any long-term protection against obesity or 
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allergic disease, cognitive ability or behaviour, compared with exclusive breastfeeding 
for three to four months with continued partial breastfeeding to six months. 
 
Data on the relationship between breastfeeding and food allergy are not sufficiently 
robust at the moment to make firm conclusions. A review by Kneepkens and Brand 
(2010) (Kneepkens and Brand, 2010) does not provide us with any additional data to 
support or reject the protective effect of breastfeeding against allergic diseases. An 
overview of existing data from meta-analyses, prospective cohort    studies and reports 
published up to date suggests that current evidence is not sufficient and that it is 
impossible to conclude that exclusive breastfeeding and/or duration of any 
breastfeeding influences the risk of atopic diseases, asthma, wheezing, or eczema 
development (Hornell et al., 2013). 
 
However, there is a suggestion that the effect of breast-feeding on food sensitization is 
influenced by genetic predisposition. Hong et al. found that the effect of breast-feeding 
on food sensitization was modified by Single Nucleotide Polymorphisms (SNPs) in the 
Interleukin (IL)12RB1, TLR9, and TSLP genes in infants both individually and jointly 
(Hong et al., 2011). This suggests that genetic variability must be considered alongside 
other factors when analyzing BM composition in relation to effects  on  atopy 
development. It is also likely that conflicting data in relation to the protective effects of 
breast feeding are due to differences in immune modulatory constituents between 
populations. Thus Tomicic et al. studying BM from Estonian and Swedish mothers found 
differences in immunological constituents (Tomicic et al., 2010),  and Amoudruz et al. 
showed that levels of IL-6, IL-8 and TGF-β1 were higher in the milk of mothers who 
migrated to Sweden from developing countries in comparison to local mothers 
(Amoudruz et al., 2009). 
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Variability in nutrional constituents may also be important and Plagemann et al found 
that BM from diabetic mothers can lead to a higher risk of obesity in comparison to 
donor milk (Scharton-Kersten et al., 1996). As asthma and obesity commonly co-exist 
the association with maternal diabetes may be relevant to atopic disease. 
 
One of the reasons why breastfeeding may have beneficial effects compared to mixed 
or exclusive feeding with bovine milk, may be species differences in protein 
composition. Milk proteins are usually classified into four main groups: caseins, 
peptones (low molecular weight peptides), whey, and milk fat globule membrane 
proteins. D’Alessandro and co-authors listed 285 human milk proteins, of which only 
106  were “protein core” based on homology in human and bovine milk (D'Alessandro et 
al., 2010). This highlights the significant difference between human and bovine milk in 
protein composition. 
 
Randomised controlled trials have shown that variations in formula milk constitution may 
alter allergy risk, and this suggests that the same may be true for variations in breast 
milk composition. Data from studies done on large cohorts have not consistently shown 
a  preventative effect of hydrolysed milk formulas on allergy and eczema development 
(von Berg et al., 2008, Foisy et al., 2011) but oligosaccharides enriched formula was 
found to have a eczema preventive effect in children with low atopy risk in 2 studies  
(Gruber et al., 2010, Piemontese et al., 2011). 
 
The majority of published studies, investigating the association between breast feeding 
and atopic disease, suffer from significant methodological shortcomings. For example 
there is a lack of data on the precise duration of breast feeding, and degree of 
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exclusivity (Kramer and Kakuma, 2012). There are problems with accurate 
measurement and control for potential confounding factors, including family allergic 
history. Finally, there is a lack of objective or unified classification of  allergic outcomes 
(Kramer, 1988). Research attempting to assess the protective effect of breast feeding 
usually do not take into account breast milk composition. Accumulated knowledge 
provides enough data to highlight that breast milk immune composition differs 
significantly from one woman to another and differences in protective effect may be 
partially explained by these individual variations. Nevertheless, current evidence taken 
together supports the concept that variations in the timing and nature of infant milk 
feeds can impact on immune development and risk of allergic disease. 
 
1.3.2 Infant milk feeding influence on GI outcomes 
Gastrointestinal infections are very common in early infancy and childhood. Rates of 
diarrhoeal disease in US were estimated to be 1.1 episodes per child per year in 
children less than 5 years of age (Imhoff et al., 2004) and in developing countries 3.2 
episodes per child per year (Parashar et al., 2003).  A review of diarrhoea morbidity in 
developing and developed countries published two decades ago stated that the risk of 
diarrhoea in infants who did not receive breast milk in the first 6 months of life was 3.5 - 
4.9 times higher compared to infants who have been breastfed exclusively (Feachem 
and Koblinsky, 1984).  88% of the studies confirmed an exclusive breast-feeding 
protective effect compared to no breast-feeding and 83% of studies found that exclusive 
breast-feeding was protective compared to partial breast-feeding. 
 
One systematic review examined the relationship between breastfeeding and 
subsequent  development of GI infections in children from developed countries aged 
less than 1 year (Chien and Howie, 2001). Authors stated that “it was not possible to 
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pool the adjusted relative measures of association” in the cohort studies reviewed. 
Using a fixed effect model, the summary crude odds ratio of the 14 cohort studies for 
the development of GI infection was [OR = 0.36, 95% CI 0.32 - 0.41; heterogeneity 
p<0.01]; and for the two case-control studies [OR = 0.54, 95% CI 0.36 - 0.80; 
heterogeneity, p=0.35].  Ip and co-authors similarly found that available evidence from 
three primary studies that controlled for potential confounders suggests that 
breastfeeding is associated with a reduction in the risk of non-specific GI infection 
during the first year of life in infants from developed countries, but highlight difficulty of 
taking into account all potential confounders, and summary adjusted effect estimate 
could not be determined (Ip et al., 2007). 
 
Breastfeeding protective effect against GI infections may be explained by the presence 
of oligosaccharides, lactoferrin, secretory IgA, other immunoglobulins and immune 
active molecules in breast milk which may protect the infant from various infections 
through passive immunity (American Academy of Pediatrics Committee on Nutrition, 
2004). Thus In vitro and in vivo binding studies have demonstrated that α1,2-linked 
fucosylated glycans, which include oligosaccharides in their free and conjugated forms 
and play an important role in innate immunologic mechanism by which breast milk 
protects babies against infections, inhibit binding by campylobacter, stable toxin of 
enterotoxigenic Escherichia coli, and major strains of caliciviruses to their target host 
cell receptors. Epidemiologic data demonstrate that higher relative concentrations of 
α1,2-linked fucosylated glycans in human milk are associated with protection of breast-
fed infants against diarrhea caused by campylobacter, caliciviruses, and stable toxin of 
enterotoxigenic E. coli, and moderate-to-severe diarrhea of all causes (Morrow et al., 
2005, Newburg et al., 2004, Morrow et al., 2004). 
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1.4 What is BM? Which immune factors may be related to gastrointestinal health 
and children allergic status? 
The human infant is born with a physiological relative immune deficiency, and is 
dependent on maternally transferred IgG antibody for systemic humoral immune 
defence. Their T cells have a predominantly naive phenotype, and the capacity of 
newborn circulating mononuclear cells to generate pro-inflammatory cytokines is low 
(Ehlers and Smith, 1991). This immune deficiency is partly compensated by immune-
active factors in human milk including IgA, anti-microbial peptides, and cytokines, in 
addition to growth factors and essential nutrients which promote development of the 
infant GALT (Playford et al., 2000, Lawrence and Pane, 2007). Cytokines from 
colostrum and BM are not destroyed in the stomach; some are protected by being 
bound to other molecules such as soluble components of their receptors (Garofalo et 
al., 1995). A variety of protease inhibitors (e.g.CST3, SERPIN-A1, A3, B1, C1, G1 and 
SPINT1) which are present in human milk have been proposed to limit the activity of 
pancreatic enzymes, (Lonnerdal, 2003, Chowanadisai and Lonnerdal, 2002) and in the 
critical first few weeks of life the gastric pH is high which considerably reduces peptic 
digestion. 
 
In the past 10 years several cytokines and other immunoreactive substances have been 
identified in human milk and colostrum (Garofalo, 2010). The actual functional and 
physiological effects of each of these factors regarding their influence on the infant’s 
evolving immune responses have not been clarified (Garofalo and Goldman, 1998, 
Lawrence and Pane, 2007). However, we know that certain immune active molecules 
(e.g. sCD14, TGF-β, HGF) are present in very high concentrations in colostrum (Jones 
et al., 2002a, Kobata et al., 2008) and levels of some, such as IFN-γ are higher in 
colostrum in comparison with maternal serum (Prokesova et al., 2006) which suggests 
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they are actively secreted in BM and may therefore be presumed to have a role in infant 
immune defence or development. It is known that TGF-β is able to promote IgA 
production (van Vlasselaer et al., 1992, Kalliomaki et al., 1999, Ogawa et al., 2004) and 
is actively involved in induction of oral tolerance (Strobel, 2002). CD14 which exists in 2 
forms, membrane bound and soluble, is expressed mainly by monocytes or 
macrophages and plays an important role in innate immunity as a component of the 
complex with endotoxin (Landmann et al., 2000, Kielian and Blecha, 1995).The levels of 
CD14 on monocytes and macrophages and sCD14 are very low in the neonate and the 
high levels in BM may compensate for this relative deficiency. sCD14 is increased in 
clinical conditions where local or systemic activation of macrophages or monocytes is 
involved (Maliszewski, 1991). 
 
1.4.1 Cells 
A variety of cells are present in human colostrum and breast milk including 
macrophages, lymphocytes, T cells, and stem cells. It is known that during early 
lactation  the infant consumes about 1010 maternal leukocytes a day. Over 80% of the 
cells present in early breast milk are so-called breast milk macrophages, emerging as 
peripheral blood monocytes that exit the bloodstream and migrate into milk through the 
mammary epithelium (Ballard and Morrow, 2013). These monocytes transform into 
potent cells which possess unique functional features, such as an ability to differentiate 
into dendritic cells that stimulate infant T-cell activity (Ichikawa et al., 2003, Yagi et al., 
2010).  Stem cells have also been found in breast milk but their actual function is still 
unknown (Patki et al., 2010, Indumathi et al., 2013). 
 
A study done a decade ago in Finland suggests that levels of certain cells may influence 
allergy development as infants subsequently developing cow's milk allergy consumed 
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breast milk with a much smaller proportion of macrophages, high proportions of 
neutrophils and eosinophils comprising >1% of milk cells (Jarvinen and Suomalainen, 
2002). 
 
1.4.2 Lipids 
A triglyceride core surrounded by a thin membrane (about 10–20 nm in cross-section) 
forming fat globules can be found in milk, and is known as the Milk Fat Globule 
Membrane (MFGM). This membrane works as an emulsifier and protects the globules 
from coalescence and enzymatic degradation. 
 
Martin and co-authors identified xanthine oxidase, an enzyme present in the MFGM, 
has properties as an antimicrobial agent in the gut (Martin et al., 2004). This protein is 
expressed in gut mucosa cells, and its antimicrobial function is associated with 
production of reactive oxygen species, superoxide and hydrogen peroxide in the gut. 
Xanthine oxidase catalyses the reduction of inorganic nitrite to nitric oxide and in the 
presence of oxygen to peroxynitrite, the latter of which has bactericidal properties. 
 
Sphingomyelin (SM) is one of the components of MFGM lipid fraction and is a major 
sphingolipid membrane component There is some evidence that SM intake plays an 
important role in neonatal gut maturation during the suckling period in rats and 
contributes to the process of myelination of the developing rat central nervous system 
(Oshida et al., 2003), but relevance to humans remains to be established. Milk 
phospholipids in the MFGM can have a  protective properties in the gut (Kivinen et al., 
1995). Phosphatidylcholine may protect the  gut mucosa from toxic attack and reduce 
the rates of necrotizing enterocolitis in preterm infants (Anand et al., 1999, Carlson et 
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al., 1998).There have been no studies on the levels of BM MFGM lipids or proteins in 
relation to infant immune function and/or outcomes. 
 
1.4.3 Oligosaccharides 
Oligosaccharides are the third largest fraction in BM after lactose and lipids. Their exact 
physiological role remains unknown. Oligosaccharides are closely related to the Lewis 
blood group and four different milk groups have been described depending on their 
specific Lewis blood group-dependent oligosaccharide patterns (Thurl et al., 1997). It is 
known that colostrum contains more oligosaccharides then mature BM (Coppa et al., 
1993) Oligosaccharides have various properties, including being prebiotic, anti-
adhesive, glycome-modifying and anti-inflammatory , which can directly or indirectly 
influence infant immune responses  (Donovan, 2009, Bode, 2009). As an illustration of 
these effects Ward et al. showed that oligosaccharides intensified the growth of 
Bifidobacterium infantis to a much higher degree than inulin or glucose (Ward et al., 
2006). Human milk oligosaccharides also inhibit attachment of intestinal bacteria to the 
surface of intestinal epithelial cells, and direct evidence for the relevance of this come 
from clinical trial findings that the addition of certain oligosaccharides to cow’s milk 
formula reduces infection risk in infants (Newburg, 1997, Newburg, 1999). 
 
Among the oligosaccharides, the monosaccharide N-acetylglucosamine, a component 
of several oligosaccharides is important for the growth of Bifidobacterium bifidums 
(Bezkorovainy, 2001) which has been found in more healthy infants faeces samples in 
comparison to those who were allergic (Ouwehand et al., 2001). 
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1.4.4 Polyunsaturated fatty acids (PUFA) 
There is some evidence that PUFA may play a role in immune development (Prescott 
and Dunstan, 2007). Some studies have shown that lower levels of n-3 PUFA and/or 
higher concentrations of n-6 PUFA in the serum  of atopic infants and in their mother’s 
BM (Reichardt et al., 2004, Duchen et al., 2000, Kankaanpaa et al., 2001) were 
associated with a higher risk of allergic disease while  others found a positive correlation 
between elevated n-3 long-chain-PUFA levels in colostrum and food or inhalant-allergen 
sensitisation and atopic eczema in infants at 6, 12 and/or 24 months of age (Stoney et 
al., 2004). 
 
The relationship between dietary linoleic acid and arachidonic acid, the intake of n-3 
PUFA and modifications in enzyme expression and activity appear to have a substantial 
impact on allergy manifestation. However, more research is required to establish the 
relationship between the availability of n-3 and n-6 LC-PUFA during breast feeding and 
atopy development in children (Enke et al., 2008). 
 
1.4.5 Exosomes  
Exosomes are small, 30–100 nm membrane vesicles, which are released extra-
cellularly after fusion of multivesicular endosomes with the cell membrane of a wide 
range of mammalian cells. The mechanism of action of exosomes within the immune 
system is not fully understood. They can be secreted by various  cells types (dendritic 
cells, mast cells, epithelial cells, B-cells, T-cells). Those secreted by mast cells, can 
induce dendritic cell maturation (Skokos et al., 2003). There is also a suggestion that 
mast cell exosomes can transport functional mRNA to recipient cells (Lotvall and Valadi, 
2007). Exosomes from B cells can present Bet v 1 peptides and stimulate Bet v 1-
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specific T-cell lines to proliferate and to produce the Th2-like cytokines IL-5 and IL-13 
(Admyre et al., 2007a). 
 
Exosomes have been identified in colostrum and mature BM expressing MHC class II, 
CD86, and the tetraspanin proteins CD63 and CD81. These milk exosome complexes 
inhibit anti-CD3-induced cytokine production from PBMC and increase the number of 
Foxp3+CD4+CD25+ T regulatory cells. These findings suggest that exosomes in human 
BM could have a significant influence on immune ontogeny, risks of atopic and other 
immune mediated diseases (Admyre et al., 2007b). 
 
1.4.6 Immunoglobulins  
Immunoglobulins are actively secreted in colostrum and mature breast milk and are 
identical to those found in blood or secretions. They are a family of bioactive protective 
proteins  divided into several classes including IgM, IgA, IgG, IgE, and IgD (Mix et al., 
2006). IgG, IgA and IgM are the major immunoglobulin classes in mammal animal 
secretions (Huang et al., 2008). 
 
Immunoglobulins are found in both colostrum and BM in significant concentrations 
(Bottcher et al., 2003, Striker et al., 2004, Bachour et al., 2012). IgA is the major 
immunoglobulin class (88-90% of total immunoglobulin), whereas IgG is the primary 
immunoglobulin class found in bovine and porcine colostrum and milk. The content of 
IgG in human colostrum is of little consequence as it is actively transported across the 
placenta to the foetus in the last trimester of pregnancy  (Hurley and Theil, 2011). 
Savilahti and co-authors found an association between low levels of IgA antibodies to 
cow's milk in colostrum and atopy and allergy development (Savilahti et al., 2005). 
Conversely Kuitunen et al. showed that high OVA IgA antibodies in colostrum were 
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associated with atopy development by 2 years of age (Kuitunen et al., 2012). Other 
studies failed to reveal any influence of sIgA on immunological outcomes in children 
(Bottcher et al., 2008, Saarinen et al., 1999, Bottcher et al., 2003, Boyle et al., 2011). 
Maternal intestinal antigens shape her GALT before pregnancy, and that GALT 
migrates to the mammary gland to produce BM immunoglobulins. These BM Igs then 
act by binding microbial and non-microbial antigens in the infant intestine, and 
preventing them from breaching infant intestinal epithelium and causing inflammation 
(Hurley and Theil, 2011). Therefore intestinal exposures in women may be priming both 
their and their own infants’ immune development. This could explain the association 
between maternal antibiotic administration during pregnancy and a higher risk of 
asthma in off-spring. 
 
1.4.7 Interleukin-2  
Interleukin 2 (IL-2) actively secreted by Th1 cells plays an important role in T cell-
mediated immune responses activation. It may increase natural killer (NK) cell cytolytic 
activity (Sakaguchi et al., 2008), influence Treg cells development and regulate the 
expansion and apoptosis among activated T cells (D'Souza and Lefrancois, 2003). IL-2 
production is known to be reduced in newborn babies (Hassan and Reen, 1996), though 
additional supply of this cytokine via breast milk may compensate for this deficit. 
 
Few studies have assessed IL-2 levels in colostrum and BM. Ustundag and co-authors 
found that the IL-2 level in colostrum from mothers of preterm infants was higher 
compared to the mothers of mature babies (Ustundag et al., 2005). However, this effect 
was diminished in later stages of lactation and an effect  on the infant’s immune  
development was not established. Bryan and co-authors (Bryan et al., 2006), found 
detectable levels of IL-2 in BM of 42 out of 52 BM samples, and a significant correlation 
CHAPTER 1: INTRODUCTION 
 
41 
 
between milk aqueous IL-2 and maternal serum IL-2, but there was considerable 
diversity in the timing when BM was collected (15 – 357 days postpartum). 
 
1.4.8 Interleukin-4 
Interleukin 4 (IL-4) is one of the key cytokines in the development of allergic 
inflammation. It is involved in institution of the ε isotype shift and secretion of IgE or 
IgG4 by B lymphocytes (Coffman et al., 1986, Gascan et al., 1991). In addition, IgE-
mediated responses are strengthened by IL-4 as it is able to upregulate IgE receptors 
on the surface of the cells via the low-affinity IgE receptor (FcεRII;CD23) on B 
lymphocytes and mononuclear phagocytic cells and high-affinity IgE receptor (FcεRI) on 
mast cells and basophils (Pawankar et al., 1997). Another known mechanism of IL-4 
contribution to airway obstruction in asthma is via induction of mucin gene expression 
and the hypersecretion of mucus (Dabbagh et al., 1999). IL-4 increases eotaxin 
expression as well as other inflammatory cytokines from fibroblasts being partly 
responsible for inflammation and lung remodelling in chronic asthma (Doucet et al., 
1998). The cell that initially produces IL-4, thus inducing Th0 differentiation, has not 
been identified yet, but recent studies suggested that basophils could be an effector cell 
(Sokol et al., 2008) but the source may be innate lymphocytic cells. They in turn are 
triggered by TSLP, Il-25 and IL33 from stressed epithelial cells. However, the most 
prominent effect of IL-4 from Th2 cells is induction of B-cell Ig class switching to IgE 
production 
 
Levels of IL-4 in colostrum vary from one study to another (<1.6 pg/mL to 172 pg/mL), 
possibly due to an individual variations, difference in laboratory methods used and time 
of colostrum collection postpartum, with a tendency to decrease in mature milk (Agarwal 
et al., 2011). 
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Studies on IL-4  in colostrum and BM of allergic and non-allergic mothers have 
produced conflicting results. Bottcher et al.  found higher concentrations of IL-4 in 
colostrum from allergic compared to non-allergic mothers (Bottcher et al., 2000). In 
contrast median IL-4 levels did not differ significantly between the two groups in a Polish 
study, nevertheless IL-4 was more often detected in the colostrum of allergic compared 
to non-allergic mothers (Marek et al., 2009). In both studies, IL-4 was less commonly 
detected in colostrum and BM, than several other cytokines (Bottcher et al., 2000, 
Marek et al., 2009). Similarly Rudloff and co-authors detected IL-4 in only 20% of the 
colostrum samples with no significant difference between allergic and non-allergic 
mothers (Rudloff et al., 1999). In the milk of allergic mothers the IL-4 rise and peak at 3 
months after delivery has been observed with the decline after this time point 
(Prokesova et al., 2006). 
 
1.4.9 Interleukin-5 
Interleukin 5 (IL-5) plays an important role in the induction of B-1 cell proliferation and 
enhances B-1 and B-2 cells differentiation into antibody secreting cells (Takatsu, 1998).  
It is produced by T helper-2 cells and mast cells and is considered as a key cytokine in 
eosinophil production, activation and localization. IL-5 alongside IL-4, IL-9, and IL-13 
together with eotaxin, plays critical roles in orchestrating and amplifying allergic 
inflammation in asthma (Larche et al., 2003, Takatsu and Nakajima, 2008). It is known 
to be a key mediator in eosinophil activation and life span determination (Takatsu and 
Nakajima, 2008) leading to eosinophils migration to the lungs in asthmatic patients who 
are known for distinct eosinophil infiltration of their lungs (Kay, 2001). It has also been 
shown that IL-5 is involved in IgA production (Schoenbeck et al., 1989). 
Concentration of IL-5 in colostrum varies from high (79 pg/mL) (Prokesova et al., 2006) 
to low (6 pg/mL) (Bottcher et al., 2000) with a similar trend seen in mature breast milk 
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(Agarwal et al., 2011). These differences in the colostral IL-5 concentration may be 
explained by individual variations, difference in laboratory methods used and time of 
colostrum collection postpartum. 
 
There are few studies analysing IL-5 levels in colostrum or BM in general. Prokesova et 
al. failed to find any difference in IL-5 concentration between mothers with atopic 
dermatitis and controls, (Prokesova et al., 2006). Two studies (Bottcher et al., 2000, 
Bottcher et al., 2003) detected IL-5 in less than 10% of the colostrum and 1 month 
mature milk samples. There was no significant difference between concentrations of IL-
5 in colostrum of allergic and non-allergic mothers, but a significant correlation between 
levels of IL-5 and IL-10 (Bottcher et al., 2000).  This is consistent with understanding of 
cytokine interactions in that IL-10 suppresses IL-12 production and therefore IFN-
gamma which will remove one of the regulatory influences on Th-2 activity. 
 
Very few studies aimed to compare the levels of IL-5 in other compartments in parallel: 
Prokesova and co-authors found similar levels of IL-5 in colostrum and maternal serum 
(Prokesova et al., 2006) and Ziska et al found that levels of IL-5 in colostrum (73.0 
pg/mL) and cord serum (86.5 pg/mL) were higher than in amniotic fluid (9.2pg/mL) 
(Zizka et al., 2007). 
 
1.4.10 Interleukin-6 
Interleukin 6 (IL-6) is a proinflammatory (Kopf et al., 1994) and anti-inflammatory 
cytokine (Xing et al., 1998) and involved in a wide spectrum of cellular mechanisms, 
including T-cell activation and immunoglobulin production by B cells, and thus it 
enhances IL-4-dependent IgE synthesis 
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IL-6 is detectable in colostrum or BM with no significant difference between the levels of 
IL-6 in colostrum of allergic and non-allergic mothers (Bottcher et al., 2003, Prokesova 
et al., 2006) although there was a correlation with IgA in colostrum as well as with IL-10 
and TGF-β which are involved in IgA synthesis (Bottcher et al., 2000). 
 
IL-6 levels do not differ much during transitioning from colostrum to mature milk but 
levels in various studies varied from 7.3 to 81 pg/mL in colostrum and up to 105 pg/mL 
in 6 month milk, with similar concentrations detected in amniotic fluid, cord serum and 
maternal serum (Agarwal et al., 2011). 
 
1.4.11 Interleukin-10 
Interleukin (IL-10) is considered to be the most important anti-inflammatory cytokine 
alongside TGF-β and IL-35. IL-10 influences three important functions of 
monocytes/macrophages: the release of immune mediators, antigen presentation, and  
phagocytosis. It suppresses all functions of monocytes/macrophages that are 
responsible for a positive role of these cells in both innate and specific immunity (Sabat 
et al., 2010). IL-10 has a range of anti-allergic and anti-inflammatory properties. It 
suppresses the synthesis of a variety of cytokines (IL-1, IL-4, IL-5, IL-6 and TNF-α) and 
chemokines (IL-8, RANTES, eotaxin and MIP-1α) (Berkman et al., 1995, Berkman et 
al., 1996, Chung et al., 1999). 
 
A very high concentration of interleukin 10 (IL-10) has been demonstrated in samples of 
human milk collected during the first 80 hours of lactation (Garofalo et al., 1995).  IL-10 
is present not only in the aqueous phase of the milk, but also in the lipid layer. Its 
bioactive properties were confirmed by experiments showing that human milk samples 
inhibited blood lymphocyte proliferation and that this property was greatly reduced by 
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the pre-incubation with anti-IL-10 antibody (Garofalo, 2010).  In contrast studies have 
either detected no IL-10 (Snijders et al., 2006), or only rarely in colostrum (12%) and 
mature milk (6%) (Bottcher et al., 2000) while others have found IL10 in most if not all 
samples (Garofalo et al., 1995, Marek et al., 2009).This variation may be due to the 
timing of colostrum collection. In the Garofallo’s study, high concentrations of IL-10 were 
detected in samples collected during the first 24 hours and concentrations were lower in 
milk collected later (Garofalo et al., 1995). The colostrum samples in the study done by 
Bottcher et al. were collected 3–4 d postpartum (Bottcher et al., 2000). 
 
IL-10 levels in colostrum and mature milk vary from < 5 pg/mL to 3304 pg/mL (Yilmaz et 
al., 2007, Garofalo et al., 1995) and 0 to 246 pg/mL, respectively (Prokesova et al., 
2006, Rigotti et al., 2006). Data analysed in the review on cytokine concentrations in 
breast milk suggests that there is no decline in IL-10 levels in milk over time (Agarwal et 
al., 2011). 
 
1.4.12 Interleukin-12 
Interleukin-12 (IL-12) plays central role in TH1 responses (Kobayashi et al., 1989, Hsieh 
et al., 1993, Manetti et al., 1993). IL-12 is rapidly produced, independently from IFN-γ 
and signals from T cells (Trinchieri, 2003). It is mainly secreted by such inflammatory 
cells as macrophages, neutrophils, DCs and monocytes (Gazzinelli et al., 1994, 
Scharton-Kersten et al., 1996).  IL-12 plays an important role in the TH1 response 
maintaining organ-specific autoimmunity as has been shown in animal models, and is 
involved in resistance mechanism to infective agents, in particular bacterial and 
intracellular parasites (Trinchieri, 1998). 
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Neutrophils, lymphocytes, and macrophages are found in human milk during the first 
few months of lactation (Smith and Goldman, 1968), and one or more of these cell types 
can secrete Interleukin 12 (IL-12). The immune environment in utero is regulated 
predominantly by Th2- cell predominance (Marzi et al., 1996). Restoration of a balance 
between Th2-type and Th1-type responses postnatally may be orchestrated, by being 
exposed to IL-12 from the milk of a breast-feeding mother (Bryan et al., 1999). 
IL-12 was detected in 62% of BM (Bryan et al., 1999) samples, but there was no 
association between IL-12 in BM and maternal atopic status or maternal 
illness/infection. There was no significant difference in the level of IL-12 in colostrum of 
allergic compared with non-allergic mothers (Snijders et al., 2006). 
 
IL-12 levels in colostrum varies from < 3 pg/mL (Ogawa et al., 2004) to 310 pg/mL 
(Bryan et al., 1999). Bryan et al. found a gradual reduction of IL-12 concentration in milk 
over time (Bryan et al., 1999), in contrast Yilmaz and co-authors failed to reveal any 
difference (Yilmaz et al., 2007). 
 
Comparable concentrations of IL-12 have been found in amniotic fluid, cord serum, and 
breast milk (Agarwal et al., 2011). 
 
1.4.13 Interleukin-13  
Interleukin-13 (IL-13) was originally described as a cytokine that inhibits inﬂammatory 
cytokine production (Minty et al., 1993, McKenzie et al., 1993). Similar to IL4 it promotes 
IgE production but also regulates eosinophilic inflammation, mucus secretion, and 
airway hyper-responsiveness in asthma patients. At the moment it is still unclear what 
regulates IL4/IL-13 receptor expression, and how this affects the functional activity of IL-
13 (Wynn, 2003).We also do not know what role IL-13 plays in colostrum. 
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Bottcher et al. (Bottcher et al., 2000) and (Bottcher et al., 2003)   detected IL-13 in only 
12 out of 48 (25%) colostrum samples but the concentration correlated with the levels of 
IL-4, IL-5 and IL-10. Prokesova and co-authors, in contrast, found IL-13 in almost every 
sample tested (Prokesova et al., 2006). This may be due to ethnic and environmental 
differences in the population groups (from Sweden and Czech Republic). 
Colostral levels of IL-13 vary in different studies averaging from 3.2 pg/mL (Bottcher et 
al., 2000) to 243 pg/mL (Zizka et al., 2007). Interestingly, levels of IL-13 and IL-4 are 
within the same limits (Agarwal et al., 2011), which may be explained by similarities in 
their immunological functions, highlighting the importance of multiple cytokine analysis, 
rather than singly, in breast milk. 
 
1.4.14 Interleukin-15  
Interleukin-15 (IL-15) is secreted by various cells but predominantly by mononuclear 
phagocytes. It has structural similarity with IL-2, and activates Natural Killer cell 
proliferation, cytotoxicity, and cytokine production and regulates Natural Killer 
cell/macrophage interaction (Fehniger and Caligiuri, 2001). This cytokine is known to 
play a key role in anti-HIV responses by stimulating both CD8 T cells and Natural Killer 
cells (Mastroianni et al., 2004). The single study of IL-15 concentrations in BM showed 
an association with decreased risk of HIV transmission.  It was hypothesised that IL-15–
mediated immunity may protect against HIV transmission during breast-feeding (Walter 
et al., 2009). 
 
1.4.15 Interferon-γ  
Interferon-γ (IFN-γ) is a TH-1 cytokine and has extensive and diverse immune-
regulatory effects on many cells including an inhibitory effect on Th2-cells. It is produced 
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by Th1 cells, natural killer cells and dendritic cells (Bogen et al., 1993, Pistoia, 1997). 
IFN-γ increases antigen presentation of macrophages and suppresses Th2 response 
(Oriss et al., 1997). Allergen-specific immunotherapy in allergic patients results in 
increased production of IFN-γ by circulating T-cells (Lack et al., 1997) and in an 
increase in IFN-γ producing T-cells in nasal biopsies (Durham and Till, 1998). 
 
IFN-γ has been found in colostrum and BM (Bocci et al., 1993, Eglinton et al., 1994) but 
biological activity in the infants gut remains to be determined. Botcher and co-authors 
detected IFN-γ in less than 10% of their samples (Bottcher et al., 2000) and Rudloff et 
al. failed to detect  any in 42 samples (Rudloff et al., 1999). In contrast, Prokesova et al. 
found IFN-γ in almost every sample  (Prokesova et al., 2006) which again raises the 
question why cytokine presence in colostrum varies so much from one study to the 
other. It may relate to differing environmental influences. It has been suggested that 
lower levels of IFN-γ in breast milk lead to higher incidence of subsequent eczema 
development in children (Linnamaa et al., 2013). 
 
Levels of IFN-γ in colostrum vary from <67 pg/mL (Bottcher et al., 2000) to 708 pg/mL 
(Prokesova et al., 2006). Results of the recent review suggest that IFN-γ concentration 
does not change over time (Agarwal et al., 2011). 
 
1.4.16 Transforming growth factor-β  
Transforming growth factor-β  (TGF-β) is a family member of regulatory cytokines that 
have pleiotropic functions in various cell lineages involved in many physiological and 
pathological processes such as embryogenesis, carcinogenesis, and the immune 
response (Cerutti et al., 1998). TGF-β regulates cell differentiation, proliferation, 
adhesion, apoptosis and migration of various cell types and promotes the production of 
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extracellular matrix proteins (Dennler et al., 2002). TGF-β plays  a crucial role in the 
maintenance of immune cell homeostasis. 
In animal model experiments TGF-β1 null mice died shortly after weaning due to 
multifocal, inflammatory disease, signs of lymphocyte infiltration into multiple organs 
(Kulkarni et al., 1993, Shull et al., 1992) and autoimmune manifestations (Christ et al., 
1994, Yaswen et al., 1996)[27, 28]. At present three members of the TGF-β family have 
been found (TGF-β1, TGF-β2, and TGF-β3) TGF-β1 is the prevalent form expressed in 
the immune system (Eglinton et al., 1994). 
 
A number of studies have shown that high levels of TGF-β in human milk are 
associated with the prevention of allergic diseases during infancy. A study done in 
Finland in 1999 found that the concentration of TGF-β was higher in colostrum in 
comparison to mature milk and infant’s serum, in infants with the onset of allergic 
disease after the weaning period comparing to babies with  an onset of allergy prior to 
weaning. This suggests  an allergy delaying  effect of TGF-β in colostrum (Kalliomaki et 
al., 1999). 
 
A systematic review summarises the associations between TGF-β in human milk and 
immunological outcomes in infants and children (Oddy and Rosales, 2010). Eight of 12 
studies quoted in this review reported an association between higher TGF-β1 or 2 levels 
in colostrum or BM and reduced risk of atopic outcomes in the infant. The authors 
suggest that TGF-β found in human milk is involved in maintaining homeostasis in the 
intestine, regulating inflammation, promoting oral tolerance and thereby reducing allergy 
development (Oddy and Rosales, 2010).  A high level of heterogeneity among the 
published studies makes interpretation difficult with large differences in study 
populations, design and methodology, TGF- β isoform type assayed, time when milk 
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samples were collected, age at which outcome was measured and, finally, lack of 
consistency in the immunological outcomes measured. 
 
Ando and co-authors showed that orally administered TGF-β can mediate its activity in 
the intestinal mucosa and enhance the induction of oral tolerance to a high-dose dietary 
antigen (Ando et al., 2007) and Nakao suggests that oral administration of TGF-β 
simultaneously with an allergen might potentially be a useful approach for the primary 
prevention of allergic diseases in infants (Nakao, 2010). 
 
1.4.17 Hepatocyte growth factor 
Hepatocyte growth factor (HGF) plays an important role in cell growth, cell motility, and 
morphogenesis regulation by activating a tyrosine kinase signaling cascade binding to 
the proto-oncogenic c-Met receptor. This makes it  a crucial marker of angiogenesis, 
tumorogenesis, and tissue regeneration. Hepatocyte growth factor is produced by 
mesenchymal cells and is involved in immunological activity as a multi-functional 
cytokine on cells of mainly epithelial origin. HGF regulates mitogenesis, cell motility, and 
matrix invasion (Gene database, 2008). Recent data, from animal models studies, 
suggests that HGF also may be involved in airway hyper-responsiveness and airway 
remodelling  in allergic asthma (Ito et al., 2005, Okunishi et al., 2009, Nakamura and 
Mizuno, 2010).  
 
Existing data show that HGF receptor C-met, can be found on the surface of the 
intestinal crypt epithelial cells as well as muscle layers of the intestine (Kermorgant et 
al., 1997). HGF and c-met mRNA expression have been detected not only in adult but 
also in fetal intestine (Kermorgant et al., 1997, Wang et al., 1994). Cummins and 
Thompson found that the infant mucosa and crypt enterocytes have increased c-met 
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mRNA and protein expression compared with adult subjects but low HGF expression in 
the neonatal ileum, suggesting that breast milk HGF interacts with c-met receptor and 
induces a response (Cummins and Thompson, 2002).  
 
Very few studies assessed HGF levels in colostrum and breast milk. It is evident that 
levels of this factor in human milk are very high (Kobata et al., 2008). A few studies 
suggest that these enormous concentrations of HGF in breast milk (20-30 times higher 
than in maternal serum) may be a part of a physiological mechanism  aiding infant GI 
maturation as well as protection within the first days of life (Srivastava et al., 1999, 
Kobata et al., 2008). 
 
Levels of HGF in colostrum vary from <0.59 ng/mL (Yamada et al., 1998) to 52.2 
(Kobata et al., 2008) ng/ml. Existing evidence does not allow us to make any 
conclusions in regards to breast milk concentration of HGF and allergic and/or 
immunological outcomes. However, HGF suppresses the antigen-presenting capacity of 
dendritic cells in murine models, thus inhibiting sensitisation (Okunishi et al., 2009), 
suggesting that HGF may be a potential therapeutic option for chronic asthma with 
airway re-modelling (Okunishi et al., 2005, Ito et al., 2008). 
 
1.4.18  EGF (epidermal growth factor) and VEGF (vascular endothelial growth 
factor) 
EGF is involved in a number of activities, including proliferation, maturation, migration, 
and apoptosis (Gleave et al., 1993) and VEGF is a key regulator of physiological and 
pathological angiogenesis and tissue repair. Studies show that VEGF may stimulate 
endothelial proliferation, motility, and capillary morphogenesis and provide vascular 
permeability regulation (Veikkola and Alitalo, 1999). Growth factors are present in  high 
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concentrations in breast milk, similar trends can be seen in VEGF. Concentration of 
both, EGF and VEGF, in breast milk is much higher than in maternal serum suggesting 
a mammary gland source  of these growth factors. (Ballard and Morrow, 2013). Breast 
milk EGF is believed to increase gut mucosal barrier development (Donovan and Odle, 
1994). Data from animal research suggest that EGF may reduce the risk of necrotizing 
enterocolitis development in infancy (Dvorak et al., 2002).  
Loui et al. found higher levels of VEGF in the BM of the mothers delivering  term babies 
when compared with preterm (Loui et al., 2012). This finding in conjunction with the 
known disregulation of VEGF in retinopathy of prematurity, which causes dysregulated 
vascularization of the retina (DiBiasie, 2006), lead to a hypothesis that VEGF in BM may 
reduce the risk of retinopathy of prematurity development (Ballard and Morrow, 2013).  
1.4.19 Soluble Cluster of Differentiation 14 
Cluster of differentiation 14 (CD14), a pattern-recognition receptor plays an important 
role in the innate immune response to endotoxin (Pugin et al., 1994). Polymorphisms in 
the promoter region for the CD14 gene have been associated with susceptibility to 
atopic sensitization (Vercelli, 2008). The soluble form (sCD14) is secreted by liver and is 
found in breast milk (Labeta et al., 1993). 
 
sCD14 is found in very high concentrations in human milk. Increased levels of 
circulating sCD14 correlate with infection and autoimmunity (Filipp et al., 2001).  
Polymorphisms in the promoter region of the DNA encoding CD14 have been 
associated with reduced levels of circulating sCD14and in turn inversely correlated with 
total IgE levels (Feachem and Koblinsky, 1984). Savilahti et al. studied a large cohort of 
4676 children in four groups, with either long or short exclusive breast-feeding (3.5 
months or 2 weeks) who subsequently were classified by the presence or absence of 
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atopy. Children with atopic symptoms and IgE sensitization at the age of 4 received 
colostrum with a significantly lower concentration of sCD14 than those without 
symptoms and IgE sensitization (Savilahti et al., 2005). Jones et al. (Jones et al., 
2002a) and found that infants who subsequently developed eczema received at 3 
months of age BM with lower levels of sCD14 than did those without eczema, however 
another study failed to show sCD14 protective effect against eczema development 
(Ismail et al., 2013). It may be partially explained by difference in CD14 genotype as it 
has been recently shown that  breastfeeding was associated with a decreased risk of 
atopic sensitization in children with CT/CC genotype (OR 0.667, 95%CI 0.463-0.960) 
(Lee et al., 2013). Jones also found lower amniotic fluid sCD14 levels were associated 
with later atopy. 
 
For many of the immunomodulatory components present in BM, there is only limited 
direct evidence for a role in the development of infant intestinal immunity or allergic 
disease. However some BM immune components are known to be important factors in 
infant immune development, or important stimuli of immune responses generally. In 
Table 1, I have summarised the evidence that variations in levels of breast milk immune 
mediators are associated with altered allergic disease risk. The evidence is perhaps 
strongest for TGF beta, which has known biological effects on intestinal immune 
responses, is actively secreted into breast milk, and has been shown in several studies 
of breast milk composition to differ significantly between populations. 
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Table 1 Relationship between BM immune composition and infant immune development – observational studies 
Author and year Country and numbers Immune modulators 
measured 
Main Outcomes 
Saarinen 1999 
(Saarinen et al., 1999) 
Finland 
108 infants with cow’s milk 
allergy; 207 healthy controls 
IgA, IgM, Cow’s milk specific 
antibodies,  
IL-6, IFN-γ, TGF-β1 
Colostrum TGF-β1 reduced for infants with IgE-mediated cow’s milk 
allergy. Other factors did not differ.  
Kalliomaki 1999 
(Kalliomaki et al., 1999) 
Finland  27 infants with 
eczema  
TGF-β1, TGF-β2 Colostrum TGF-β1 and TGF-β2 reduced for infants with pre-weaning 
onset of eczema compared with post-weaning onset  
Jones 2002 (Jones et 
al., 2002a)  
UK  8 infants with eczema; 21 
without 
sCD14 sCD14 levels reduced in infants with eczema. 
Rautava 2002 (Rautava 
et al., 2002) 
Finland (BM from 30 women 
taking probiotics and 32 
taking placebo) 
TGF-β1, TGF-β2 The risk of developing atopic eczema during the first two years of life 
in infants whose mothers received probiotics was significantly lower 
compared with infants whose mothers received placebo. Higher levels 
of TGF-β2 were found in BM of mothers receiving probiotics. 
Bottcher 2003 
(Bottcher et al., 2003) 
Sweden 53 infants IL-4, IL-5, IL-6, IL-8,  
IL-10, IL-13, IL-16,  
IFN-γ, TGF-β1, TGF-β2, 
RANTES, eotaxin, SIgA 
No difference in mediator levels with respect to atopy, allergic 
symptoms or salivary IgA in the first 2 years of life 
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Oddy 2003 (Oddy et al., 
2003) 
Australia 243 infants TGF-β1, IL-10, TNF-α, 
sCD14 
Prolonged breast feeding and high TGF-β1 in breast milk at 2 weeks 
were associated with reduced infant wheezing 
Reichardt 2004 
(Reichardt et al., 2004) 
Germany  
218 infants 
n-3 and n-6 polyunsaturated 
fatty acids 
No association between fatty acid levels and infant atopic eczema. 
High colostrum linoleic acid (n-6) associated with high milk-IgE. 
Low colostrum docosapentaenoic acid (n-3) associated with high total 
IgE at 1 year.  
Savilahti 2005 
(Savilahti et al., 2005) 
Finland 228 children total IgA, IgA antibodies to 
cow's milk, casein, sCD14, 
and TGF-β1, TGF-β2 
Low colostrum IgA casein antibodies and low sCD14 concentration 
were associated with atopy. Low levels of specific IgA antibodies to 
cow's milk and sCD14 in colostrum were associated with atopy and 
allergic symptoms (eczema, allergic rhinitis, conjunctivitis, asthma) by 
four years of age. 
Rigotti 2006 (Rigotti et 
al., 2006) 
Italy 22 infants TGF-β1, IL-10 TGF-β and IL-10 did not influence immunological outcomes at the age 
of 6 months  
Snijders 2006 
(Snijders et al., 2006) 
Netherlands 307 infants TGF-β1, IL-10,  
IL-12, sCD14 
None of the studied immune factors in breast milk at 1 month, were 
associated with infant's atopic outcomes. 
Bryan 2007 (Bryan et 
al., 2007) 
Australia (36 milk samples 
from mothers of infants 
hospitalized with bronchiolitis 
and 63 mothers of 
postpartum age-matched 
healthy controls) 
IFN-γ, IL-2, IL-4, IL-8,  
IL-10, RANTES 
IL-10 level in BM of mothers of infants with bronchiolitis was lower 
compared with mothers of healthy infants. 
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Bottcher 2008 
(Bottcher et al., 2008) 
Sweden (colostrum and 
mature milk from women 
treated with L. reuteri (n = 54) 
or placebo (n = 55) from 36 
weeks  gestation until labour) 
Total IgA, SIgA, TGF-β1, 
TGF-β2, IL-10, TNF, sCD14, 
Na/K ratios 
Infants receiving BM with low levels of TGF-β2 were less likely to 
become sensitized or developing eczema during their first 2 years of 
life.  
 
Lowe 2008 (Lowe et al., 
2008) 
Australia 194 infants n-3 and n-6 polyunsaturated 
fatty acids 
High levels of n-3 fatty acid in colostrum were associated with 
increased risk of infantile atopic eczema, while total n-3 concentration 
in BM was associated with increased risk of non-atopic eczema. 
Higher levels of total n-6 fatty acid in colostrum were associated with 
increased risk of childhood rhinitis. There was no evidence of 
associations between fatty acid profile and risk of asthma. 
Tomicic 2010 (Tomicic 
et al., 2010) 
Sweden, Estonia 39 Estonian 
and 60 Swedish infants 
SIgA, IL-4, IL-10, IL-13, IFN-
γ, TGF-β1, TGF-β2 
High levels of IL-13 in colostrum were associated with allergic 
sensitization during infancy in Swedish cohort, but not in the Estonian 
cohort. 
Boyle 2011 (Boyle et al., 
2011) 
Australia (7 days and 28 days 
BM samples from 38 mothers 
receiving placebo and 35 
receiving probiotic) 
Total IgA, sCD14, TGF-β Prenatal Lactobacillus rhamnosus GG supplementation did not have 
any effects on infants immunological outcomes. Maternal probiotic 
supplementation resulted in reduced levels of IgA and sCD14 in BM.  
Thijs 2011 (Thijs et al., 
2011) 
Netherlands 315 infants n-3 polyunsaturated fatty 
acids 
Higher concentrations of n-3 PUFAs in breast milk at 1 month, are 
associated with atopic dermatitis, parent reported eczema and 
sensitization at one year of age. 
Kuitunen 2012 
(Kuitunen et al., 2012) 
Finland 364 infants Total IgA, 
IgA antibodies to cow's milk, 
casein, β -lactoglobulin, 
ovalbumin, TGF-β2, IL-10 
High OVA IgA antibodies in colostrum were associated 
with the atopy development by 2 years of age. Low levels in BM were 
is a risk factor for eczema development by the age of 2. High levels of 
TGF- β 2 in BM at 3 months was associated with more allergic 
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disease and eczema at 2 years. 
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1.5 Immune active molecules to be assessed in this Thesis 
Data from recent proteomics studies show that BM contain hundreds of proteins 
(D'Alessandro et al., 2010), including cytokines, growth factors, signalling molecules 
and other factors which may interact with infants immunity. Previous research found 
some associations between a variety of maternal and environmental exposures and 
levels of a certain immune active molecules as well as associations with subsequent 
health outcomes in children. In the ideal world proteomics, lipidomics and analysis of 
cytokines and growth factors should be done at once and considered as a "gold 
standard" study design. Unfortunately, it is impossible to fulfil these criteria due to the 
following reasons: 
a) Colostrum is very difficult to obtain and usually only small volumes of this 
biological  fluid can be collected. It is especially prevalent in primiparous mothers 
and those women undergo caesarean section. This does not allow to provide 
colostrum analysis for all cytokines and growth factors of interest.  
b) Financial limitations enforced me to restrict amount of cytokines analysed. 
The final choice of cytokines was based on the data from other studies, I selected those 
immune active molecules which have been reported to be influenced by various 
exposures and/or been associated with short-term health outcomes (especially allergic 
disease) in children, even when existing evidence was somehow conflicting. I also 
considered methodological issues as some cytokines cannot be analysed on a single 
multiplex plate due to  difference in protocols. A summary of the immune factors known 
to be present in human breast milk, and their association with infant health outcomes 
especially allergic outcomes, is shown below and has been published in the Clinical & 
Experimental Allergy Journal as a review article (Munblit et al., 2014). 
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It was not possible to add more immune active molecules into my laboratory 
experiments due to the lack of funds as well as feasibility of laboratory analysis. 
The final list of immune active molecules included a selection of Th1, Th2 cytokines and 
growth factors involved in a number of immunological interactions and consisted of IL2, 
IL4, IL5, IL10, IL12, IL13, IFNγ, HGF, TGFβ1, TGFβ2 and TGFβ3. 
 
1.6 Environmental influence on BM immune composition 
Levels of factors with the potential to influence infant immune development, may be 
modifiable. There is evidence that a number of different exposures can influence 
maternal breast milk and colostrum components, and even a limited body of evidence 
that such interventions can alter infant immune outcomes. Below I have summarised 
some of the exposures/maternal variables which have been associated with altered 
breast milk or colostrum composition, with or without direct evidence of effects on infant 
immune outcomes. 
 
1.6.1 Tobacco smoke 
It is well established that tobacco smoke is immuno-toxic, but the effect of smoking on 
the immunological function of the mammary gland of smoking mothers has not been 
well studied. Current recommendations state that maternal smoking is not an absolute 
contraindication to breastfeeding (American Academy of Pediatrics, 2012). 
 
Zanardo et al. (2005)suggested that exposure to tobacco smoke during pregnancy may 
affect the development of the immunologic function of the mammary gland, significantly 
influencing colostral milk provision of the proinflammatory cytokine IL-1α for breast-
feeding infants. (Zanardo et al., 2005), and Agostoni and co-authors found that both 
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total lipid content and absolute amounts of the fatty acids linoleic, arachidonic, a-
linolenic and docosahexaenoic acid in BM were lower in smoking vs. non-smoking 
mothers at 1 month. The latter study also showed that at 3 months after delivery, the 
BM of smoking mothers contained less docosahexaenoic than the BM of non-smoking 
mothers (Agostoni et al., 2003). 
 
Ermis et al. found significant differences in breast milk malondialdehyde (p=0.002) 
levels, superoxide dismutase (p=0.011), but not glutathione peroxidase (p=0.11) 
activities, and antioxidant potential (p=0.29) in active-smoking, compared with passive-
smoking, and nonsmoking mothers.  This suggests that breast milk is vulnerable to 
oxidative stress and lipid peroxidation (Ermis et al., 2005). Maternal smoking may 
influence sleep/wake patterns in infants as they spent significantly less time sleeping 
during the hours immediately after their mothers smoked (53.4 minutes), in comparison 
to sessions when their mothers abstained from smoking (84.5 minutes) (Mennella et al., 
2007). 
 
Tobacco smoke contributes significantly to breast milk contamination by polycyclic 
aromatic hydrocarbons (PAH), organic chemicals formed in all the incomplete 
combustion processes of organic matter. The condensate contained in the cigarettes 
smoked daily by each subject was strongly related with the polynuclear hydrocarbon 
content of BM (R2=0.92, p<0.005) (Zanieri et al., 2007). 
 
1.6.2 Gestation 
The effects of premature delivery on BM composition have been highlighted in the study 
done by Castellote et al. (Castellote et al., 2011) who found that levels of IL-6, TGF-β1 
and TGF-β2 were higher in colostrum following preterm compared with term delivery. 
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The cohort size was small, with 10 prematurely and 22 term delivered women, and 
further studies are needed to confirm this finding. 
 
1.6.3 Physical activity 
Increasing metabolic-equivalent tasks, and thus caloric expenditures, can increase pro-
inflammatory cytokines in the BM (Groer and Shelton, 2009). This is a novel idea but 
the study was cross-sectional, used self-reported data, and the exercise instrument 
used has not been validated. These observations require further elaboration. If there 
truly is a relationship between maternal physical activity and BM composition, then this 
is one possible mechanism through which modern lifestyles with reduced physical 
activity might lead to altered infant immune development. 
 
1.6.4 Maternal diet 
Maternal diet during pregnancy and lactation could significantly influence allergy 
development. Maternal diet can influence breast-milk fatty acid and immune mediator 
composition (Hoppu et al., 2012, Laiho et al., 2003, Lauritzen et al., 2006). A study done 
by Urwin et al. showed that salmon consumption during pregnancy leads to a higher 
proportion of individual and total n-3 PUFA in BM during early lactation and a lower ratio 
of n-6 : n-3 PUFA as well as lower sIgA levels (Urwin et al., 2012). 
 
Dunstan and co-authors showed that giving fish oil to atopic pregnant women led in 
their infants  to a lower cytokine response to common allergens and less severe atopic 
dermatitis by one year of age compared with a placebo group, taking olive oil (Dunstan 
et al., 2003). In contrast, Johansson and co-authors suggest that diet is not so important 
in that women with a combination of eczema and respiratory allergy had lower BM 
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levels of several PUFAs and lower ratio of long-chain n-3/n-6 PUFAs than healthy 
women, despite similar fish consumption (Johansson et al., 2011). 
 
A recent study from Finland (Linnamaa et al., 2013) provides intriguing results 
suggesting that black currant seed oil supplementation during pregnancy leads to a 
lower level of IL-4 and higher level of IFN-γ in breast milk in comparison to control group 
having olive oil. However, there were no differences in the levels of IL-5, IL-10, IL-12 
and TNF. 
 
Probiotic supplementation during pregnancy and lactation also may influence atopy 
development. Prescott et al. showed that giving L. rhamnosus HN001 or 
Bifidobacterium lactis HN019 resulted in higher levels of TGF-β1 and IgA in BM 
compared with placebo (Prescott et al., 2008) and Dotterud and co-authors showed that 
probiotic milk containing Lactobacillus rhamnosus GG, L. Acidophilus La-5 and 
Bifidobacterium animalis subsp. lactis Bb-12 intake by women from 36 weeks of 
gestation to 3 months post-natally during breastfeeding,  resulted in a lower incidence of 
eczema in their babies compared with placebo group (Dotterud et al., 2010). A recent 
dietary intervention study by Hoppu et al. on 125 Finish mothers suggests that diet 
(favourable fat intake (SFA, MUFA,PUFA)) on its own and diet in conjunction with 
probiotic intake can influence cytokine and fatty acid composition in BM. They found 
higher levels of n-3 fatty acids and α-linolenic acid in BM in both dietary intervention 
groups and concentrations of IL-2, IL-4, IL-10 and TNF-α was higher in BM of mothers 
in diet and probiotic group (Hoppu et al., 2012).  Kuitunen and co-authors found that 
probiotic intervention has been associated with increased IL-10 levels and decreased 
casein IgA levels in BM and TGF-β2 levels in colostrum (Kuitunen et al., 2012). Boyle et 
al. (Boyle et al., 2011) found that prenatal treatment with Lactobacillus rhamnosus GG 
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was not sufficient to prevent eczema. However, total IgA levels at day 28 and sCD14 at 
day 7 in BM, were lower in the group receiving probiotics compared to placebo group. 
 
Together these data all support the principle that maternal dietary composition can 
influence BM immune composition, although the precise nature of the effects of different 
dietary components and the mechanisms through which they influence BM composition 
need further investigation. 
 
1.6.5  Parity 
The “hygiene hypothesis” remains one of the most  widely discussed explanations for 
the high prevalence of immune mediated diseases in the affluent world and the early-life 
origins of atopy  (Strachan, 1989). The inverse relationship between the risk of atopic 
diseases, associated with a Th2 immune response, and  early-life exposure to infections 
promoting Th1 responses, such as later birth order or sibship size, early attendance at 
day care, and early exposure to pets or other animals is well described (Strachan, 
2000). 
 
One study has suggested that the risk of scleroderma and systemic sclerosis increases 
with increasing birth order, which is the reverse of the reported risk associated with 
allergic and atopic disorders (Cockrill et al., 2010). These observations might suggest 
that increased Th1 activity in early life reduces allergy but increases the risk of auto-
immune disease. However, other population studies have shown a higher risk of allergic 
problems in patients who also have the auto-immune disease, type 1 diabetes mellitus. 
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There are very few data on parity in relation to immune modulators in human milk. 
Higher concentrations of IgA and IgM have been found in maternal colostrum of 
primiparous women in comparison with multiparous (Striker et al., 2004) 
 
It would be reasonable to hypothesise that if there is an effect of parity on BM immune 
composition, then microbial exposures which impact on BM immune mediator levels 
(Peroni et al., 2010) may explain these differences in mediator levels in relation to 
parity. Thus mothers breastfeeding higher birth-order infants will be exposed to a wider 
array of organisms from their other children and these will affect milk cytokine levels as 
shown in some probiotic trials. 
 
1.6.6 Habitat 
Environmental influences on BM immune composition and maternal atopy/allergy effect 
on BM composition are summarised in Table 2. Variability in BM composition has been 
shown to be important in other settings – for example BM from diabetic mothers can 
lead to a higher risk of obesity in offspring compared with BM from non-diabetic milk 
donors (Scharton-Kersten et al., 1996). In the context of allergy, it is clear that BM of 
mothers living in different settings, and even of mothers in the same setting but with 
different childhood exposures, differs significantly (Tomicic et al., 2010, Amoudruz et al., 
2009). It is supposed that, the pathway for this latter finding is that enteral exposures of 
the mother during her own infancy prime her intestinal immune cell development such 
and when immune cells migrate from the maternal intestine to the mammary gland, 
there is altered BM composition (Brandtzaeg, 2010). 
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Table 2 Environmental influences on BM immune composition and maternal atopy/allergy effect on BM composition 
Author and year Country and numbers Immune modulators 
measured 
Exposure of interest Main Outcomes 
Islam 2006 (Islam et al., 
2006) 
Bangladesh (colostrum 
from 105 mothers) 
IgA, IgM, IgG, 
peripheral immune 
cells 
Age, BMI, Parity Maternal age, BMI, parity and income level did not 
correlate with immunoglobulin concentration in 
colostrum. 
Hoppu 2012 (Hoppu et 
al., 2012) 
Finland (colostrum and/or 1 
month BM samples from 
125 mothers) 
IL-2, IL-4, IL-6, IL-10, 
TNF-α, IFN-γ, n-3 
polyunsaturated fatty 
acids 
Fatty acid 
supplementation 
The concentrations of TNF-alpha, IL-10, IL-4 and 
IL-2 were higher in both dietary intervention groups 
compared with controls and γ-linolenic acid in the 
diet/probiotic group was higher compared with the 
diet/placebo group.  
Urwin 2012 (Urwin et al., 
2012) 
UK (BM from 123 mothers) sCD14, TGF-β1, TGF-
β2, sIgA, fatty acid 
composition 
Fatty acid 
supplementation 
Salmon consumption during pregnancy lead to a 
lower n-6 PUFA : n-3 PUFA ratio. Higher proportion 
of individual and total n-3 PUFA has been found 
and n-6 PUFA proportions did not differ Breast milk 
secretory IgA (sIgA) was lower in the salmon 
group. All breast milk immune factors decreased 
between days 1 and 28. 
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Amoudruz 2009 
(Amoudruz et al., 2009) 
Sweden (32 born in 
Sweden and 32 migrated 
from developing countries) 
IL-6, IL-8, TGF-β1, 
TGF-β2, sCD14 
Habitat Mothers from developing countries had significantly 
higher levels of BM IL-6, IL-8 and TGF-β1.  
Holmlund 2010 
(Holmlund et al., 2010) 
Sweden, Mali (30 from 
Mali, 32 Swedish 
immigrants and 33 native 
Swedish women) 
TGF-β1, sCD14 Habitat Women from Mali and immigrant women from 
Sweden contained higher levels of TGF-β1than 
milk from native Swedish women. Mali women also 
had significantly higher levels of sCD14 in BM 
compared with other two groups. 
Peroni 2010 (Peroni et al., 
2010) 
Italy (colostrum and 1 
month BM of 45 mothers 
from farming environment 
and 69 from urban 
environment) 
TGF-β1, IL-10 Habitat Exposure to farming environment has been 
associated with higher concentrations of TGF-β1 
and IL-10 in BM compared with mothers from urban 
environment. 
Tomicic 2010 (Tomicic et 
al., 2010) 
Sweden, Estonia 
(colostrum and 1 month BM 
from 39 Estonian and 60 
Swedish mothers) 
SIgA, IL-4, IL-10, IL-
13, IFN-γ, TGF-β1, 
TGF-β2 
Habitat Lower levels of TGF-β2 and higher levels of SIgA, 
IL-10, and IFN-γ have been found in BM from 
Estonian mothers compared with Swedish mothers.  
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Striker 2004 (Striker et 
al., 2004) 
Brazil (colostrum from 82 
mothers having vaginal 
delivery, caesarean section 
with labor or elective 
caesarean section) 
IgA, IgG, IgM Labour type Occurrence of labor together with surgical stress 
induce higher IgA concentrations in colostrum of 
women submitted to emergency caesarean section. 
Rudloff 1999 (Rudloff et 
al., 1999) 
Germany (milk from 19 
allergic and 23 non-allergic 
mothers) 
IL-4, IL-10, IFN-γ,  
MIP-1α 
Maternal Atopy/Allergy Concentrations of proinflammatory markers and 
cytokines in BM did not differ significantly between 
allergic and non-allergic mothers. 
Bottcher 2000 (Bottcher 
et al., 2000) 
Sweden (colostrum and 1 
month BM from 19 allergic 
and 20 non-allergic 
mothers) 
IFN-γ, IL-4, IL-5, IL-6,  
IL-10, IL-13, TGF-β1, 
TGF-β2 
Maternal Atopy/Allergy Concentrations of IL-4, IL-5 and IL-13 were higher 
in colostrum from allergic mothers compared with 
non-allergic. 
Laiho 2003 (Laiho et al., 
2003) 
Finland (BM from 43 
allergic and 51 non-allergic 
mothers) 
TGF-β2, TNF-α, IL-4,  
IL-10, prostaglandin 
E2, cysteinyl 
leukotrienes, fatty acid 
composition 
Maternal Atopy/Allergy Allergic mothers had a lower level of TGF-β2 in BM 
compared with non-allergic. Other cytokines 
concentrations and fatty acid composition were not 
different between the groups. Positive association 
observed between TGF-β2 and proportion of 
polyunsaturated fatty acids.  
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Prokesova 2006 
(Prokesova et al., 2006) 
Czech Republic (colostrum 
and BM from 21 allergic 
and 21 non-allergic 
mothers) 
IL-4, IL-5, IL-6, IL-10,  
IL-13, IFN-γ, TGF-β 
Maternal Atopy/Allergy No significant difference found in colostrum of 
healthy and allergic mothers. Higher levels of IL-4 
and lower of IL-10 observed in mature milk of 
allergic mothers. 
Rigotti 2006 (Rigotti et 
al., 2006) 
Italy (BM from 13 allergic 
and 9 non-allergic mothers) 
TGF-β1, IL-10 Maternal Atopy/Allergy TGF-β1 in mature milk was lower in allergic  
mothers compared to non-allergic. IL-10 level did 
not differ much between allergic and non-allergic 
mothers.  
Snijders 2006 (Snijders 
et al., 2006) 
Netherlands (1 month BM 
from 182 allergic and 125 
non-allergic mothers; 123 
sensitised and 164 non-
sensitised mothers) 
TGF-β1, IL-10,  
IL-12, sCD14 
Maternal Atopy/Allergy Higher sCD14 levels detected in mothers with a 
positive vs. negative allergic history and in mothers 
who were sensitised vs. non-sensitised. IL-10 was 
not detected. 
Sidor 2008 (Sidor et al., 
2008) 
Poland (colostrum and 1 
month BM from 12 allergic 
mothers and 30 non-
allergic mothers) 
β-casomorphin-5,  
β-casomorphin-7 
Maternal Atopy/Allergy Content of β-casomorphin-5 in colostrum of women 
from control group was three times higher 
compared with an allergic group. 
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Marek 2009 (Marek et al., 
2009) 
Poland (colostrum from 30 
allergic mothers and 46 
non-allergic) 
IL-4, IL-10, TGF-β1 Maternal Atopy/Allergy TGF-β1 median concentration was higher in the 
allergy group than in the control. IL-10 was present 
in colostrum of all women and median IL-10 
concentration did not differ between the allergy and 
control groups. Median IL-4 level did not differ 
significantly between the two groups but found 
more often in colostrum of allergic mothers 
compared with nonallergic.  
Rautava 2002 (Rautava 
et al., 2002) 
Finland (BM from 30 
women taking probiotics 
and 32 taking placebo) 
TGF-β1, TGF-β2 Probiotic Giving probiotics to pregnant and lactating women 
increased TGF-β2 in their milk compared with 
mothers receiving placebo.  
Bottcher 2008 (Bottcher 
et al., 2008) 
Sweden (colostrum and 
mature milk from women 
treated with L. reuteri (n = 
54) or placebo (n = 55) 
from 36 weeks  gestation 
until labour) 
Total IgA, SIgA, TGF-
β1, TGF-β2, IL-10, 
TNF, sCD14, Na/K 
ratios 
Probiotic L. reuteri supplementation during pregnancy was 
associated with low levels of TGF-β2 and slightly 
increased levels of IL-10 in colostrum.  
Prescott 2008 (Prescott 
et al., 2008) 
New Zealand (1 week, 3 
month and 6 month BM 
from 34 mothers receiving 
Lactobacillus rhamnosus 
HN001; 35 mothers - 
Bifidobacterium lactis 
IL-6, IL-13, IFN-γ, 
TNF-α, IL-10, TGF-β1, 
IgA sCD14 
Probiotic TGF-β1 levels were higher in early 1 week BM from 
groups taking probiotics. IgA concentration was 
also higher in  BM from both the B. lactis HN019 
and the L. rhamnosus HN001 group. 
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HN019 and 36 taking 
placebo beginning 2-5 
weeks before delivery and 
continuing for 6 months into 
lactation)  
Boyle 2011 (Boyle et al., 
2011) 
Australia (7 days and 28 
days BM samples from 38 
mothers receiving placebo 
and 35 receiving probiotic) 
Total IgA, sCD14, 
TGF-β 
Probiotic Prenatal probiotic (Lactobacillus rhamnosus GG) 
supplementation was associated with decreased 
BM soluble CD14 and IgA levels 
Kuitunen 2012 
(Kuitunen et al., 2012) 
Finland (364 colostrum and 
321 BM samples) 
Total IgA, 
IgA antibodies to cow's 
milk, casein, β -
lactoglobulin, 
ovalbumin, TGF-β2, 
IL-10 
Probiotic Probiotic intervention (Lactobacillus rhamnosus 
GG, L. rhamnosus, Bifidobacteriumbreve, 
Propionibacterium freudenreichii ssp. shermanii JS) 
was associated with increased IL-10 levels and 
decreased casein IgA levels in BM and TGF-β2 
levels in colostrum. 
 
Zanardo 2005 (Zanardo 
et al., 2005) 
Italy (colostrum and 10-th 
day BM from 42 smoking 
and 40 non-smoking 
mothers)  
IL-1α, β-endorphin, 
leptin 
Smoking IL-1α concentrations were lower in smokers' 
colostrum compared with non-smoking mothers. IL-
1α, β-endorphin, leptin levels in transitional milk did 
not differ significantly.  
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1.7 Methodological issues of BM immune factor analysis  
One of the modern approaches to list the proteomic profile in various biological samples 
is protein micro-array.  There are convenient and commercially available multiplex 
techniques based on antigen–antibody binding. The cytokine array is a very useful tool 
that can give precise information on relative changes in cytokine concentrations, but 
they unfortunately do not provide specific quantitative information. For protein level 
quantification ELISA can be used. It is important to mention that the sensitivity for each 
protein of particular interest varies because of differences in antibody affinity (Kverka et 
al., 2007). 
Mass spectrometry is a powerful method of immunity assessment and nutritional 
immune modulation. It is a relatively underused technology because it is mostly located 
in large institutions. This method allows very accurate and sensitive diagnostics in 
immunology and nutrition. It can lead to the detection of biomarkers relevant to immune 
status and human nutrition. Various food products have been investigated using mass-
spectrometry, analysing their protein composition. Reviews by De Roos and McArdle 
reviewed proteomics use, as a basis for biomarker development in nutrition research 
(de Roos and McArdle, 2008, de Roos, 2008) They provide a comprehensive summary 
of various nutritional studies related to immunity using by mass spectrometry as a 
diagnostic tool. 
At present, the vast majority of the studies on human’s colostrum and/or breast milk 
composition, especially immune modulators were done using ELISA, but not mass-
spectrometry. I am not aware of any studies so far, on the difference in the protein 
composition of colostrum and/or breast milk in allergic and non-allergic mothers or 
mothers of babies who subsequently developed atopy using proteomics tool. 
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The "gold standard" for breast milk collection is considered to be samples of all milk 
expressed over 24 hours, with collection of a large number of samples from the same 
person over time (Bauer and Gerss, 2011, Ballard and Morrow, 2013). This method is 
ideal but at the same time utopian as it is time consuming, associated with high costs 
and compliance issues. The usual approach in breast milk research is standardisation 
of collection at a specific time of a day and collection from the breast collateral from the 
last feed as well as collection on multiple occasions from the same mother (Geraghty et 
al., 2005). 
 
It is essential to underline that different research groups use various sample 
preparations prior to lab tests and currently there are no “gold standards” in collection 
and processing samples. Investigators employed a range of non-standardised collection 
from their participants at different times of day; at different times within a feed; or at 
various stages of lactation (Ballard and Morrow, 2013).  Centrifugation details given in 
rpm do not provide complete information because rotor radius is also very important in g 
calculation. The range of methodologies used in various studies are presented in Table 
3. 
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Table 3 Methodology used for immune modulators measurement in colostrum and breast milk in various studies 
Author and year Collection process Colostrum and/or breast milk centrifugation Sample 
storage 
Method used for analysis 
Rudloff 1999 
(Rudloff et al., 
1999) 
By manual expression at 
least 1 hour after the last 
feeding  
In 2 steps for further analysis:  
2000 rpm for 10 min at room temperature to 
remove the cells and 6000 rpm for 10 min at 4°C 
later on to remove fat 
-20°C ELISA (Genzyme, Cambridge, USA) and  
(R&D Systems, Wiesbaden, Germany) 
Bottcher 2000 
(Bottcher et al., 
2000) 
Mothers collected breast 
milk at home in sterile 
plastic tubes, using a 
manual breast-pump 
In 2 steps for further analysis:  
680×g for 10 min at 4°C, after which the 
supernatants were removed and centrifuged at 
10 000 ×g for 30 min at 4°C (all samples were 
centrifuged after thawing) 
-20°C ELISA (Research Diagnostics Inc., 
Flandern, NJ) and (R&D Systems Inc., 
Minneapolis, MN); concentrations of IL-5 
were analyzed on high-binding, half-area 
Costar 3690 plates, coated with 
monoclonal rat anti-human IL-5 
 
Laiho 2003 (Laiho 
et al., 2003) 
 
Infants were allowed to 
suckle for a few minutes 
before a breast milk 
sample was collected by 
manual expression, and 
then feeding continued 
 
Once at 8832×g for 5 min, at room temperature 
(after thawing) 
 
–70°C 
 
ELISA (R&D Systems Europe Ltd, 
Abindgon, U.K.) 
Savilahti 2005 
(Savilahti et al., 
2005) 
No specific description is 
given 
Once at 10000×g for 30 min, at unknown 
temperature regime, (after thawing) 
-80°C ELISA (IBL Inc. Hamburg, Germany) and  
Quantikine Human TGF-β1 and TGF-β2 
Immunoassays (R & D Systems, 
Minneapolis, MN) 
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Ustundag 2005 
(Ustundag et al., 
2005) 
By manual expression 
within 2 hours of the first 
feeding in the morning  
(8 AM to 11 AM) 
Once at 690×g for 20 minutes at unknown 
temperature regime 
-40°C Chemilumminessence method, and 
BIODPC diagnostic kits (BIODPC, 
Istanbul, Turkey, DPC, Calif) with 
IMMULITE 
2000 hormon auto-analyzer (BIODPC, 
Istanbul, Turkey, 
DPC, Calif) 
Bryan 2006 (Bryan 
et al., 2006) 
Samples were collected 
from mothers at home on 
three consecutive days 
and in hospital. Samples 
were collected in the 
morning (manual 
expression at home and 
using an electric pump at 
clinic) 
On day 3-4, samples collected at home, were 
thawed and processed at 900×g for 5 min. 
Samples collected in clinic processed without 
freezing and centrifuged at 890×g for 30 min 
Those collected 
at home stored 
then at -20°C 
until transport to 
the laboratory. 
Those collected 
in clinic and 
centrifuged 
stored at  
-80°C until 
ELISA 
ELISA (R&D Systems, 
Abingdon, UK) 
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Snijders 2006 
(Snijders et al., 
2006) 
In the morning, 
before breastfeeding the 
child, from the contra-
lateral 
breast (since the last 
feeding) 
Once at 400×g, for 12 min at 4°C   -80°C ELISA (R&D Systems Europe Ltd., 
Abingdon, UK) and (Biosource Int., 
Camarillo, CA, USA) 
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1.8 Immunological changes during pregnancy 
Changes in maternal immunity aim to tolerate the semi-allogeneic fetus. It involves 
changes in the mucosal lining of the pregnant uterus (decidua) (Trundley and Moffett, 
2004), and changes in peripheral immune responses (Veenstra van Nieuwenhoven et 
al., 2003). When implantation occurs, trophoblast cells (fetally derived placental cells) 
infiltrate uterine endometrium; later the endometrium develops into decidua ensuring 
anchorage of the placenta and therefore proper fetal nutrition. This process needs to be 
regulated accordingly to protect the corporal integrity of the uterine wall of the mother 
(Herberts et al., 2010). There is some evidence suggesting that failure of human 
cytotrophoblasts to mimic vascular adhesion receptors may be associated with pre-
eclampsia (Zhou et al., 1997). 
 
The developing fetus requires maternal immunoglobulins for future passive immunity 
protection from infection during the fetal and newborn period (Poole and Claman, 2004). 
Fc-γ receptors (FcγRI, FcγRII, and FcγRIII) expressed by fetal macrophages, are 
involved in catching immune complexes and protecting the fetus from rejection (Simister 
and Story, 1997). 
 
Two decades ago Wegmann and co-authors proposed that a shift from Th1 to Th2 is 
needed for a successful pregnancy (Wegmann et al., 1993). This concept may be seen  
clinically as about 70% of women experience some remission of rheumatoid arthritis 
symptoms (TH1 mediated) during pregnancy (Da Silva and Spector, 1992), while Th2 
immunity disorders flare during pregnancy and after birth (Wegmann et al., 1993). A 
variety of immune active molecules are known to play active role in fetus protection (IL-
4, IL-5) (Roberts et al., 2001, Wegmann et al., 1993) and growth and development of 
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trophoblast cells (IL-3, IL-10, GM-CSF, CSF-1) (Roth et al., 1996, Athanassakis et al., 
1987). 
 
Overall, current evidence indicates that anti-inflammatory cytokines at the maternal–
fetal interface facilitate survival of the fetus (Poole and Claman, 2004). It is still unknown 
to what extend the "cytokine orchestra" in utero influences subsequent breast milk 
immunological composition, although few studies have approached this topic (Jones et 
al., 2001, Thornton et al., 2002, Jones et al., 2002b, Power et al., 2002, Thornton et al., 
2003b, Thornton et al., 2003a, Thornton et al., 2009, Holloway et al., 2009). 
 
In this thesis I will focus on assessment of cytokines and growth factors in human BM 
and colostrum, rather than immunoglobulins. Growth factors are critical for infant 
intestinal development, and the role of cytokines in human BM, which potentially may 
skew infant immune responsiveness to Th1 or Th2 depending on their specific 
composition, is controversial. 
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1.9 Aims and Hypothesis 
1.9.1 Aims 
 To investigate associations of exposures with the levels of immune modulators in 
colostrum and mature breast milk and the relation to the development of atopy in 
infancy 
 To investigate the difference in colostrum and breast milk immune modulators 
depending on maternal and environmental factors 
 To establish correlations between the immune modulator levels in mother’s 
colostrum and breast milk and the prevalence of reported allergic events and 
disease during infancy 
 To ascertain if the immune modulator levels in colostrum and breast milk of 
atopic mothers are significantly different when compared with non-atopic mothers 
 
1.9.2 Hypothesis 
Primary hypothesis: In lactating women maternal and environmental factors influence 
colostrum and breast milk immune modulator composition. 
Secondary hypothesis: There is a relationship between the colostrum and breast milk 
composition and subsequent atopy, allergy, GI outcomes development and prevalence 
in children. 
Tertiary hypothesis: Lactating women can be grouped according to a specific 
immunological profile of their breast milk (lacto-type). 
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2 Materials and methods 
 
2.1  Study population and questionnaires 
2.1.1 Ethics and Research and Development (R&D) Approval 
The investigations and sample collection have been conducted following ethical 
approval by Ethics committee in three countries participating in the study: West London 
Rec 3 (UK) (Ref.number 10/H0706/32) and all paperwork has been completed 
according to the hospital R&D Joint Research Office (UK) (JROSM0072) policy; Ethical 
Committee of the Azienda Ospedaliera di Verona (Italy) (approval N°1288) and Moscow 
Institute of Paediatrics and Child Health of Ministry of Health of Russian Federation 
(Russia) (approval № 1-MS/11). 
 
2.1.2 Study design and subject recruitment 
In this prospective study (Figure 1) of human participants and their biological samples   
women and their newborn babies living in London from St.Mary's Hospital were 
recruited. Collaborations were established with the Moscow Institute of Paediatrics, 
Russia and the University of Verona, Italy which facilitated recruitment of additional 
participants overseas. 
 
Women and their newborn infants have been enrolled in the study from the postnatal 
unit and birth centre. Women who consented underwent an allergy skin prick test and 
answered a 10 minute questionnaire regarding their medical history, particularly for the 
presence of any allergic or other immunological disease or treatment. Their medical file 
has been reviewed to extract any relevant health information, and they have been 
asked to provide samples of breast milk as described below. 
CHAPTER 2: MATERIALS AND METHODS 
 
80 
 
All mothers have been given a pot in which they collected colostrum in the first 6 days 
and mature breast milk 4-6 weeks postpartum. 
Contact details have been recorded at the enrolment visit, and as the infant reached 6 
months age participants have been contacted to ask about the infant’s health. At 1 year 
of age we have begun follow-up assessments for allergy development which include 
skin tests on babies to egg, milk, peanut, cod and common aeroallergens. 
 
Figure 1 Study timeline 
 
 
 
 
 
 
Recruitment, questionnaire 1, maternal SPT and colostrum samples 
collection (2011-2012) 
4-6 weeks postpartum - mature Breast milk collection (2011-2012) 
6 months postpartum - questionnaire  2  (phone questionnaire) (2012) 
12 months postpartum - follow-up, questionnaire 3, baby check-up and 
babies SPT (2012-2013)
Colostrum and Breast Milk lab analysis for IL2, IL-4, IL-5, IL-10, 
IL-12, IL-13, IFN-γ, HGF and TGF-β 1, 2, 3 using Mesoscale Discovery 
multiplex plates (2013)
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2.1.3 Study Population 
Total of 398 mothers (London n=101, Moscow n=221, Verona n=76) voluntarily 
provided the samples and participated in this study. Demographic data of the 
participants presented in Table 4. 
 
All women were generally healthy, aged 19 to 50. None of them were taking any anti-
inflammatory medication at the time of enrolment. Colostrum was collected from all 
mothers during the first 6 days postpartum and mature breast milk in interval between 4 
to 6 weeks. All those mothers who have been able to produce and donate milk have 
been included into the study. 
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Table 4 Demographic data 
 London  
(all 
participants)  
London  
(colostrum 
analysed)  
Moscow  
(all  
participants)  
Moscow  
(colostrum 
analysed)  
Verona  
(all participants)  
Verona  
(colostrum 
analysed)  
Pos Maternal Allergy history (n) (%) 
(self-reported Allergy)        
Pos Maternal confirmed Atopy  
42/123 (34)  33/101 (33)  
 
33/92 (36) 
87/277 (31)  63/221 (29)  
 
23/156 (15) 
30/81 (37)  26/76 (34)  
 
9/41 (22) 
Maternal Age (Years)  
Mean (SD)  
 
32.4 (4.98)  
 
32.8 (4.78)  
 
29.3 (4.49)  
 
29.8 (4.45)  
 
37.6 (5.58)  
 
37.4 (5.38)  
Mode of Delivery (n) (%)  
Vaginal  
Caesarean Section  
 
84/123 (68)  
34/123 (28)  
 
69/100 (69)  
31/100 (31)  
 
232/277 (84)  
43/277 (15)  
 
188/219 (86)  
31/219 (14)  
 
64/81 (79)  
17/81 (21)  
 
63/76 (83)  
14/76 (17)  
Gestational Age (weeks)  
Mean (SD)  
 
40.0 (1.49)  
 
40.1 (1.45)  
 
39.5 (1.19)  
 
39.6 (1.03)  
 
39.1 (1.7)  
 
39.7 (1.52)  
Baby Gender (n) (%)  
Male  
 
61/123 (49)  
 
53/101 (53)  
 
144/277 (52)  
 
118/217 (54)  
 
43/83 (52)  
 
41/76 (54)  
Baby Weight (grams)  
Mean (SD)  
 
3455 (487.35)  
 
3527 (535.37)  
 
3509 (494.15)  
 
3526 (438.97)  
 
3319.5 (473.9)  
 
3328.3 (476.95)  
Previous Pregnancies (n) (%)  
Primigravida 
Multigravida  
 
53/123 (43)  
65/123 (53)  
 
42/97 (43)  
55/97 (57)  
 
99/277 (36)  
172/277 (62)  
 
70/217 (32)  
147/217 (68)  
 
33/81 (41)  
47/81 (58)  
 
26/75 (35)  
49/75 (65)   
Smoking (n) (%)  
Smokers  
Exposed to smoke  
 
4/123 (3)  
34/123 (28)  
 
3/99 (3)  
30/99 (30)  
 
13/277 (4.5)  
176/277 (64)  
 
11/213 (5)  
135/218 (62)  
 
3/81 (4)  
25/81 (31)  
 
3/76 (4)  
25/76 (33)  
Antenatal Medications (n) (%)  
Positive  
 
39/123 (32)  
 
34/100 (34)  
 
169/277 (61)  
 
131/212 (62)  
 
46/81 (57)  
 
56/76 (74)  
Antenatal Infections (n) (%)  
Positive  
 
17/123 (14)  
 
16/100 (16)  
 
73/277 (26)  
 
61/211 (29)  
 
30/81 (37)  
 
29/76 (38)  
Contact with Mould/Mildew (n) (%)  
Positive  
 
25/123 (20)  
 
22/95 (23)  
 
49/277 (18)  
 
38/218 (17)  
 
28/81 (35)  
 
28/76 (37)  
Time of colostrum collection (hours) 
Mean (SD)  
  
58.605 (33.2)  
  
50.03 (14.34)  
  
57.84 (26.52)  
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2.1.4 Inclusion and Exclusion Criteria 
Mothers had to meet inclusion criteria for the study in order to participate (Table 5). 
Table 5 Inclusion and exclusion criteria 
Inclusion Criteria Exclusion Criteria 
 
 Healthy term infants (full-term newborns) 
and their mothers, born at Birth centres 
and/or postnatal units of the hospitals in 
London, Verona and Moscow during the 
study period 
 
 Willingness to comply with the study 
procedures 
 
 
 
 
 Premature infants (<37 weeks) 
 Mothers taking immunosuppressive 
agents during lactation 
 Major birth defects 
 Admission to NICU 
 Intrauterine growth restriction (weight 
below 2nd centile) 
 Significant maternal or infant illness, 
such that participation will place an 
unreasonable burden on the mother or 
child e.g. maternal postnatal depression 
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2.2 Informed Consent 
All participants were given an information sheet to read. Mothers had about 60 minutes 
to think if they wished to participate in the study. They were also given time to ask 
questions. No pressure was exerted on the mothers to participate in the study. No 
financial benefits were offered or given, as the  study is completely voluntary. Those 
who signed informed consent were recruited into the study. 
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2.3 Questionnaires 
All participants were asked to fill in the questionnaire 1 (Appendix A) asking simple 
questions about their general health focusing on allergic conditions. At 6 months 
postpartum participants have been asked over the phone to answer simple questions 
from questionnaire 2 (Appendix B) on breastfeeding patterns and early development of 
their baby. At 12 months mothers have been asked to come into clinic with their babies. 
They have been asked questions according to questionnaire 3 (Appendix C) and 
measurements of maternal and child's height and weight have been performed 
alongside prick test in order to find out if baby is atopic to any of the allergens listed in 
questionnaire 3. 
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2.4 Clinical data collected 
 Maternal self-reported Allergy 
 Maternal Atopy (positive sensitivity according to skin prick test) 
 Paternal Allergy History 
 Country of the sample collection 
 Infant gender 
 Mode of delivery (Elective Caesarean/ Caesarean with labor/ Vaginal) 
 Maternal Gravidity 
 Maternal Parity 
 Home pet ownership 
 Mould at home 
 Baby's weight, length, head circumference at birth and at 12 months 
 Maternal BMI at 12 months 
 Gestation at birth in weeks 
 Maternal age (at infant birth) 
 Maternal medications (antibiotics) intake during pregnancy and first month of 
lactation 
 Maternal infections during pregnancy 
 Maternal smoking (active/passive) 
 Maternal alcohol consumption 
 Maternal educational level (at recruitment) 
 Mode of infant feeding – duration of exclusive breast feeding and any 
breastfeeding 
 Time of non-human mammalian milk introduction 
 Time of egg introduction 
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 Time of peanut introduction 
 Cumulative incidence of reflux and/or vomiting (moderate or severe) in 12 
months 
 Cumulative incidence of colic before 12 months 
 Self-reported eczema at 6 months 
 Eczema presence at 12 months 
 Sensitisation at 12 months – aeroallergen sensitization; food allergen 
sensitization; any allergen sensitisation 
 Self-reported Food intollerance/allergy at 6 months 
 Food Allergy at 12 months 
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2.5 Skin Prick Testing (SPT) 
After completing the questionnaire mothers were skin prick tested to common allergens. 
We used the following allergen solutions for Skin Prick Test (SPT): Histamine Positive 
Control, Negative Control, House Dust Mite (Dermatophagoides pteronyssinus), Cat fur 
(Felix domesticus), 5 Grasses mix, Ryegrass, Peanut, Hazelnut, Whole hen’s egg 
(Stallergens, SA 92160 Anthony, France) and Cow’s milk raw (ALK-Abello, Hǿrsholm, 
Denmark). Skin pricking was performed using lancets (ALK-Abello, Hǿrsholm, 
Denmark). 
 
A drop of solution was placed on the skin of the forearm and lancet pushed through the 
drop to prick the skin without drawing blood. After pricking the skin the remaining fluid 
has been removed using pieces of paper tissue. Results have been interpreted 10 -15 
minutes later, using a ruler to measure the wheal diameter. Mothers were considered to 
be sensitised if the positive control wheal was  ≥3 mm and any allergen wheals were ≥3 
mm or in event of a reaction to the negative control >greater than negative control. 
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2.6 Laboratory methods 
I used modern and ultra-sensitive kits in order to measure the levels of cytokines and 
growth factors. Three different plates have been used for laboratory analysis: 
 Th1/Th2 7-plex Human cytokine kit 
 HGF Human kit 
 TGF-beta 1,2,3 prototype Human kit 
An overview of technical information, relevant to the diagnostic tool is found in Table 6. 
 
I decided to use a median for LLOD from all plates to avoid bias in results. 
Table 6 Technical data of MesoScale 7-plex, TGF-beta and HGF plates 
Cytokine Average lower limit of 
detection (LLOD) 
Standard curve range 
IFN-γ 3,49  
 
 
0-2500 pg/ml 
IL-2 2,06 
IL-4 1,83 
IL-5 2,89 
IL-10 1,50 
IL-12p70 3,50 
IL-13 4,60 
HGF 73,00  
0-100000 pg/ml 
TGF-β 1 8,73 
TGF-β 2 265,00 
TGF-β 3 8,37 0-50000 pg/ml 
 
2.6.1 Electrochemiluminescence Multiplex 
For the study I used Human TH1/TH2 7-Plex Assay Ultra-Sensitive Kit (MesoScale 
Discovery). This diagnostic kit can provide a rapid method for measuring the levels of 
proteins within a single small-volume sample, which is very convenient. In the multiplex 
assay, an array of capture antibodies against different targets is patterned on distinct 
spots in the same well. 
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The Human TH1/TH2 7-Plex Assay detects IFN-γ, IL-2, IL-4, IL-5, IL-10, IL-12p70, and 
IL-13 in a sandwich immunoassay format (Diagram 1). The same principle applies to 
HGF and TGF-beta triplex plates. 
 
The plate was pre-coated with capture antibody on spatially distinct spots – antibodies 
for IFN-γ, IL-2, IL-4, IL-5, IL-10, IL-12p70, and IL-13. Using this kit I added the sample 
and a solution containing the labelled detection antibodies - anti-IFN-γ, anti-IL-2, anti-IL-
4, anti-IL-5, anti-IL-10, anti-IL-12p70, and anti-IL-13 labelled with an 
electrochemiluminescent compound, MSD SULFO-TAG™ label - over the course of one 
or more incubation periods. 
 
Analytes in the sample bind to capture antibodies immobilized on the working electrode 
surface; recruitment of the labelled detection antibodies by bound analytes completes 
the sandwich. After read buffer addition, which provides the appropriate chemical 
environment for electrochemiluminescence, the plate can be loaded into an MSD 
SECTOR® instrument (Figure 2) for analysis. 
 
Figure 2 MSD Sector Imager 2400 
 
Inside the SECTOR instrument, a voltage applied to the plate electrodes causes the 
labels bound to the electrode surface to emit light. The instrument measures intensity of 
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emitted light to afford a quantitative measure of IFN-γ, IL-2, IL-4, IL-5, IL-10, IL-12p70, 
and IL-13 present in the sample. 
 
 
 
 
 
  
 
 
Diagram 1 Diagram showing placement of analyte capture antibody. (Adapted from MDS 7-plex 
Manual) 
 
2.6.2  Total protein and sodium assesment in breast milk 
In an attempt to correct for time of collection influence on growth factor levels we used 
Abbott Architect Analyser in order to detect the levels of total protein and sodium in 
colostrum. The details of this method are present in the relevant section of chapter 5. 
 
 
 
 
 
 
 
 
Working Electrode  Capture Antibody 
MSD Multispot 96-Well 7 
Spot Plate 
1 
2 
3 
4 
7 
5 
6 
1- IFN-γ 
2- IL-2 
3- IL-4 
4- IL-5 
5- IL-10 
6- IL-12p70 
7- IL-13 
Analyte 
Labeled detection 
Antibody 
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2.7 Colostrum and breast milk samples analysis 
Samples from all three centres are stored at -80°C in the freezer in Paediatric Research 
Unit, St.Mary's hospital. After thawing samples were centrifuged at 1500 ×g for 15 
minutes at 4°C. The lipid layer is trimmed off with a pipette and aqueous fraction is 
analysed for immune modulators later on, according to protocols described below. 
2.7.1 Protocol for Th1-Th2 7-plex plate  
 
 
 
 
 
 
 
 
 
 
 
 
 
1Calibrator preparation:  
 
Calibrator for the Human TH1/TH2 7-Plex Assay is supplied at 400-fold higher 
concentration than the recommended highest calibrator. For Calibrator preparation it is 
needed to dilute the stock Calibrator 100-fold in Diluent 2. MSD recommends the 
preparation of an 8-point standard curve. Each well requires 25 μL of Calibrator. For this 
assay, MSD recommends 4-fold serial dilution steps and Diluent 2 alone for the 8th 
Addition of 25 μL/well of Diluent 2 and incubation incubation at room 
temperature with shaking for 30 minutes 
 
Washing plates 3 times with Phosphate Buffered Saline (PBS) 
Addition of 25 μL/well of a Calibrator1 for Standards and Samples and 
incubation at room temperature with shaking for 2 hours  
 
 
Washing plates 3 times with PBS  
 
 
Adding 25 μL/well 1X Detection Antibody Solution2 and incubate at 
room temperature with shaking for 2 hours  
 
 
Washing plates 3 times with PBS  
 
 
Adding 150 L/well 2X Read Buffer T and plate reading on SECTOR 
Imager 2400 after Read Buffer addition 
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point.  It is needed to prepare the diluted stock Calibrator by transferring 10 μL of the 
Human TH1/TH2 7-Plex Calibrator Blend (Ultra-Sensitive) to 990 μL of Diluent 2. Then 
it is needed to prepare the highest Calibrator point by transferring 50 μL of the Human 
TH1/TH2 diluted stock Calibrator to 150 μL Diluent 2. Repeat 4-fold serial dilutions 6 
additional times to generate 7 Calibrators. For 8th Standard just Diluent 2 is used as a 
zero Calibrator. 
 
2Detection Antibody Reagent preparation:  
MSD 7-plex Detection Antibody Blend is provided at 50X stock solution. The final 
concentration of the working Detection Antibody Solution should be at 1X. For each 
plate used it is needed to dilute a 60 μL aliquot of the stock Detection Antibody Blend 
into 2.94 mL of Diluent 3. 
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2.7.2 Protocol for HGF plate  
 
 
 
 
 
 
 
 
 
 
 
 
 
1Calibrator preparation:  
Each well requires 25 μL of Calibrator. Upon thawing of Human HGF Calibrator stock 
solution I vortex it and prepared the required concentrations by serially diluting 
Calibrator stock into Diluent 13. I followed a recommended Calibrator dilution procedure 
preparing an initial high Calibrator at100000 pg/ml by adding 10 μL of Human HGF 
Calibrator at 1 μg/mL to 90 μL Diluent 13, and then prepare six additional 1:10 serial 
dilutions. I used Diluent 13 alone as the zero Calibrator concentration as recommended. 
The resulting Calibrator levels are: 100000, 10000, 1000, 100, 10, 1, 0.1, and 0 pg/mL 
HGF. 
2Detection Antibody Reagent preparation:  
Each well requires 25 μL of Detection Antibody Reagent. I prepare 3 mL per plate 
combining in a 15 mL tube 2.97 mL of Diluent 8 and 30 μL of 100X SULFO-TAG Anti-
hHGF Antibody to reach a final concentration of 1X. 
Addition of 150 μL/well of Blocker A and incubation at room 
temperature for 1-2 hours 
Washing plates 3 times with PBS 
Addition of 25 μL/well of a Calibrator1 for Standards and Samples and 
incubation at room temperature with shaking for 2 hours  
 
 
Washing plates 3 times with PBS  
 
 
Adding 25 μL/well Detection Antibody Reagent2 and incubate at room 
temperature with shaking for 2 hours  
 
 
Washing plates 3 times with PBS  
 
 
Adding 150 L/well 1X Read Buffer T and plate reading on SECTOR 
Imager 2400 after Read Buffer addition 
 
 
Addition of 25 μL/well of Diluent 13  
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2.7.3 Protocol for TGF-β triplex plate  
 
 
 
 
 
 
 
 
 
 
 
 
 
1Calibrator preparation:  
Each well requires 25 μL of Calibrator. Upon thawing of Human TGF-β 1,2 and 3 
Calibrator stock solutions I vortex it and prepared the required concentrations by serially 
diluting Calibrator stock into Diluent 9. I prepare an initial highest Calibrator point by 
transferring 20 μL of the 1000000 pg/ml of Human TGF-β1 Calibrator stock, 20 μL of the 
1000000 pg/ml of Human TGF-β2 Calibrator stock, and 10 μL of the 1000000 of Human 
TGF-β3 Calibrator stock to 150 μL of Diluent 9, and then prepare six additional 1:4 
serial dilutions. I used Diluent 9 alone as the zero Calibrator concentration as 
recommended. 
 
 
 
Addition of 150 L/well of Blocker A and incubation at room temperature 
for 1 hour 
 for 1-2 hours or overnight at 4 oC.  
 
 
Add 150 L/well of Blocker A and incubate at room temperature for 1-2 
hours or overnight at 4 oC.  
 
Add 150 L/well of Blocker A and incubate at room temperature for 1-2 
hours or overnight at 4 oC.  
 
Add 150 L/well of Blocker A and incubate at room temperature for 1-2 
hours or overnight at 4 oC.  
 
Washing plates 3 times with PBS 
Addition of 25 μL/well of Diluent 7 
 
Addition of 25 μL/well of a Calibrator1 for Standards and Samples2 and 
incubation at room temperature with shaking for 2 hours  
 
 
Washing plates 3 times with PBS  
 
 
Adding 25 μL/well Detection Antibody Reagent3 and incubate at room 
temperature with shaking for 1 hour  
 
 
Washing plates 3 times with PBS  
 
 
Adding 150 L/well 1X Read Buffer T and plate reading on SECTOR 
Imager 2400 after Read Buffer addition 
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2Samples preparation for TGF-β triplex analysis:  
Analysis of samples for TGF-β 1,2 and 3 requires preliminary sample preparation. 
Samples should be treated and neutralised before they may be used in the assay 
analysis. 
 
 
 
 
 
 
 
3Detection Antibody Reagent preparation:  
Each well requires 25 μL of Detection Antibody Reagent. I Combine 60 μL of  50X 
SULFO-TAG Human TGF-β1 Detection Antibody, 60 μL of  50X Biotinylated Human 
TGF-β2 Detection Antibody, 60 μL of  50X Biotinylated Human TGF-β3 Detection 
Antibody, and 6 μL of 500 μg/mL SULFO-TAG Streptavidin into a final volume of 3 mL 
in Diluent 100. 
 
 
 
 
 
 
 
 
Addition of 20 μL of 1N HCl to 40 μL of colostrum or breast milk. Each 
sample should be well mixed. Then incubation at room temperature for 
10 minutes 
 for 1-2 hours or overnight at 4 oC.  
 
 
Add 150 L/well of Blocker A and incubate at room temperature for 1-2 
hours or overnight at 4 oC.  
 
Add 150 L/well of Blocker A and incubate at room temperature for 1-2 
hours or overnight at 4 oC.  
 
Add 150 L/well of Blocker A and incubate at room temperature for 1-2 
hours or overnight at 4 oC.  
 
Acidified samples neutralisation by addition of 20 μL of 1.2 NaOH, 0.5 
HEPES. Each sample should be well mixed. 
Each activated sample should then be diluted 2-fold with Diluent 9, 
adding 50 μL of activated sample to 50 μL of Diluent 9. 
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2.7.4 Reagents used 
All reagents used in experiments are listed in Table 7. 
Th1/Th2 7-Plex HGF TGF-β1,2,3 
Diluent 2 and Diluent 3 Diluent 8 and Diluent 13 Diluent 7, Diluent 9 and  
Diluent 100 
Human Th1/Th2 7-plex 
Calibrator blend  
(for Ultra-Sensitive plates) 
Human HGF Calibrator Human TGF-β1 Calibrator 
Human TGF-β2 Calibrator 
Human TGF-β3 Calibrator 
SULFO-TAG Detection 
Antibody blend 
SULFO-TAG Anti-hHGF 
Antibody  
SULFO-TAG TGF-β1 
Detection Antibody 
Biotinylated TGF-β2 Detection 
Antibody 
Biotinylated TGF-β3 Detection 
Antibody 
PBS 
Read Buffer T 
 Blocker A 
Table 7 Reagents used in laboratory experiments 
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2.7.5 Immune active molecules in Breast milk and maternal blood serum 
When breast milk immune profile is analysed a reasonable question arises, whether 
immune molecules present in breast milk are just a mirror of those cytokines and growth 
factors found in maternal serum. I supervised work done by Dr. Gabriella Feketea for 
her MSc in Allergy thesis; she collected paired colostrum (day 2), transitional milk 
(day8) and maternal serum samples from twenty healthy women from Amaliada, 
Greece, who had given birth by caesarean section to term neonates and breastfed their 
infants. Her data (Table 8) suggests that neither the level of cytokines, nor growth 
factors concentration correlate with levels present in the maternal blood serum 
(Feketea, 2014).  
Table 8 Correlations between breast milk and serum for different mediators, in day 2 and day 8 
samples 
 Day 2 Day8  
 Breast milk: Serum Breast milk: Serum 
 r p r p 
HGF 0.31 0.19 -0.01 0.96 
IL-2 -0.55 0.11 0.19 0.61 
IL-4 0.16 0.66 0.54 0.11 
IL-5 -0.13 0.73 0.36 0.31 
IL-10 -0.006 1 0.36 0.31 
IL-12p70 -0.19 0.61 -0.09 0.81 
IL13 0.52 0.13 0.55 0.10 
IFN-γ 0.66 0.04* -0.12 0.76 
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2.8 Statistical analysis 
Statistical analysis methods varied for different outcomes and are described in detail in 
relevant sections of the result chapters. 
 
In principle, the following methods were used: 
 
Chapter 3: Standard descriptive statistics. Non-parametric tests were used as data was 
not normally distributed to compare independent observations of different populations 
for unadjusted analyses. Mixed-effect regression model were used for the data analysis. 
 
Chapter 4: Spearman rank coefficient have been calculated in order to establish 
correlations between the growth factors level and time of collection. 
 
Chapter 5: Descriptive statistics, cross tables, correlation and statistical tests were 
performed. "Best" statistical model using GL Multi and LASSO for each health outcome 
was used. 
 
Chapter 6: Principal component analysis of environmental and maternal data; colostrum 
immune profile and infant health outcomes have been performed. 
 
All results have been adjusted to Parity, Maternal Atopy, Maternal age, Site (Country) of 
collection, Mode of delivery labour versus no labour, Mould presence at home, Pets at 
home or regular contact; Exposure to tobacco smoke ie smoker or living in household 
with smoker or self-reported passive smoker, at recruitment; At least 1 self-reported 
maternal infections during pregnancy; Maternal diet - fish intake at least once per week 
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versus less often; daily fresh fruit versus less often; daily probiotic versus none/less 
often. 
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3 Determinants of growth factor levels and cytokines detectability in 
colostrum and breast milk of mothers from Moscow, London and 
Verona   
 
3.1 Abstract  
Background: Cytokines and growth factors in colostrum and breast milk (BM) play an 
important role in infant immunity maturation and potential beneficial effects include 
protection against infections and atopy/allergy development. Breast milk composition 
varies between populations, but the environmental and maternal factors influencing this 
are still not clear. I examined the relationship between maternal and environmental 
factors and levels of immune modulators in colostrum and breast milk of women from 3 
separate international cohorts. 
Objectives: To examine whether environmental and/or maternal factors influence levels 
of immune active components in colostrum and breast milk. 
Methods: A prospective cohort study of mother/infant pairs in London (N=105), 
Moscow (N=200) and Verona (N=80).  Participants underwent allergy testing, and 
questionnaire interview. Colostrum samples (days 0-6) and Mature Breast Milk (4-6 
weeks) were analysed in duplicate at Imperial College London using 
electrochemiluminescence (Meso Scale Discovery®) for level of TGF-β 1,2,3; HGF, IL2, 
IL4, IL5, IL10, IL12, IL13, IFN-γ. Analyses used mixed models adjusting for study site, 
mode of delivery, parity, maternal age, maternal diet, maternal atopy, smoking 
exposure, contact with pets, mould exposure and time of sampling to identify 
determinants of human milk composition. All P values were adjusted for multiple 
comparisons using mixed models. 
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Results:  There was an inverse correlation between time after birth and all growth 
factors levels in colostrum:  HGF (p<0.001); TGF-β1 (p=0.01); TGF- β3 (p<0.001). HGF 
was lower in the colostrum/milk of Verona mothers (Beta=-0.63, p<0.001), and TGFβ2 
and 3 were higher in London mothers (Beta from 0.33 to 0.74, p<0.001). TGFβ1 was 
higher in London for colostrum only (Beta=0.27, p=0.01). Primiparous mothers had a 
trend to higher HGF (p=0.05), TGF-β3 (p=0.06) in colostrum only. Fish consumption at 
least once a week was associated with lower concentrations of TGFβ1 (p=0.04). Ability 
to detect IL2, IL5, IL10, IFN-γ and IL13 in colostrum negatively correlated with the time 
of colostrum collection (p from 0.04 to <0.001), with a similar trend for IL4 and IL12 
(p=0.22 and p=0.12 respectively). IL5 was less detectable in mothers having infections 
during pregnancy (p=0.04) 
Conclusions: Growth factor levels in colostrum drop rapidly after birth so assessment 
must be corrected for time after birth in future studies. There were similar trends with 
cytokines in colostrum, and detection diminishes over time. Results of this study, 
combined with existing knowledge provide additional data to highlight a degree of 
difference between colostrum and mature milk. It seems that colostrum is almost a 
"different substance"  but larger cohorts needed to address this question in a future 
research. Cytokines in colostrum and BM are detected in a very low concentration, 
close to the lower level of detection for most of the samples, which questions their 
biological importance at this early stage of infant development. There were significant 
differences between breast milk immune profiles of mothers living in different countries 
but these cannot be explained by variations in mode of delivery, parity, maternal age, 
maternal diet, maternal atopy, smoking pet or mould exposure between sites. Further 
work is needed to understand the reasons for variations between sites in human milk 
composition. 
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3.2 Introduction  
There have been few attempts to investigate relationships between maternal and 
environmental factors and immune active profiles of BM. Data from a variety of studies 
suggest that factors, such as country of maternal origin, diet, exercise, exposure to 
smoke or farming environment in early life may influence colostrum and BM constituents 
(Hoppu et al., 2012, Urwin et al., 2012, Amoudruz et al., 2009, Holmlund et al., 2010, 
Peroni et al., 2010, Tomicic et al., 2010, Striker et al., 2004, Bottcher et al., 2000, Laiho 
et al., 2003, Prokesova et al., 2006, Rigotti et al., 2006, Marek et al., 2009, Sidor et al., 
2008, Snijders et al., 2006, Bottcher et al., 2008, Boyle et al., 2011, Prescott et al., 
2008, Rautava et al., 2002, Kuitunen et al., 2012, Zanardo et al., 2005). There is still no 
certainty which particular factors influence specific immune active molecules and how 
they may affect infant development long-term.  
Inverse relationships between the risk of atopic diseases, associated with T-helper 
lymphocyte type 2 (TH2) immune response, and indicators of early-life exposure to 
infections, such as high birth order or sibship size, early attendance at day care, and 
early exposure to pets or other animals are well described (Strachan, 2000). The 
“hygiene hypothesis ” remains one of the most popular current hypotheses on early-life 
exposures and allergy risk (Strachan, 1989). It has been suggested that farming 
environment (Peroni et al., 2010), higher bacterial exposure (Tomicic et al., 2010) or 
maternal country of origin (Holmlund et al., 2010) may have a significant impact on BM 
immune composition , and such effects on BM composition may be an important 
pathway through which early variations in microbial exposures influence risk of allergy 
development. 
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This study aimed to prospectively investigate the relationship between maternal and 
environmental factors and levels of HGF, TGFβ 1,2,3 and detectability of TH1 and TH2 
cytokines using colostrum and BM samples collected from birth cohorts in three 
countries, representing UK, continental Europe and eastern Europe respectively.  
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3.3 Methods 
3.3.1 Statistical analysis 
Maternal factors and characteristics of cytokines or grown factors were summarised 
using standard descriptive statistics. As response variables were not normal distributed, 
non-parametric tests such as paired Mann–Whitney U test, was used to compare 
independent observations of different populations for unadjusted analyses. Univariate 
analysis have been performed prior to multivariate approach. Data from univariate 
analysis is not presented in this thesis as these data was a preliminary step for the 
multivariate analysis and does not provide any definitive and accurate information when 
not adjusted for a number of potential confounders.  
 
Since concentration of grown factors and cytokines were assayed twice for a number of 
specimens, mixed-effect regression model have been used to account for the absence 
of independence between those two measures and to manage a broad range of 
variable types. Model selection was a key part of the analysis, this aimed to choose a 
parsimonious model from a large set of candidate statistical models, therefore 
compared model selection methods based on major approaches such as Akaike 
information criterion (AIC) and Bayesian information criterion (BIC). These criteria 
represent a measure of the relative quality of statistical models for a given set of data. 
(Burnham and DR, 2004). 
 
Difference between group effects (maternal and environmental factors) as well as within 
subject effects were evaluated using the following multilevel mixed-effect regression 
model: 
log⁡(𝑦ik) = β0 + μ0i + β1(Time)ik + β2X2ik +⁡…+⁡βpXpik + eik 
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where log⁡(𝑦ik)⁡is the log of concentration level of each cytokine investigated for the i
th 
subject on the kth time of measurement; β0 is the overall intercept; β1 is the regression 
coefficient for time; β2…βp are the regression coefﬁcients for the covariates, these are 
ﬁxed effects and included both maternal and environmental variables; μ0ik⁡is the random 
intercept at the subject level, and eik is the residual error. 
 
To optimize power, the analysis evaluated the relationship between concentrations of 
grown factors and both environmental and maternal exposures by fitting the models 
based on prior knowledge. All tests were two-sided, and P<0.05 were considered 
significant. 
 
For the purpose of this analysis, data on cytokines are presented as detectable or 
undetectable. Upon statistical analysis it became evident that this approach provides 
much clearer results and facilitates good quality statistical analysis. 
 
Factors analysed and used as a covariates in mixed models were: Parity, Maternal 
Atopy, Maternal age, Site (Country) of collection, Mode of delivery - labour versus no 
labour, Mould presence at home, Pets at home or regular contact; Exposure to tobacco 
smoke ie smoker or living in household with smoker or self-reported passive smoker, at 
recruitment; At least 1 self-reported maternal infection during pregnancy; Maternal diet - 
fish intake at least once per week versus less often; daily fresh fruit versus less often; 
daily probiotic versus none/less often. 
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3.4 Results  
3.4.1 Population characteristics 
Mothers from London had the highest rates of allergic sensitisation in comparison to 
Verona and Moscow (p<0.01), with more than a third having a positive SPT result to 
one or more allergen. Median age of women from Verona was higher than in both 
Moscow and London. Rate of caesarean mode of delivery was highest in London with 
more than 30% of women from UK having c/section. Mothers from Moscow were 
exposed to smoke during pregnancy significantly (p<0.01) more often than women from 
London and Verona. Mean colostrum collection time was earlier in Moscow in 
comparison to London and Verona. Detailed demographic statistic on our cohort is 
presented in Table 4. 
3.4.2 Influence of time on colostrum and breast milk immune composition 
Among the environmental and maternal factors analysed, the time of colostrum 
collection postpartum had the most significant influence on growth factors (HGF, TGFβ1 
and TGFβ3) level and cytokine (IL2, IL5, IL10, IFNγ) detectability with no significant 
influence but similar trends for TGFβ2, IL4, IL12 and IL13 ( 
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Table 10). Levels of HGF, TGFβ1, 2 and 3 were significantly (p<0.001 for every growth 
factor) higher in colostrum in comparison to BM. IL10 was more commonly detected in 
colostrum than  in BM (p<0.001) with an opposite trend for IL4 (p=0.04) and IFNγ 
(p<0.001) and no significant difference for other cytokines ( 
 
 
 
 
 
 
 
Table 10).  
3.4.3 Other influences on colostrum and breast milk immune composition 
There was a significant influence of country of residence on growth factors 
concentration with HGF to be lowest in the colostrum/milk of Verona mothers (Beta=-
0.63, p<0.001), whilst TGFβ2 and 3 were higher in London mothers (Beta from 0.33 to 
0.74, p<0.001) and TGFβ1 was higher in London for colostrum only (Beta=0.27, p=0.01) 
(Table 9). 
Significantly higher levels of HGF (p=0.05) were present in primiparous mothers 
compared with multiparous, with a similar trend for TGFβ3 (p=0.07). 
Mothers who reported fish consumption less than once a week had significantly higher 
levels of TGFβ1 (p=0.03) when compared with women having fish more often. 
Women reporting infections during pregnancy had detectable IL5 less often in 
comparison to mothers reporting no antenatal infections (p=0.04). 
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Levels of HGF, TGFβ1, 2 and 3 were significantly (p<0.001 for every growth factor) 
higher in colostrum in comparison to BM. IL10 was more detectable in colostrum than  
in BM (p<0.001) with an opposite trend for IL4 (p=0.04) and IFNγ (p<0.001). Information 
on changes from colostrum to BM provided in Table 11. 
All detailed data on mixed models of environmental and maternal factors influencing 
growth factors level and cytokine detectability are presented in Appendix D.
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Table 9 Concentration (pg/ml) of Growth Factors in Colostrum and Breast Milk. Exposures significantly influencing Growth Factors level in Colostrum 
and Breast Milk are presented in the right column.  
All analyses were adjusted to the following factors: Parity, Maternal Atopy, Maternal age, Site (Country) of collection, Mode of delivery - labour versus no 
labour, Mould presence at home, Pets at home or regular contact; Exposure to tobacco smoke ie smoker or living in household with smoker or self-
reported passive smoker, at recruitment; At least 1 self-reported maternal infection during pregnancy; Maternal diet - fish intake at least once per week 
versus less often; daily fresh fruit versus less often; daily probiotic versus none/less often. 
 Median (IQR) pg/ml Important growth factor level difference 
 between the groups 
Colostrum 
HGF 2055.31 (964.825 - 6239.798) UK > Italy 
β=0.599 ; SE=0.152; p<0.001 
Russia > Italy 
β=0.609; SE=0.141; p<0.001 
Primiparous > Multiparous 
β=0.174; SE=0.090; p=0.05 
TGFβ1 731.534 (505.266 - 1142.029) UK > Italy 
β=0.276 ; SE=0.094; p=0.01 
Fish consumption  
< Once a week > ≥ Once a week 
β=0.152; SE=0.072; p=0.034 
TGFβ2 42209.88 (23847.86 - 98597.95) UK > Russia 
β=0.328; SE=0.119; p=0.016 
UK> Italy 
β=0.393; SE=0.128; p=0.006 
TGFβ3 1535.081 (847.555 - 3395.457) UK > Russia 
β=0.342; SE=0.118; p=0.010 
UK > Italy 
β=0.741; SE=0.130; p<0.001 
Russia > Italy 
β=0.398; SE=0.134; p=0.008 
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Breast Milk 
HGF 784.041 (508.175 - 1189.644) Primiparous > Multiparous 
β=0.174; SE=0.090; p=0.05 
TGFβ1 493.514 (375.595 - 653.208) Russia > UK 
β=0.396; SE=0.126; p=0.005 
Russia > Italy 
β=0.495; SE=0.128; p<0.001 
TGFβ2 14040.62 (10080.95 - 27262.09) UK > Russia 
β=0.328; SE=0.119; p=0.016 
UK> Italy 
β=0.393; SE=0.128; p=0.006 
TGFβ3 279.41 (183.132 - 395.768) UK > Russia 
β=0.342; SE=0.118; p=0.010 
UK > Italy 
β=0.741; SE=0.130; p<0.001 
Russia > Italy 
β=0.398; SE=0.134; p=0.008 
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Table 10 Detectability of Th1 and Th2 Cytokines in Colostrum and Breast Milk and exposures influencing cytokines detectability.  
All analyses were adjusted to the following factors: Parity, Maternal Atopy, Maternal age, Site (Country) of collection, Mode of delivery - labour versus no 
labour, Mould presence at home, Pets at home or regular contact; Exposure to tobacco smoke ie smoker or living in household with smoker or self-
reported passive smoker, at recruitment; At least 1 self-reported maternal infection during pregnancy; Maternal diet - fish intake at least once per week 
versus less often; daily fresh fruit versus less often; daily probiotic versus none/less often. 
Immune 
Modulator 
Colostrum Breast Milk Factors influencing cytokines detectability 
IL2 Detectable - 49/342 (14%) Detectable - 38/190 (20%) No significant influence 
IL4 Detectable - 35/342 (10%) Detectable - 30/190 (16%) No significant influence 
IL5 Detectable - 77/342 (23%) Detectable - 27/190 (14%) Antenatal infections 
OR 0.49 (95% CI 0.25 - 0.98) 
IL10 Detectable - 225/342 (66%) Detectable - 69/190 (36%) No significant influence 
IFNγ Detectable - 66/342 (19%) Detectable - 92/190 (48%) No significant influence 
IL12 Detectable - 63/342 (18%) Detectable - 31/190 (16%) No significant influence 
IL13 Detectable - 86/342 (25%) Detectable - 58/190 (31%) No significant influence 
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Table 11 Time of colostrum collection postpartum influence on concentration of growth factors and detectability of cytokines in colostrum and changes 
from colostrum to breast milk.  
All analyses were adjusted to the following factors: Parity, Maternal Atopy, Maternal age, Site (Country) of collection, Mode of delivery - labour versus no 
labour, Mould presence at home, Pets at home or regular contact; Exposure to tobacco smoke ie smoker or living in household with smoker or self-
reported passive smoker, at recruitment; At least 1 self-reported maternal infection during pregnancy; Maternal diet - fish intake at least once per week 
versus less often; daily fresh fruit versus less often; daily probiotic versus none/less often. 
 
Immune 
Modulator 
Difference between Colostrum and Breast Milk Time of colostrum collection influence 
HGF Conc. Col > BM β=1.35; p<0.001** β=-0.01; p<0.001** 
TGFβ1 Conc. Col > BM β=0.93; p<0.001** β=-0.003; p=0.01* 
TGFβ2 Conc. Col > BM β=1.12; p<0.001** β=-0.003; p=0.12 
TGFβ3 Conc. Col > BM β=2.03; p<0.001** β=-0.011; p<0.001** 
IL2 Detect. BM > Col β=0.32; p=0.30 β=-0.02; p=0.02* 
IL4 Detect. BM > Col β=0.72; p=0.04* β=-0.01; p=0.22 
IL5 Detect. Col > BM β=0.54; p=0.09 β=-0.03; p<0.001** 
IL10 Detect. Col > BM β=1.66; p<0.001** β=-0.02; p=0.001** 
IFNγ Detect. BM > Col β=1.20; p<0.001** β=-0.012; p=0.04* 
IL12 Detect. Col > BM β=0.11; p=0.73 β=-0.01; p=0.12 
IL13 Detect. BM > Col β=0.09; p=0.72 β=-0.01; p=0.09 
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3.5 Discussion 
It is evident that breast milk composition may be influenced by a number of maternal 
and environmental factors. There are many reasons such as small cohort size, limited 
number of immune modulators assessed, heterogeneity of the population, and 
difference in methodology which create uncertainty and controversy as to which factors 
may suppress or stimulate particular cytokine secretion into breast milk. 
This study is one of the first which attempts to assess breast milk samples from different 
countries distinct in population genetics, diet and environmental influences. I have 
confirmed earlier findings of significant differences in milk composition between sites, 
but was not able to explain these differences by maternal or environmental factors. 
Further work is needed to understand differences between sites in human milk 
composition, and the influence that such variations have on infant health. In particular, it 
would be important to assess maternal diet in more detail as this has previously been 
suggested to influence BM composition especially the lipid fraction (Urwin et al., 2012). 
It has been previously shown that breast milk  immune active constituents differ 
between mothers living in different environments in two cohorts from neighbour 
populations, although with significant differences in lifestyle, environment, and allergy 
prevalence (Tomicic et al., 2010). A recent study by Orivuori and co-authors attempted 
to address differences in BM composition collected in a few European Union countries 
(Orivuori et al., 2014). This study has assessed how maternal and environmental factors 
influenced immune active molecule concentrations in breast milk of mothers from an 
international cohort recruited in UK, Mediterranean region and Eastern Europe.  This 
has allowed evaluation of country of residence influence, taking into account multiple 
environmental and maternal factors. 
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3.5.1 Parity 
It is a well established fact that family size and birth order are related to an allergy 
prevalence (Strachan, 1989). It was originally used to explain what has become known 
as the hygiene hypothesis. However, it has not been established if birth order influences 
breast milk composition and thus affects immune system maturation and subsequent 
risk of allergy development. A number of studies suggest that "in utero" environment 
changes with each subsequent pregnancy. Karmaus et al. stated that there may be a 
decreasing risk of having raised cord blood IgE levels with increasing birth order 
(Karmaus et al., 2001), as Bergmann et al. found earlier that IgE levels decreased with 
increasing parity (Bergmann et al., 1995). 
 
The risk of scleroderma and systemic sclerosis increases with increasing birth order, 
which is the reverse of the reported risk associated with allergic and atopic disorders 
(Cockrill et al., 2010). While this might be assumed to be explained mechanistically by 
the mutual exclusivity of Th1 and Th2 responses it fails to explain how early childhood 
exposure to multiple infectious agents and/or other mechanisms changes the risks of 
autoimmune disease. 
 
Grulich et al. studying risk of non-Hodgkin lymphoma in relation to parity (Grulich et al., 
2005) found that first-born children had an approximately fifty percent reduction in non-
Hodgkin lymphoma risk compared with fourth or later-born children. Another study done 
by Becker and co-authors is consistent with earlier observations and showed an inverse 
relationship between atopic disorders and risk of lymphomas (Becker et al., 2007). 
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Various explanations of the parity influence on atopic diseases and other immune 
related conditions development have been proposed. Cullinan suggested that variations 
in constituents of breast milk (Cullinan, 2006) may be related to birth order or family size 
and could be due to different exposures to domestic allergens (Atkinson et al., 1999). 
Rangaraj and Doull assumed that immunological shift from Th1 to Th2 during 
pregnancy takes place because of the hormonal factors (WHO/UNICEF, 2003) and has 
less relation to “hygiene”. I assume that breast milk composition may be also partially 
responsible for this phenomenon assuming that each subsequent pregnancy and birth 
changes breast milk immune profiles. 
 
Wegienka and co-authors proposed that pregnancy “educates” the immune system in a 
way that persists into the postpartum period and that these pregnancy-associated 
immune changes may affect the immune status of women in their subsequent 
pregnancies. They found that change in percentages of Treg cells may vary depending 
on the number of previous births (Wegienka et al., 2011). Lagadari and co-authors 
demonstrated that parity influences the number of placental macrophages, finding much 
higher levels in multiparous women (Lagadari et al., 2004). Assumed that maternal 
immunology changes with each pregnancy it is possible that it also influences the 
immunological composition of breast milk and consequently allergy development in 
children. 
Some studies have demonstrated that parity may have a significant effect on milk 
composition, with primiparous women having higher concentrations of protein and fat, 
and multiparous women having a reduction in the content of major components in milk 
with each subsequent pregnancy (Bachour et al., 2012). The effect was most prominent 
in the group of women who had third and fourth babies, increasing lipid content by  
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103% and 72% respectively. Unfortunately, sample size of this study was very small 
and doesn't allow firm conclusions. 
Significantly higher neutrophil – macrophage cells count in colostrum was observed with 
increase of parity (Islam et al., 2006). In the earlier works some authors suggested that 
this difference may be explained by specific anti-fetal cell-mediated priming as a result 
of repeated pregnancy (Narula et al., 1982). 
Kim and co-authors reported increased IL-4 levels in maternal serum of primigravida 
and suggested an inverse relationship between parity and the degree of Th2 
polarization. This may explain, in part, allergic prevalence with different birth order  
independent from the hygiene hypothesis (Kim et al., 2008),unless the presence of 
young children with frequent infections in the house-hold of pregnant women moderates 
their Th2 activity. Groer et al. previously found that IL-10 showed big differences in 
relation to parity, with the highest levels found in primiparas and was undetectable in the 
breast milk of mothers with parity higher than two (Groer and Shelton, 2009). 
Primiparous mothers with less previous live births had higher concentration of IL7 in 
their BM when compared with multiparous women (Walter 2007). 
Amoudruz et al. found that a larger number of previous pregnancies was associated 
with significantly lower levels of sCD14 and IL-8 (Amoudruz 2009) with parity having a 
trend towards being a weak negative predictor for sCD14 and TGF-b2 (Urwin 2012). My 
results show similar patterns for HGF and TGF-β3, with significantly higher levels of 
HGF with a similar trend seen for TGF-β3 in colostrum of primiparous mothers in 
comparison to multiparous. 
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Data from other studies suggests that parity does not influence BM composition 
significantly (Urwin et al., 2012, Ismail et al., 2013). In agreement to these results I 
failed to highlight any significant difference in detectability of any cytokine in colostrum 
and breast milk of primiparous and multiparous women. 
My data (Figure 3) in conjunction with results of other studies (Table 12) suggests that 
there is a trend in higher levels of certain markers in primiparous mothers which may be 
an additional mechanism to explain decreased allergy risk with an increase of birth 
order. Pregnancy is a significant challenge to the maternal immune response as 
tolerance to the fetus is crucial for a successful outcome. Current hypothesis suggests 
that Th1 to Th2 shift (Saito et al., 1999, Saito and Sakai, 2003) provides in utero 
defense for the fetus and possibly the first pregnancy primes the maternal immune 
response such that it is more adaptable for  subsequent pregnancies. 
 
It is still poorly understood what happens with maternal immunity with an increased 
number of pregnancies. No data on how Th1/Th2 ratio varies between multiparous and 
primiparous mothers during pregnancy are available (Luo et al., 2007). More work is 
needed to assess parity/gravidity influence on maternal immunity during ante and 
postnatal periods. 
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Figure 3 Parity influence on HGF concentration (pg/ml) in colostrum and breast milk, mean (CI) is 
shown in the figure. Multiparous mothers have lower levels of HGF in their colostrum (p=0.05) but 
not breast milk. 
 
  
Table 12 Outcomes of the studies which accounted for parity influence on Breast Milk 
composition  
Study Outcomes 
Walter 
2007 
↑IL7 Primiparous 
Groer 2009 no significant influence on IL1a, IL1b, IL2, IL4, IL5, IL6, IL7, IL8, IL12, IL13, IL15, 
IL17, Ip10, TNFα, IFNγ, Eotaxin, MCP1, MIP1a, GMCSF 
↑IL10 Primiparous 
Amoudruz 
2009 
no significant influence on IL-1b, IL-6, IL-10, IL-12p70,TNF 
↑sCD14 and IL-8 in Primiparous 
Urwin 
2012 
no significant influence on sCD14, TGF-β1, TGF-β2, sIgA and fatty acids 
Ismail 
2013 
no significant influence on TGF-β1, sCD14 and total IgA 
Our data no significant influence on concentration of TGFβ 1 and 2, detectability of IL2, IL4, 
IL5, IL10, IL12, IL13, IFN-γ 
↑HGF and a trend for ↑TGFβ3 in Primiparous 
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3.5.2 Maternal Atopy 
Existing data suggests that breastfeeding has a certain protective effect against allergy 
with the most prominent effect seen on asthma development (Gdalevich et al., 2001b, 
Dogaru et al., 2014), in both allergic and non-allergic mothers, but it is still unclear which 
immunological factors within breast milk are responsible for this. At present we do not 
possess strong evidence on allergic maternal status influence on qualitative and 
quantitative immunological constituents in human breast milk. Does maternal atopy lead 
to changes within BM composition copying similar patterns seen in serum? Few 
attempts have been undertaken in order to assess allergy/atopy influence on BM 
immunological profile. Studies done up to date have produced conflicting results in 
regards to both immunological profile and PUFA composition. 
Women with a history of eczema and respiratory allergy had lower levels of PUFA's as 
well as lower ratio of long-chain n-3 PUFAs/n-6 PUFAs in their breast milk compared 
with non-allergic (Johansson et al., 2011). Two other studies found no influence of 
maternal atopy on PUFA composition (Laiho et al., 2003, Lauritzen et al., 2006). 
Snijders et al. found higher sCD14 levels, in atopic mothers (Snijders et al., 2006). 
Savilahti et al. reported no difference in total IgA concentration, sCD14 and cow's milk-
specific IgA levels between allergic and non allergic mothers (Savilahti et al., 2005). 
No difference in TGF-β2 (Bottcher et al., 2000, Savilahti et al., 2005, Prokesova et al., 
2006, Kondo et al., 2011) and TGF-β1 (Snijders et al., 2006, Marek et al., 2009, Ismail 
et al., 2013, Orivuori et al., 2014) levels between allergic and non-allergic mothers have 
been reported in a number of studies done in different parts of the world. Data from a 
single study suggested allergic mothers have lower levels TGF-β2 in BM compared with 
non-allergic (Laiho et al., 2003). Rigotti and co-authors reported the same trend for  
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TGFβ1 levels in mature milk of allergic mothers (Rigotti et al., 2006) while Urwin et al., 
in contrast, found higher both, TGF-β1 and TGF-β2 concentrations in the milk of allergic 
women (Urwin et al., 2012). The limitation of both studies was small sample size. 
In a study done in Czech Republic allergic mothers had substantially higher IL-10 
concentration in 3 months BM and reduced levels of IL10 and IL-13 in 6 months BM 
comparing to healthy mothers (Prokesova et al., 2006). In contrast other studies 
revealed no significant difference in the levels of IL-10 in BM (Rudloff et al., 1999, Laiho 
et al., 2003, Rigotti et al., 2006, Snijders et al., 2006, Marek et al., 2009, Kuitunen et al., 
2012). Recent data from the study done by Linnamaa et al. suggests that mothers 
having atopic dermatitis have significantly reduced levels of IL-10 in their BM compared 
to healthy women (Linnamaa et al., 2013) adding more uncertainty to the topic. 
Bottcher et al., in a small cohort recruited in Sweden (Bottcher et al., 2000), observed 
higher IL-4 concentrations in colostrum but not in mature milk but no changes for IL-5, 
IL-6, IFN-γ. IL-4 was detectable more often in the colostrum of allergic mothers in a 
study done in Poland (Marek et al., 2009). 
In a recent study done in Japan levels of 26 cytokines, including IL-2, IL-4, IL-5, IL-6, IL-
10, IL-12, IL-13 and IFN-γ did not differ between breast milk from allergic and non-
allergic mothers (Ochiai 2013). 
I did not find any relationship between the levels of growth factors and/or detectability of 
cytokines and maternal allergy (Table 13). Analysis of data from other studies  suggest 
that there is no obvious trend in BM composition of allergic mothers compared to non 
allergic.  
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Differences observed in some studies may be explained by analysis simplification and 
most probably would disappear if adjusted for appropriate confounders. 
Table 13 Outcomes of the studies accounted for atopic status influence on Breast Milk 
composition. 
Study Outcomes 
Rudloff 1999 no significant influence on IL4, IL10 and IFN-γ 
Bottcher 2000 no significant influence on IL-5, IL-6, IL-10, IL-13, IFN-γ and TGF-β  
↑IL-4 in Allergic mothers  in colostrum but not in mature milk 
Laiho 2003 no significant influence on TNF-α , IL-4, IL-10, prostaglandin E2, cysteinyl 
leukotrienes and fatty acids  
↓TGFβ2 in BM Allergic mothers  
Savilahti 2005 no significant influence on IgA  TGF-β1, TGF-β2, sCD14 and cow's milk-
specific IgA levels  
Ustundag 2005 no significant influence on IL-1β, IL-2, IL-6, TNF-α 
↑IL-8 in BM of Allergic mothers 
Prokesova 2006 no significant influence on IL-4, IL-5, IL-6, IFN-γ, TGF-β 
Allergic mothers ↑IL-10 in 3 month BM 
Rigotti 2006 no significant influence on IL-10 
↓TGFβ1 in BM of Allergic mothers 
Snijders 2006 no significant influence on IL-12, TGF-β1, IL-10  
↑sCD14 levels in Atopic mothers 
Johansson 2011 ↓ PUFAs in BM of Allergic women 
Kondo 2011 no significant influence on TGFβ2 
Urwin 2012 ↑ TGF-β1 and TGF-β2 in early BM 
Kuitunen 2012 no significant influence on IgA, casein, β-lactoglobulin, ovalbumin, IL10 
↓TGFβ2 in BM ↑ IgA to casein in BM 
Ismail 2013 ↑sCD14 in Allergic mothers 
Linnamaa 2013 ↓IL-10 in BM of mothers with Atopic Dermatitis   
Orivuori 2014 no significant influence on TGFβ1 and sIgA  
Our data We did not reveal any significant influence of Atopic maternal status on 
growth factors concentration and cytokines detectability 
 
3.5.3 Dietary preferences 
With the development of ‘hygiene hypothesis’ many researchers focused their research 
on the protective effects of environmental exposures during pregnancy and early life, 
during a period of time when infant gut colonization and immunity development normally 
takes place. Breast milk PUFA and immunological composition  in relation to maternal 
dietary preferences has been assessed in a number of observational and intervention 
studies (Dunstan et al., 2003, Prescott et al., 2008, Hoppu et al., 2012, Urwin et al., 
2012, Linnamaa et al., 2013). Accumulated knowledge (Table 14) on diet influence on 
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breast milk composition is still very inconclusive but suggests that certain dietary 
changes may influence breast milk profile. 
In a large cohort study done in Denmark PUFA composition of the breast milk was 
associated with PUFA intake, energy intake and macronutrient composition (Lauritzen 
et al., 2006). Fish and shellfish consumption did not influence levels of long-chain 
PUFA's in breast milk (Johansson et al., 2011). 
Prescott et al. found that higher levels of TGF- β1 and IgA levels in week one breast 
milk of mothers receiving B. lactis HN019 probiotics, and higher IgA levels alone in 
those receiving L. rhamnosus HN001. In contrast probiotics supplementation did not 
seem to have an effect on the rest of BM immunological profile (IL-13, IFN-γ, IL-6, TNF-
a, IL-10 and sCD14) (Prescott 2008). 
Finnish scientists studied the effect of black currant seed oil on breast milk composition 
and found lower levels of IL-4 and increased IFN-γ in breast milk, with no differences in 
IL-5, IL-10, IL-12 and TNF levels, in comparison to an olive oil fed group (Linnamaa 
2013). 
Rist and co-authors showed that levels of rumenic acid and trans-vaccenic acid in 
breast milk were higher in mothers following a diet containing organic dairy and meat 
products, in comparison with women on a conventional diet (Rist 2007). 
Two studies reported mothers receiving probiotics during pregnancy had no effect on 
TGFβ levels in breast milk (Boyle et al., 2011, Kondo et al., 2011) with opposite results 
shown by Rautava and co-authors (Rautava et al., 2002). 
My study did not employ an intervention but it has been possible to analyse the data 
from the questionnaires on the frequency of fresh fruits, and pro-/prebiotic yoghurts 
CHAPTER 3: DETERMINANTS OF GROWTH FACTOR LEVELS AND CYTOKINES DETECTABILITY IN 
COLOSTRUM AND BREAST MILK OF MOTHERS FROM MOSCOW, LONDON AND VERONA 
 
124 
 
intake reported by the mother. The only significant difference was that fish intake 
influenced TGFβ1 levels in colostrum, with higher levels reported in women eating fish 
less than once a week (Figure 4). A limitation of the study is that it was not possible  
from the questionnaire to distinguish lean from oily fish. It is not clear why less regular 
fish consumption resulted in lower TGFβ1 levels but existing data is conflicting, with 
Urwin and co-authors  reported TGF-β1 levels to be highest in the colostrum of women 
residing in the river and lake region of China , well known for high fish consumption and 
Hawkes et al failed to find any influence of fish consumption on TGFβ1 levels (Hawkes 
et al., 2001). 
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Table 14 Outcomes of the studies accounted for dietary influence on Breast Milk composition. 
 
Study Outcomes 
Hawkes 2001 no significant influence of fish consumption on TGF-β1 and TGF-β2 
Dunstan 2004 ↑n-3  in BM from women supplemented with fish oil  
↓n-6 in BM from women supplemented with fish oil  
no significant influence on IgA, sCD14 levels 
Bottcher 2008 supplementation of L. reuteri during pregnancy ↓TGF-β2 in colostrum 
supplementation of L. reuteri during pregnancy ↑IL-10 in colostrum 
no difference in IgA, SIgA, TGF-b1, TNF, sCD14, and Na/K ratio in BM 
Prescott 2008  no significant influence on IL6, IL10, IL13, IFN-γ, TNF-α, sCD14, total IgA 
↑TGF-β1 in 7 days BM from  Bifidobacterium lactis HN019 group 
Boyle 2011 no significant influence of Lactobacillus rhamnosus GG on TGF-β 
↓ sCD14 and IgA levels in BM 
Hoppu 2011 no significant influence on IFN-γ ↑IL-2, IL4, IL10 TNF-α in probiotic group 
Kondo 2011 probiotics use no difference in TGF-β2 
Ribeiro 2011 ↓ratio of n-6/n-3 PUFA in BM lipids of fish oil group compared with the 
control group 
Kuitunen 2012 ↑IL-10 in probiotics group (Lactobacillus rhamnosus,  Bifidobacterium 
breve,  Propionibacterium freudenreichii) in BM 
↓casein IgA antibodies in BM 
Urwin 2012 b salmon group ↑ EPA (80%), docosapentaenoic acid (30%), andDHA(90%) in 
day 5 BM compared with controls 
↓n-6 PUFA : n-3 PUFA ratio and sIgA  in salmon group 
no significant influence on TGF-b1, TGF-b2 and sCD14 
Ismail 2013 no significant influence of Lactobacillus rhamnosus GG consumption during 
pregnancy on TGF-β1, sCD14 and total IgA 
Linnamaa 2013 no significant influence on IL-5, IL-10, IL-12 and TNF levels 
↓IL-4 in blackcurrant seed oil group 
↑IFN-γ in blackcurrant seed oil group 
Orivuori 2014 raw milk consumption no influence on TGF-β1 and sIgA 
Our data ↓TGFβ1 in colostrum of mothers eating fish more than once a week 
no significant influence on concentration of HGF, TGF-β 2 and 3 and 
detectability of IL2, IL4, IL5, IL10, IL12, IL13, IFN-γ 
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Figure 4 Fish consumption influence on TGFβ1 concentration (pg/ml) in colostrum and breast 
milk, mean (CI) is shown in the figure. It can be seen that levels of TGFβ1 is significantly higher 
(p=0.03) in colostrum of mothers having fish less than once a week. There is no significance 
associated with the levels of TGFβ1 in breast milk.  
 
 
3.5.4 Changes in the levels of immune modulators in breast milk over time and 
between colostrum and Breast Milk 
It is well established that colostrum is particularly rich in immunologically active 
molecules and that levels of immunological markers usually drop when compared to 
mature BM (Takahata et al., 2001, Ustundag et al., 2005, Rigotti et al., 2006, Peroni et 
al., 2010). This may be explained by a higher requirement of the developing infant in 
immunologically active molecules and growth factors in particular, as they may stimulate 
rapid gut immunity maturation. I also observed a predictable, very significant, drop in the 
concentration of all growth factors analysed from colostrum to breast milk, depending on 
the geographical location (Figure 5). 
Apart from well known changes of BM immune composition from colostrum to mature 
milk there was also a rapid decline in growth factors levels and detectability of cytokines 
in colostrum with each subsequent hour. This fact could well explain the diversity of 
results between studies because few authors define the timing of colostrum collection. 
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Soto-Ramirez et al. found none of the immune markers to correlate with the time of milk 
collection in a study done in USA (Soto-Ramirez et al., 2012). In contrast, I found a 
significant decline in HGF, TGFβ1, TGFβ3, concentration and detectability of IL2, IL5, 
IL10, IFNγ over time with a similar pattern for the rest of immune modulators (Table 11). 
The steady decline of immunological markers over time has not been consistently 
demonstrated (Table 15). Striker et al. reported negative correlation between IgA levels 
and time of colostrum collection (Striker et al., 2004). In a study done in China 
river/lake, coastal and inland regions levels of sCD14, TGF-b1, TGF-b2, sIgA 
decreased over time (Urwin 2012). Lauritzen and co-authors detected significantly 
higher concentrations of n-6 and lower of n-3 PUFA's in breast milk of atopic mothers in 
their study (Lauritzen et al., 2006), however upon adjustment to time of collection and 
dietary preferences this difference lost its significance. This highlights importance of 
multivariate analysis in breast milk research as adjustment to crucial maternal or 
environmental factors may change the final result. Ignorance of important confounding 
factors may lead to inappropriate interpretation of the data. 
In addition assessing the concentration of immune modulators in milk does not provide 
an assessment of the absolute amount reaching the infants intestinal mucosa. As the 
volume of feed increases it is possible that absolute quantity remains the same despite 
a lower concentration. Whether or not this makes any difference to the biological effects 
of modulators is unknown. 
Considering the importance of collection time I conducted an additional analysis 
attempting to correct for the stage of lactation. Protein and sodium were used as a 
correction factors. Results of this study are presented in the following chapter.  
CHAPTER 3: DETERMINANTS OF GROWTH FACTOR LEVELS AND CYTOKINES DETECTABILITY IN 
COLOSTRUM AND BREAST MILK OF MOTHERS FROM MOSCOW, LONDON AND VERONA 
 
128 
 
Table 15 Outcomes of the studies taking into account changes in breast milk composition over 
time in their analysis. 
Study Outcomes 
Takahata 2001 ↑levels of IL-18 in colostrum than early milk, mature milk and maternal 
serum 
Ustundag 2005 ↑IL-2 and TNF-α levels were higher in colostrum, but reduced in later 
stages of lactation 
no changes for IL-1, IL-6 and IL-8 
Lauritzen 2006 Time of collection influences PUFA profile of breast milk 
Rigotti 2006 ↑TGF-β1 in colostrum than in mature milk in samples from allergic 
mothers 
Kobata 2007  ↓VEGF, HGF, and EGF over time 
Peroni 2010 ↑TGF-b1 concentrations in colostrum than in mature milk In farming 
mothers  
no significant changes in TGFβ1 and IL10 concentration from colostrum to 
BM 
Urwin 2012 b ↓sCD14, TGF-b1, TGF-b2, sIgA over time  
Soto-Ramirez 2012 IL-1β, IL-4, IL-5, IL-6, CXCL8, IL-10, IL-12(p70), IL-13, CXCL10, CCL11, and 
IFN-γ did not correlate with the time of milk collection 
Our data ↓ HGF, TGFβ1, TGFβ3, concentration and detectability of IL2, IL5, IL10, 
IFNγ over time 
no significant influence on TGFβ2concentration and IL4, IL12, IL13 
detectability 
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Figure 5 Growth factors concentration (pg/ml) in colostrum and breast milk in average, across all sites (overall) and at each site of collection 
(UK, Russia and Italy) 
CHAPTER 3: DETERMINANTS OF GROWTH FACTOR LEVELS AND CYTOKINES DETECTABILITY IN 
COLOSTRUM AND BREAST MILK OF MOTHERS FROM MOSCOW, LONDON AND VERONA 
 
130 
 
3.5.5 Site of collection 
Recent work by Sozanska et al. highlights the importance of the local environment 
influence on the allergy development (Sozanska et al., 2014). Their study showed that 
an increase in atopy prevalence over a very short period of time in a Polish population 
was associated with a decrease in  farming exposures due to a new European Union 
agricultural rules implementation. 
 
Some researchers suggest that breast milk composition "from women from different 
geographic, ethnic, and socioeconomic backgrounds is remarkably similar, particularly 
in reference to the macronutrients. Any differences observed are more likely to be the 
result of dietary variation, rather than genetic modification of composition" (Darragh, 
Lonnerdal 2011). 
Data from a variety of studies suggests that colostrum and breast milk constituents may 
be influenced by the country of origin and a number of environmental conditions which 
may differ significantly from one location to the other (Table 16). 
Amoudruz and co-authors showed that immigrant women, living their first ten years of 
life in a developing country but giving birth in Sweden, had statistically significantly 
higher levels of breast milk interleukin-6 (IL-6), IL-8 and TGF-β1 than native Swedish 
women (Amoudruz et al., 2009). Later another study done by the same research team 
highlighted Mali women having higher levels of TGF-β1 in comparison with women born 
in Sweden and higher levels of sCD14 in comparison to both, immigrants and local 
Swedish women (Holmlund et al., 2010). In agreement with this Peroni et al. reported 
higher concentrations of TGF-β1 and IL-10 in breast milk of women living in a farming 
environment with a higher bacterial exposure in comparison to mothers living in the city 
(Peroni et al., 2010). Similar trends have been observed by Tomicic and co-authors with 
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Estonian mothers have lower levels of TGFβ in total and TGFβ2 in particular, but higher 
levels of SIgA, IL-10, and IFN-γ in their breast milk than Swedish mothers (Tomicic et 
al., 2010) which the authors explained by the differences in microbial load. 
 
Local dietary habits may also have a strong influence on breast milk composition as it 
has been demonstrated by Urwin and co-authors reporting higher concentrations of 
sCD14, sIgA and TGFβ1 in the colostrum from the river and lake region of China 
compared with the coastal and inland regions (Urwin et al., 2012). 
Recent study by Orivuori et al. assessed breast milk samples collected in four countries 
of continental Europe and Finland and showed TGFβ1 levels to be highest in Finland 
and sIgA lowest in Germany (Orivuori et al., 2014). The reasons  behind these 
differences are unclear. 
 
My data suggests that HGF levels were lower in the colostrum/milk of Verona mothers  
and TGFβ2 and TGFβ 3 were higher in colostrum/milk of London mothers with the 
same significant difference for colostral TGFβ1 (Figure 6). London, Moscow and Verona 
do not differ much in regards to microbial load. It could be explained by genetic 
variations between the populations but most the probable explanation of these 
differences is heterogeneity of London population in comparison to Moscow and 
especially Verona, where the populations' ethnic origins are much more homogeneous. 
 
It becomes more evident that future breast milk research should be focused on 
multicentre studies involving different countries to evaluate genetic and epigenetic 
influence on breast milk composition. 
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Table 16 Outcomes of the studies assessing differences in breast milk immunological 
composition between sites of collection. 
Study Outcomes 
Amoudruz 
2009 
no significant influence on IL-1β, IL-10, IL-12p70,TNF and sCD14 
↑ IL-6, IL-8 TGF-β1 of in BM from Immigrants from a developing country 
Holmlund 
2010 
↑TGF-b1 in Mali women vs. native Swedish women  
↑sCD14 in Mali women vs. immigrating to Sweden and native women from Sweden 
Peroni 
2010 
↑TGF-b1 in colostrum and BM of farming mothers and ↑IL10 in BM of farming 
mothers compared with BM of women from urban population 
Tomicic 
2010 
↑ TGF-β (especially TGF-β2) in Swedish mothers compared to Estonian mothers 
↑ sIgA, IL-10, and IFN-γ in BM of Estonian mothers compared to Swedish mothers 
no significant influence on IL-4 and IL-13 
Urwin 
2012 
↑sCD14, sIgA and TGF-b1 in colostrum from the river and lake region compared 
with the coastal and inland regions of China 
Orivuori 
2014 
↑TGF-β1 levels in breast milk of mothers from Finland (compared to Austria, 
France, Germany and Switzerland) 
↓sIgA levels in breast milk of mothers from Germany (compared to Austria, 
France, Finland and Switzerland) 
Our data ↓HGF levels in colostrum/milk of Verona mothers (compared to Moscow and 
London) 
↑TGFβ2 and TGFβ3 in colostrum/milk of London mothers (compared to Moscow 
and Verona) 
↑ TGFβ1 in colostrum of London mothers  (compared to Moscow and Verona) 
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Figure 6 Site of collection influence on Growth factors concentration (pg/ml) in colostrum and breast milk, mean (CI) for each country is shown in 
the figure. Significant differences can be seen in both, colostrum and breast milk. β and p values for this figure can be found in Table 9. 
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3.5.6 Other factors 
I found that maternal infections during pregnancy reduced the likelihood to detect IL5 in 
colostrum. While the underlying cause remains unclear, this suggests that maternal 
health will also influence breast milk composition. 
Few studies assessed smoking influence on breast milk profiles.  Two studies showed 
conflicting results of smoking influence on IL1α levels in colostrum and breast milk 
(Zanardo et al., 2005, Szlagatys-Sidorkiewicz et al., 2013). Smoking supplementation 
use did not influence TGF-β2 levels in the study done in Japan (Kondo et al., 2011). In 
the international multicentre study done in continental Europe and Finland, Orivuori and 
co-authors reported higher levels of TGFβ1 in the smokers BM. In contrast to this data I 
did not find any statistically significant differences in growth factors concentration and 
cytokine detectability (Table 17). 
Breast milk of teenage girls has a significantly lower concentration of lactose and some 
macro-minerals compared to adults. Authors suggest that diet may play an important 
part in this difference in that teenagers diets are often suboptimal when compared to 
adults (Darragh, Lonnerdal 2011). In a single study maternal age was positively 
correlated with eosinophil count in breast milk (Islam 2006). From my data there was no 
influence of age on growth factors concentration and cytokines detectability. 
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Table 17 Outcomes of the studies which included potential influence of smoking exposure on 
breast milk immunological composition. 
Study Outcomes 
Agostoni 2003 no significant influence on colostrum Total Lipid  content 
↓absolute amounts of linoleic, arachidonic, a-linolenic and docosahexaenoic 
acid in 1 month BM of smokers  
↓docosahexaenoic acid in 3 month BM in smokers 
Zanardo 2005 ↓IL-1α in the colostrum of smokers 
Kondo 2011 no significant influence on TGF-b2 
Bachour 2012 no significant influence on sIgA levels 
↓ lipids and proteins in BM of smokers 
Szlagatys-
Sidorkiewicz 
2013 
no significant influence on IL-1β, IL-6, IL-8, IL-10, TNF-α 
↑IL-1α in BM of smokers 
Orivuori 2014 ↑TGFβ1 in BM of smokers 
Our data We did not reveal any significant influence of smoking on growth factors 
concentration and cytokines detectability 
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3.6 Conclusion  
Colostrum and mature human milk composition research is important to identify the 
reasons for conflicting results from observational studies of the protective effects of 
breast feeding on health outcomes in the infants.  Growth factor levels in colostrum drop 
hourly after birth and the decline continues from colostrum to mature milk. Thus it is 
important to correct for time after birth in any further research. A similar trend occurs 
with other immune active molecules, as they are less detectable in colostrum over time 
after birth. Cytokines in colostrum and BM are detected in tiny concentrations, within the 
border line for the lower level of detection for most of the samples, making their 
detection reliable solely on the sensitivity of the plate. Extremely high levels of growth 
factors and border line detectable cytokines questions biological importance of the latter 
at the early stage of infants’ development. My results accord with limited existing data 
suggesting that country of residence may have a significant influence on breast milk 
immune profile, highlighting the importance of defining populations in multicentre 
international prospective studies. However, there are no specific maternal or 
environmental exposures which significantly and consistently influence BM composition.  
Future studies should explore alternative environmental and maternal factors, 
particularly maternal genotype, microbiome and diet – in order to better understand the 
underlying factors which determine BM composition. Further work is also needed to 
optimize the collection and analysis of BM components, especially the correction of 
colostrum component levels for stage of lactation. Some preliminary experiments on 
correction of colostrum levels for stage of lactation presented in Chapter 4. 
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4 Protein and Sodium as a potential correction factors for immune 
active molecules over time changes in colostrum 
 
4.1 Abstract 
Background: Colostrum is an important source of nutrients and immunologically active 
components which facilitate normal development in early infancy. Recent data adds 
some evidence showing a significant decline in levels of cytokines and growth factors 
over time postpartum. Even a few hours difference may lead to substantial changes in 
breast milk immune composition. This may explain discrepancies in both, breast milk 
constituents as well as health outcomes, seen in many studies published from around 
the globe. In an attempt to normalize data between studies by the application of a 
correction factor in relation to the post-partum timing of sample collection, I analysed 
levels of total protein and sodium in colostrum from the international cohort. 
Objectives: To assess a potential approach to correct for the stage of lactation using 
total sodium and protein levels in colostrum. 
Methods: Colostrum samples (day 0-6) from 298 mothers (n=160 Moscow, n=74 
Verona, n=64 London) were analysed by Abbott Architect Analyzer using turbidimetric 
procedure for protein and ion selective electrodes for sodium levels. I used Spearman's 
correlation to assess the relationship between the concentration of growth factors (HGF, 
TGFβ1,TGFβ2 ,TGFβ3)  and time of colostrum collection postpartum. The same 
method was applied to the levels of growth factors, when corrected for total protein and 
sodium. 
Results: Growth factors levels declined over time after birth (HGF r= -0.39, p<0.001; 
TGFβ1 r=-0.21, p<0.001; TGFβ2 r=-0.16, p=0.01; TGFβ3 r=-0.35, p<0.001). Total 
protein and sodium levels also declined over time (protein r= -0.42, p< 0.001; sodium r= 
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-0.38, p<0.001 respectively). When growth factor levels were corrected for total protein 
or sodium levels, significant relationships with time (either positive or negative) 
persisted HGF (r=-0.39, p<0.001 protein; r=-0.19, p=0.003 sodium), TGFβ1  (r=0.21, 
p<0.001protein; r=0.25, p<0.001 sodium),TGFβ2 (r=0.16, p=0.01 protein; r=0.20, 
p=0.004 sodium) and TGFβ3 (r=-0.35, p<0.001 protein; r=-0.06, p=0.34 sodium). 
Conclusions: Growth factor levels markedly decline in concentration in human 
colostrum over time after birth, and so do total protein and sodium levels. However 
correction of growth factor levels for total protein or sodium levels did not account for 
the effect of time, suggesting that these are not useful correction factors for maturation 
of colostrum in comparisons between human populations. The kinetics of decline of 
each growth factor differed significantly, suggesting that more complex approaches are 
needed to account for maturation of colostrum when comparing human populations. 
Differences in correlation of absolute and relative concentrations of a particular growth 
factor suggest that they have different biological importance at the first days of life. 
Although all growth factors decline over time, proportion of TGFβ1 and 2 within the 
protein content of colostrum increases over time. This tendency needs to be studied 
further. 
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4.2 Introduction 
Human breast milk contains a large variety of immune active molecules and we know 
that it provides the developing infant with a range of bioactive factors influencing  
immune system maturation, physical and cognitive development and the infant intestinal 
microbiome (Borsutzky et al., 2004). A large number of cytokines, growth factors, 
signaling molecules and other factors playing their roles in immunity, are found in 
colostrum and BM (D'Alessandro et al., 2010). 
 
Many authors reported decline in cytokine concentration in colostrum over time and  
levels of immunological markers to be higher in colostrum when compared to mature 
BM (Takahata et al., 2001, Ustundag et al., 2005, Rigotti et al., 2006, Peroni et al., 
2010, Striker et al., 2004, Lauritzen et al., 2006, Urwin et al., 2012, Prescott et al., 
2008). It has been assumed that the higher levels will stimulate rapid gut immune 
maturation in the critical few days after birth. I also observed this significant, drop in the 
concentration of all growth factors analysed over time. One US study failed to find an 
association between time and immune markers (Soto-Ramirez et al., 2012),which may 
be partially explained by a wide range in collection times (week one to eight). 
 
The aim of this study was to determine if protein and/or sodium concentrations could  be 
used as a correction tool for stage of lactation, to facilitate comparison of human early 
breast milk (colostrum) composition between populations. 
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4.3 Materials and Methods 
4.3.1 Study population 
Study population has been described in detailed in the main Methods section of this 
thesis. Colostrum samples (day 0-6) from 298 mothers (n=160 Moscow, n=74 Verona, 
n=64 London) were analysed by Abbott Architect Analyzer using turbidimetric procedure 
for protein and ion selective electrodes for sodium levels. 
 
4.3.2 Protein and Sodium analysis  
Abbott Architect Analyser (Pic. 1) have been used to determine total protein and sodium 
levels in colostrum. The laboratory analysis of protein and sodium was carried by fourth 
year medical students Ms. Shreya Sheth (Sheth, 2014) and Ms. Priya Abrol (Abrol, 
2014) for their BSc project, under my supervision. 
 
Picture 1 Abbott Architect c8000 Clinical Chemistry Analyser 
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Abbott Architect Analyser has been assessed and evaluated to match the analytical 
performance of a highly precise Beckman Array nephelometer technique and has been 
shown to improve laboratory efficiency. Standard urine protein assay was used for 
colostrum protein analysis. 
 
Colostrum proteins were denatured by benzethonium chloride, forming a fine 
suspension, which is then measured turbidimetrically at 404nm. 
 
During the validation step, 24 colostrum samples were randomly selected from the 
breast milk bank. Samples were centrifuged at 1500g for 15 minutes at 4°C. The fat 
layer was trimmed off and supernatant transferred in the tubes and loaded into the 
analyser. 
 
As colostrum is highly lipaemic, mass spectrometry was conducted to examine 
suitability of the assay. Supernatant was manually diluted at 1:10 in normal saline prior 
to analysis. The Architect device was programmed to generate on board 1:2 dilutions for 
samples where protein levels were above the detection range. 4 of the 24 samples 
required a dilution factor of 40 for protein levels to be within the detectable range 
(appendix E). 
 
To assess the nature of the dilutions and achieve an ideal protein detection range, 
serial dilutions were carried out on two of the samples, ranging from 1:2 to a 1:32 
dilution using saline solution. This established that an on board dilution factor of 30 
would allow an appropriate protein detection range (appendix F). 
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Sodium levels were measured at the same time in these 24 samples, using ion-
selective electrodes in the Abbott Architect Analyser®. A voltage is generated between 
the reference and measuring electrodes according to the Nernst equation. This voltage 
is then compared to previously determined voltages and converted into sodium 
concentrations in mmol/L. 
 
4.3.3 Protein analysis 
Following a successful validation step, all colostrum samples (n=298) were prepared for 
analysis. All samples were thawed and centrifuged at 3000g for 15 minutes at 4°C. 
300μl of supernatant were carefully transferred to the tubes and loaded into the 
Architect device for the analysis. 
 
An on board 1:30 dilution was programmed into the Architect to avoid the risk of errors 
with manual dilutions, allowing a protein detection range of 3 –60g/L. For this dilution, 
the analyser picked up 5μl of sample and dispensed it into a cuvette with 145μl of 
saline, analysing a sample from that dilution. Therefore the residual samples were left 
unaffected by the dilution, and could undergo further analysis whilst in the system. 
 
Remaining colostrum from the 24 samples analysed in the pilot study were analysed 
again for protein levels, allowing assessment of method reproducibility. 
The protein values measured for all colostrum samples in g/L were converted into 
pg/mL, aligned with growth factors concentration. 
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4.3.4 Sodium analysis 
Sodium levels were detectable in all colostrum samples using the same laboratory 
system, and sample dilution was not required. The lower limit of detection was 
20mmol/L,and samples with sodium levels below this were assigned a value of 
10mmol/L for   data analysis. 
 
4.3.5 Statistical analysis 
For the purpose of this chapter I provide a graphical representation of HGF, TGFβ1,2 
and 3 and HGF/Protein, TGFβ1/Prorein, TGFβ2/Protein and TGFβ3/Protein decline, 
using non-linear and linear regressions. Since different models are used for the 
assessment of absolute and relative values of the growth factors analysed, it is 
impossible to compare them. Linear regression models showed better strength and that 
is the reason for them to be the model of choice for this Chapter analysis. Spearman 
rank correlation coefficient has been calculated for all correlations assessed. Results 
were considered significant when p-values were reported at a level less than 0.05. 
Correlations between absolute or relative concentrations of growth factors with time of 
collection allow assessment of the patterns of decline for both. Statistical analysis was 
carried out using SPSS Software Version 22.0 and GraphPad Prism Version 6.0. 
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4.4 Results 
 
4.4.1 Protein and Sodium in colostrum 
Levels of protein and sodium in human colostrum are highly correlated (r=0.72, 
p<0.001) and their concentrations decline over time in a very similar fashion (r=-0.42 
and -0.38 respectively, with p<0.001 for both) (Figure 7). Sodium levels were 
undetectable in 107 samples out of 298, which meant that protein was more suitable for 
correction purposes. Correction for sodium is presented in Appendix G. 
CHAPTER 4: PROTEIN AND SODIUM AS A POTENTIAL CORRECTION FACTORS FOR IMMUNE ACTIVE MOLECULES OVER TIME CHANGES IN COLOSTRUM 
 
145 
 
Figure 7 Protein and Sodium concentration in colostrum decline over time. 
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4.4.2 Growth factors in colostrum changes over time 
All growth factor levels demonstrated a significant decline over time (Figure 12). The 
declines of HGF and TGFβ 3 are almost linear; TGFβ1 and 2 are non-linear. Upon 
correction the pattern became very linear, as it can be seen from the Figures 8 - 11.  
I assessed correlation between the levels of growth factors and time of colostrum 
collection. Same  approach has been used for growth factors/protein ratio. As it can be 
seen from the table below correction for protein allows us to see the pattern of changes 
of absolute and relative growth factors concentration over time. 
Absolute concentration/ Time of collection  Relative concentration (Protein)/ Time of 
collection 
 
HGF concentration/ Time of collection   
r=-0.39, p<0.001 ↓ 
 HGF/Protein ratio/ Time of collection   
r=-0.19, p=0.003 ↓ 
 
TGFβ1 concentration/ Time of collection   
r=-0.21, p<0.001 ↓ 
 TGFβ1/Protein ratio / Time of collection   
r=0.25, p<0.001 ↑ 
 
TGFβ2 concentration/ Time of collection   
r=-0.16, p=0.01   ↓ 
 TGFβ2/Protein ratio / Time of collection   
r=0.20, p=0.004 ↑ 
 
TGFβ3 concentration/ Time of collection   
r=-0.35, p<0.001 ↓ 
 TGFβ3/Protein ratio / Time of collection   
r=-0.06, p=0.34 ↓ 
 
↑ - Positive correlation with time of collection 
↓ - Negative correlation with time of collection
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Figure 8 HGF absolute concentration (pg/ml) and relative (as a HGF/Protein ratio) concentration changes in colostrum over time  
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Figure 9 TGFβ1 absolute concentration (pg/ml) and relative (as a TGFβ1/Protein ratio) changes in colostrum over time 
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Figure 10 TGFβ2 absolute concentration (pg/ml) and relative (as a TGFβ2/Protein ratio) changes in colostrum over time 
CHAPTER 4: PROTEIN AND SODIUM AS A POTENTIAL CORRECTION FACTORS FOR IMMUNE ACTIVE MOLECULES OVER TIME CHANGES IN COLOSTRUM 
 
150 
 
 
 
  
 
 
 
 
 
  
Figure 11 TGF-β3 absolute concentration (pg/ml) and relative (as a TGFβ3/Protein ratio) changes in colostrum over time 
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Trends in growth factors changes over time
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Figure 12 Trends in growth factors change over time 
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4.5 Discussion 
It is well established that levels of total protein as well as Na+ in human breast milk 
decrease over time, with the opposite trends seen for lactose and K+ with the most 
prominent changes seen from colostrum to transitional milk (Kulski and Hartmann, 
1981). The natural decline may be due to a simple dilution as the infants volume 
requirements increase. It would be possible if this was the case to correct for maturation 
of milk. We found that the kinetics of decline in different constituents in early human milk 
differ markedly, even between closely related growth factors, such that a unifying 
correction factor cannot be found. This means that much of the decline in growth factor 
levels is independent of dilution effects in colostrum, and that more sophisticated 
methods are needed to account for time changes in colostrum. 
 
4.5.1 Protein in human breast milk 
Protein content of breast milk has a multifunction role, providing amino acids essential 
for growth and development, immunoglobulins representing passive immunity 
transmission (Hurley and Theil, 2011), oligosaccharides having pre-biotic properties 
involved in protection against infections, and a variety of immunologically active 
molecules possessing different immunological functions (D'Alessandro et al., 2010). 
 
On average, mature breast milk contains 0.9 - 1.2 g/dL of protein, 3.2 - 3.6 g/dL of fat 
and 6.7 - 7.8 g/dL of lactose (Ballard and Morrow, 2013). Breast milk protein levels 
undergo  a steady decline over the first 4 to 6 weeks (Bauer and Gerss, 2011) and 
existing data suggest that composition differs between preterm and term milk, with 
higher  protein and fat content in preterm milk (Ballard and Morrow, 2013). 
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Existing evidence suggests that breast milk nutritional composition does not differ in 
mothers from different geographic, ethnic, and socioeconomic backgrounds and any 
variations are more likely due to dietary preferences rather than genetic differences 
(Darragh and Lönnerdal, 2011). 
 
There is some evidence that maternal weight may have an influence on protein and lipid 
concentration in breast milk, and Nommsen et al. reported decreasing levels associated 
with post pregnancy weight loss (Nommsen et al., 1991) or in those women, producing 
higher breast milk volume. Authors did not reveal any influence of maternal diet on 
protein content. 
 
Immunologically active part of breast milk protein composition is presented by 
cytokines, signalling molecules and growth factors (D'Alessandro et al., 2010). These 
factors play an important role during early infant immunity development but we still do 
not possess enough data to draw proper conclusions regarding importance of each 
particular immune active molecule during a particular phase of infant development. 
 
Immune active constituents of colostrum and breast milk represent a minor  component  
but the most biologically active part of the breast milk total protein. Most studies 
concentrate on a particular part of the human breast milk composition, completely 
ignoring other important constituents. Most studies assessing protein in breast milk are 
interested in nutritional composition, ignoring the immunologically active components 
and vice versa. 
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4.5.2 Growth factors concentration changes over time 
As it has been discussed in Chapter 2, existing knowledge suggests that there is a 
steady decline in the levels of immunologically active factors in colostrum over time. 
There are a variety of the potential explanations behind this phenomenon. The 
neonates' immune immaturity may be compensated by high concentrations of 
modulators in colostrum (Ehlers and Smith, 1991).  This is illustrated by the observed 
direct correlation between the levels of TGFβ in human milk and concentration of IgA in 
the infants serum (Ogawa et al., 2004). As the infants' immune response matures there 
is likely to be less need for an extrinsic supply of immune stimulants. 
Another potential explanation is dilution. During the first week of life the infant’s volume 
requirements are low. Later levels of the immune active molecules decrease as the 
infants volume and nutritional requirements increase. 
In this study I attempted to address growth factors decline over time, in order to facilitate 
merging of data. The uncorrected results showed visible and likely biologically 
significant decline of HGF, TGFβ 1, 2 and 3 levels over time. Correction for colostrum 
total protein resulted in a significant differences in the results in that the decline in the 
levels of TGFβ 1 and 2 disappeared and transformed into a steady rise when evaluated 
as a ratio with total protein levels (Figures 9 and 10). This implies more active transport 
of these growth factors. If we assume biological relevance, then these results suggest 
that infants need relatively higher amounts of TGFβ1 and 2 for longer than that of other 
immune mediators. TGFβ3/Protein ratio on the other hand,  had a different pattern with 
decreasing ratio over time.  This difference may be explained by TGFβ3 being 
significantly different from TGFβ1 and 2 in its detailed tertiary structure of the active 
domain despite homology in amino acid sequence (Laverty et al., 2009). There is some 
evidence (Laverty et al., 2009) that TGFβ3 isoform may be distinct in its functions to 
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other TGFβ isoforms. It is known that TGFβ3 is up-regulated by milk stasis,  and not by 
circulating concentration, and induces apoptosis in mammary gland epithelium during 
involution, in contrast to TGFβ1 and 2 (Nguyen and Pollard, 2000), which may explain 
variations in TGFβ isoforms decline over time. Another classic example of TGFβ isoform 
differences have been observed in cutaneous scarring experiments done on animal 
models (Ferguson and O'Kane, 2004), mammalian embryos showed healing with no 
scarring and full skin recovery (Whitby and Ferguson, 1991b) with expression of high 
levels of TGFβ3 seen and contrasting, low levels of TGFβ1 and 2 (Whitby and 
Ferguson, 1991a) and similar TGFβ3 function have been shown in human scarring 
physiology (Ferguson et al., 2009). 
 
4.5.3 Limitations of the study 
The main limitation is that this was a cross-sectional study with single specimens from 
each subject. The only way to elaborate on the dynamics of transport of each 
constituent over time is to collect breast milk longitudinally from the same mother. 
There are currently no markers to utilize which will correct for time of colostrum 
collection. As this one of the most important factors influencing the levels of immune 
markers it is required to normalize data from diverse studies. v. As there are no "gold 
standard" methods of colostrum maturity I attempted to provide a correction using total 
protein and sodium levels in BM. The limitation of the study is that no subgroup analysis 
has been performed because of limited numbers. There is a chance that time of 
collection postpartum would have a more prominent effect in breast milk of the 
multiparous mothers who delivered by lower segment c/section. Furthermore the 
analysis covered only a small number of growth factors. 
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4.6 Conclusion 
Despite the lack of a correction factor for the time of collection influence on the levels of 
immune active molecules concentration, correction for total protein level shows some 
potential. It gives a different perspective on the absolute and relative declines of 
immune active molecules over a period of time, highlighting the potential importance of 
a certain immune modulators during the very early period of infant development. More 
work on a larger sample size, preferably collected longitudinally, is needed in order to 
address existing pitfalls.  The results suggest that breast milk research should be very 
diverse, multi-functional and aim to cover as many breast milk constituents as possible.  
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5 Growth factor levels and cytokines detectability in colostrum and 
breast milk of mothers from Moscow, London and Verona and infant 
health outcomes at six months and one year of age 
 
5.1 Abstract  
Background: The role of breastfeeding in improving outcomes in early childhood is still 
unclear. Cytokines and growth factors in colostrum and breast milk (BM) could play an 
important role in infant immune maturation and potential beneficial effects include 
protection against GI and respiratory infections and atopy/allergy development. 
Environmental and maternal factors may influence the levels of immune active 
molecules in breast milk but there is uncertainty over which factors are responsible. I 
examined the relationship between maternal and environmental factors and levels of 
immune modulators in colostrum and breast milk of women from a multi-national cohort 
and assessed outcomes in their children at 6 and 12 months of age. 
Objectives: To identify associations between environmental and/or maternal factors 
and levels of immune mediators in colostrum and breast milk and the influence on 
outcomes at 6 and 12 months of age. 
Methods: A prospective cohort study of pregnant mother/infant pairs in London 
(N=105), Moscow (N=200) and Verona (N=80).  Participants underwent allergy testing, 
and questionnaire interview. Colostrum samples (days 0-6) and Mature Milk (4-6 weeks) 
were analysed in duplicate at Imperial College London using electrochemiluminescence 
(Meso Scale Discovery®) for level of TGF-β 1,2,3; HGF, IL2, IL4, IL5, IL10, IL12, IL13, 
IFN-γ. Statistical analyses used mixed models adjusting for the site of collection, parity 
and maternal atopic status. Fever, cough or wheeze, food allergy/sensitivity/intolerance, 
recurrent eczematous rash presence, were assessed at 6 months. Symptoms of upper 
respiratory tract infection symptom frequency, reflux and/or vomiting were assessed 
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both at 6 and 12 months and infant atopy and stool consistency using Bristol chart at 12 
months of age. The "best" statistical model for each outcome has been used for health 
outcomes analysis. All models included adjustment for site of collection. 
Results:  Higher TGFβ2 concentration in BM was associated with more eczematous 
rash reported at the age of 6 months OR 1.04 (95% CI 1.01 - 1.06), with detectable IL13 
in BM showing protective effect OR 0.18 (95% CI 0.04 - 0.92). Boys had less 
eczematous rash at the age of 6 months compared with girls OR 0.2 (95% CI 0.05 - 
0.84). 
Food allergy, sensitivity, intolerance events reported by the mother were negatively 
associated with detectability of IL13 in colostrum OR 0.1 (95% CI 0.01 - 0.83).  
No significant association of any factor analysed with  cough or wheeze development at 
the age of 12 months was demonstrated.  
Mothers living in Moscow reported lower fever incidence at the age of 12 months OR 
0.2 (95% CI 0.06 - 0.74) and runny nose or cold by the age of 12 months OR 0.02 (95% 
CI 0.01 - 0.23). HGF in breast milk showed some protective effect in regards to runny 
nose or cold incidence at first year of life OR 0.19 (95% CI 0.04 - 0.92). Runny nose or 
cold events have been reported more often in boys OR 4.27 (95% CI 1.08 - 16.90). 
Conclusions: Data from this study suggests that differences in individual immune 
composition of breast milk may have an influence on early life infant health outcomes. 
The data shows that increased TGFβ2 levels in breast milk are associated with a higher 
incidence of reported recurrent eczematous rash, with detectable IL13 in colostrum 
showing protective effects. Detectable IL13 in breast milk is associated with less food 
allergy, sensitivity, intolerance events reported by the mother. HGF is associated with 
some protective effect on cold and runny nose incidence at one year of age. Although 
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several different potential relationships were explored in this project, the associations 
reported were significant despite adjustment for multiple comparisons. However the 
data are observational in nature, so that it is not possible to make definitive conclusions 
that the associations are causal in nature, due to the possibility of hidden confounding. 
Finally we did not assess gene-environment relationships, which are an area of interest 
for future work. Future studies should be focused on maternal genotype, breast milk 
microbiome and diet as influences on breast milk immune composition and both, short 
and long term health outcomes in the infant. More studies on babies at high risk of 
allergy development are needed to highlight the most important immune active 
molecules playing a role in allergy prevention. 
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5.2 Introduction 
Breast milk (BM) is known to contain a large variety of immune active components 
(D'Alessandro et al., 2010) which are present in differing concentrations (Agarwal et al., 
2011). Despite many published studies little is known about the human milk immune 
composition’s influence on short and long term health outcomes. 
 
Which factors influence short and long term health outcomes in infants is still a matter of 
discussion, despite a number of studies aimed to address this question (Table 18). Most 
of the authors focused on allergic sensitisation, eczema, early wheezing and/or asthma 
and allergic rhinitis development as the main phenotypic outcomes. Breast milk immune 
active molecules, which potentially could influence immunological outcomes in infancy 
and early childhood included not only cytokines, growth factors, soluble receptors and 
but also polyunsaturated fatty acids and other nutritional factors. 
 
The aim was of this component was to assess the impact of maternal and 
environmental factors in relation to colostrum and BM immune active components 
composition and health outcomes at the age of six and twelve months.
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Table 18 Studies done up to date, assessing Breast milk immune composition and immunological outcomes in children. 
Study Immunological 
Outcomes 
Relationship between breast milk composition and outcomes 
Kalliomaki 1999 Eczema (up to 12 months) ↑TGF-β1 and TGF-β2 in colostrum in infants with postweaning-onset atopic disease 
Jones 2002 Eczema  
(up to 6 months) 
↓sCD14 levels in 3 month BM lead to a higher eczema incidence at 6 months of age  
 
Bottcher 2003 Allergic sensitisation  
(up to 2 years) 
Salivary IgA (up to 2 years) 
Eczema (up to 2 years) 
No influence of IL4, IL5, IL6, IL8, IL10, IL13, IL16, IFN-γ, TGF-b1, -b2, RANTES, eotaxin or SIgA on 
atopy and/or allergy 
Oddy 2003 Asthma-like symptoms (up 
to 12 months) 
TNF-α, sCD14 and IL10 had no significant association with infant wheeze 
↑TGF-β1 lower odds of wheeze in infancy 
Ogawa 2004 Serum IgA levels 
assessment 
↑ IgA in newborns serum during 1 month of life correlated significantly with levels of TGF-β1 
and TGF-β2 in colostrum 
Savilahti 2005 Allergic sensitisation  
(up to 4 years) 
Eczema (up to 4 years) 
↓IgA casein antibodies and sCD14 in colostrum of mothers of babies who developed atopy 
Snijders 2006 Eczema  
(up to 12 months) 
Allergic sensitisation  
(up to 2 years) 
Wheezing  
(up to 2 years) 
TGF-β1, IL-10, IL12 and sCD14 had no significant association with any of the atopic manifestations 
Bryan 2007 Infant bronchiolitis  
(up to 12 months) 
IL2,IL8,IFNγ had no significant association 
↓IL-10 in BM of mothers of infants subsequently developed bronchiolitis 
Zanardo 2007 Neonatal jaundice ↑IL-1β in colostrum from breast-feeding mothers whose infants had Neonatal Jaundice 
Bottcher 2008 Allergic sensitisation  
(up to 2 years) 
Eczema (up to 2 years) 
↓TGF-b2 reduced incidence of sensitisation during the first 2 years of life and a trend of 
protective effect on eczema development 
Lowe 2008 Eczema (up to 2 years) 
Asthma (up to 7 years) 
Allergic rhinitis (up to 7 
years) 
↑n-3 fatty acids in colostrum were associated with higher risk of atopic eczema  
total n-3 fatty acids concentration in breast milk was associated with increased risk of non-
atopic eczema  
↑total n-6 fatty acids in colostrum were associated with increased risk of childhood rhinitis 
Walter 2009 HIV transmission ↑IL-15 concentrations were associated with a decreased risk of HIV transmission  
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Thijs 2011 Eczema  
(up to 2 years) 
Allergic sensitisation  
(up to 2 years) 
↑n-3 PUFAs as well as ruminant fatty acids were associated with lower risk of parent-reported 
eczema, eczema, and sensitisation at 12 months of age 
Kuitunen 2012 Allergic diseases  
(up to 5 years) 
Eczema  
(up to 5 years) 
Allergic sensitisation  
(up to 2 years) 
↑TGF-β2 concentration in 3 month BM was associated with more allergic disease and eczema 
at 2 years of age 
IL10 had no significant association with allergic manifestations at 2 years of age  
TGF- β2 and IL-10 were not significantly associated with allergy outcomes at 5 years 
Soto-Ramirez 2012 Asthma-like symptoms (up 
to 12 months) 
↑total n-6 PUFAs in BM were associated with an increased risk of asthma-like symptoms    
↑ total n-3 PUFAs decreased the risk of atopy 
Soto-Ramirez 2012 b Asthma-like symptoms (up 
to 12 months) 
Infants in the highest quartile of IL5 and IL-13 in BM were at a higher risk of asthma-like 
symptoms development 
Ismail 2013 Eczema (up to 12 months) 
Allergic sensitisation  
(up to 12 months) 
TGF-β1, sCD14, total IgA had no significant association with any of the atopic manifestations 
Orivuori 2014 Eczema (up to 4 years) 
Asthma (up to 6 years) 
Allergic sensitisation (up to 
6 years) 
TGF-β1 had no significant association any of investigated health outcomes 
sIgA levels were inversely associated with AD up to the age of 2 years 
sIgA had no significant association with atopy or asthma up to the age of 6 
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5.3 Methods 
5.3.1 Study population 
Demographic data has been described in detail in the Methods section of the Thesis. 
 
5.3.2 Colostrum and breast milk analysis 
Laboratory approaches used has been described in detail in the Methods section of the 
Thesis. 
 
5.3.3 Outcome definitions 
Babies health outcomes were assessed at the age of six months by means of a phone 
questionnaire and at one year of age by completing a questionnaire during the follow-up 
visit. All questions were carefully explained to the mothers. All health outcomes were 
self-reported by the mother of the infant except atopic sensitization which was assessed 
by skin prick test. Fever, cough or wheeze, runny nose or cold, eczematous rash, reflux 
and vomiting cumulative incidence, food allergy/sensitivity or intolerance incidence have 
been assessed. 
Runny nose or cold was defined as at least one episode of runny nose or cold lasting 
for a minimum of 3 days. 
Cough or wheeze outcome was defined as at least one episode of recurrent cough or 
wheezing prior to assessment at one year of age. Current atopic eczema symptoms 
were considered present if the child had ever had an eczematous rash intermittently at 
any time during the last 6 months. 
Eczematous rash incidence was defined as children with at least one episode of an 
intermittent eczematous rash. 
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 A baby was considered to be atopic if s/he had positive control wheal of ≥3 mm and 
any of the allergen induced wheals being ≥3 mm greater than negative control. 
 
For exclusive breastfeeding the WHO recommended definition "that the infant receives 
only breast milk” was used. No other liquids or solids are given – not even water – with 
the exception of oral rehydration solution, or drops/syrups of vitamins, minerals or 
medicines" (WHO, 2009a). 
 
5.3.4 Statistical analysis  
Statistical analysis was performed using R statistical package version 3.1.0. 
 
Factors included into the models were: 
levels of growth factors in colostrum and breast milk, detectability of cytokines in 
colostrum and breast milk, site of collection, maternal atopic status, delivery type. 
 
Descriptive statistics, cross tables, correlation and statistical tests were performed on 
each explanatory variable to describe the importance of each variable and identify 
which may be the most useful in explaining and predicting the outcome variable. 
 
Outcomes assessed using models were: 
fever, food allergy/sensitivity/intolerance, recurrent eczematous rash presence have 
been assessed at 6 months. Runny nose or cold incidence, reflux and/or vomiting, 
cough or wheeze have been assessed both at 6 and 12 months. 
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Since a model with a large number of predictors can ‘overfit’ the data, a “parsimonious 
model" or "best model” can be evaluated using selection methods such as forward, 
backward, and stepwise selection. The aim was to maximize explanatory power and 
minimise the number of predictor variables in the model in order to increase statistical 
power and obtain more valid parameter estimates. 
 
Prior to multivariate analysis univariate analysis and correlation matrix has been 
performed. Then model selection methods (LASSO and glmulti) have been applied. 
 
LASSO selection technique performs variable selection and estimates coefficients for 
predictors in linear regression. Although it does handle multicollinearity and group 
structure, it cannot select more predictors than the sample size. LASSO provides a 
point estimate of coefficients for relevant and selected predictors but not confidence 
interval and p-values unless bootstrapping or cross validation procedure are used.  
 
For the analysis the candidate predictors, previously defined, were included in the 
model along with the interaction terms between colostrum collection time and growth 
factors. 
 
The key feature of LASSO is the tuning parameter which controls the amount of 
shrinkage and so the selection of variables; for this reason, the tuning parameter 
lambda was selected by repeating 10 fold cross validation 100 times in order to reduce 
randomness and to average the error curves. In addition, 1000 bootstrap samples were 
used to estimate SE, p-values and CI.  
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Bootstrap is a simulation method which enables approximation and estimation of  the 
LASSO distribution providing measures of accuracy such as bias, variance and 
confidence interval. However, such technique has some limitations as explained in 
many research papers. 
The glmulti package in R provides an automated model selection and multi-model 
inference with GLMs. This technique enables fitting of all possible candidate models 
and selection of only one which satisfies IC profile and AIC criteria. Although this 
method can be time consuming, it allows the inclusion of uncertainty into the model and 
so in the statistical inference.  
 
It converged very efficiently on the actual best models. However even the convergence 
is not perfect, but the procedure appears to be robust. This is consistent with what is 
known of IC-based model selection: the identity of the single “best” model or of the few 
best models may be subject to model-selection bias and are random variables over 
samples. Synthetic statistics of the confidence set of models (e.g., multi-model 
parameter estimates, relative support for the variables, etc.) are expected to be more 
robust. 
  
An important characteristic of the GLM model selection framework is that all terms are 
equally frequent in the candidate models, so that the candidate set of variables is 
”balanced”. 
A faster genetic algorithm approach was used as allowed me to include a huge number 
of candidate predictors, perform model selection and estimate coefficients of relevant 
predictors. The aim of this statistical analysis is to explain the probability of babies 
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having several conditions (each of those are binary variables) from predictors, using a 
binomial GLM.  
 
Interaction terms between growth factors and colostrum collection time were excluded 
to make the computation faster, increase the power of the analysis and to avoid 
discarding further missing values. 
 
The resulting term importance was plotted in order to graphically visualize the effects of 
predictors. Such plots estimate the importance or relative evidence weight of candidate 
predictors, these weights are computed as the sum of the relative evidence weights of 
all models in which the term appears. 
Sensitivity analysis was performed for both methods and all models; a different number 
of variables were included to make sure that those selected had a real and sensible 
effect on the outcome.  
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5.4 Results 
Influence of immune active molecules in colostrum and breast milk in conjunction with 
environmental and maternal factors was analysed in relation to a number of health 
outcomes at the age of 6 and 12 months. The "best" statistical model for each outcome 
highlighted those factors having the most significant influence on a particular outcome. 
All results are adjusted for the site of collection as a potential confounder. The average 
Importance of the variables for a particular health outcome across all possible models 
are visualised on the graphs. 
All factors found to be important at least in a single model and any significant 
associations with health outcomes are presented in the table below.  
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  BM TGFβ2 Detectable BM 
IL13 
Detectable Col 
IL 13 
Sex baby - Male Verona Moscow BM HGF 
Eczematous rash OR 1,04 (95% CI 
1,01 - 1,06) 
OR 0,18 (95% CI 
0,04 - 0,92)  
Not important OR 0,2 (95% CI 
0,05 - 0,84) 
Not important Not important Not important 
Food 
Allergy/Sensitivity/ 
Intollerance 
Not important Not important OR 0,1 (95% CI 
0,01 - 0,83) 
Not important OR 0,13 (95% CI 
0,01 - 1,46)  
OR 2,07 (95% CI 
0,47 - 9,02)  
Not important 
Fever Not important Not important Not important Not important OR 1,56 (95% CI 
0,36 - 6,76)  
OR 0,2 (95% CI 
0,06 - 0,74) 
Not important 
Cough or wheeze Not important Not important Not important Not important Not important Not important OR 1,89 (95% CI 
0,94 - 3,78) 
Runny nose or cold 
6 months 
Not important Not important Not important Not important Not important Not important Not important for 
the model 
Runny nose or cold 
12 months 
Not important Not important Not important OR 4,27 (95% CI 
1,08 - 16,90) 
Not important OR 0,02 (95% CI 
0,01 - 0,23)  
OR 0,19 (95% CI 
0,04 - 0,92)  
Baby atopy Not important Not important Not important Not important Not important Not important Not important 
Reflux and/or 
vomiting 12 months 
Not important OR 0,21  (95% CI 
0,04 - 1,04) 
Not important Not important Not important Not important Not important 
 
Important for the model,  statistically significant  and OR < 1.0  
 
Important for the model,  statistically significant  and OR > 1.0 
 
Important  for the model but statistically not significant 
 
Important for the model, statistically not significant, but there is a trend to 
report 
CHAPTER 5: GROWTH FACTOR LEVELS AND CYTOKINES DETECTABILITY IN COLOSTRUM AND BREAST MILK 
OF MOTHERS FROM MOSCOW, LONDON AND VERONA AND INFANT HEALTH OUTCOMES 
 
170 
 
5.4.1 Eczematous rash reported at 6 months of age 
Three variables had an impact on eczematous rash reported by the mother at the age of 
six months. As it is shown in the Figure 7,  TGFβ2 concentration in BM was the most 
important. Infants having breast milk with higher levels of this growth factor were at 
significantly higher risk OR 1,04 (95% CI 1,01 - 1,06) of eczematous rash development. 
In contrast, detectable IL13 in breast milk showed some protective effect OR 0,18 (95% 
CI 0,04 - 0,92) on eczematous rash development.  Boys tended to have eczematous 
rash at the age of 6 months less often OR 0,2 (95% CI 0,05 - 0,84) compared with girls.  
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Figure 7 Importance of variables influence on  eczematous rash development and OR of eczematous rash development due to the most important 
factors. 
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5.4.2 Food Allergy/Sensitivity/Intolerance reported at 6 months of age 
Country of collection and detectability of IL13 in colostrum were found to be the most important for any form of allergy, sensitivity or 
intolerance reported by the mother at the age of 6 months (Figure 8).  IL13 detectability in colostrum showed protective effects OR 0,1 
(95% CI 0,01 - 0,83) on these health outcomes, whilst country of collection effect failed to reach significance OR 0,13 (95% CI 0,01 - 
1,46) and OR 2,07 (95% CI 0,47 - 9,02) for Verona and Moscow respectively.  
Figure 8 Importance of variables influence on food allergy/sensitivity/intolerance reported at 6 months and OR of food allergy/sensitivity/intolerance 
development due to the most important factors. 
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5.4.3 Fever incidence reported by mother at 12 months 
The only factor associated with a higher incidence of fever reported by one year of age was country of collection (Figure 9). Mothers of 
infants born in Moscow reported episodes of fever significantly less OR 0,2 (95% CI 0,06 - 0,74). Women from Verona tend to report 
fever more often, but failing to reach significance OR 1,56 (95% CI 0,36 - 6,76). 
Figure 9 Importance of variables influence on fever incidence reported at 12 months and OR of fever incidence due to the most important factors. 
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5.4.4 Runny nose or cold reported by mother at 6 months 
There were no associations of factors with maternal reports of at least one episode of 
runny nose or cold at the  age of 6 months (Figure 10). 
Figure 10 Importance of variables influence on runny nose or cold incidence reported at 6 
months. 
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5.4.5 Runny nose or cold reported by mother at 12 months 
Three variables seem to be important (Figure 11) for runny nose or cold development in children participated in the study, and the infants 
gender . At least one episode of runny nose or cold at the age of 12 months was reported less often OR 0,02 (95% CI 0,01 - 0,23)  by 
mothers living in Moscow.  HGF concentration in breast milk was associated with less runny nose or cold development OR 0,19 (95% CI 
0,04 - 0,92) with boys tend to develop it significantly more often than girls OR 4,27 (95% CI 1,08 - 16,90). 
 Figure 11 Importance of variables influence on runny nose/cold reported at 12 months and OR of runny nose/cold episodes incidence due to the most 
important factors. 
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5.4.6 Infant allergic sensitisation (at 12 months) 
There was no association between any factor and infant allergic sensitisation at one 
year of age (Figure 12). It may be explained by a very small sample size as only 14 
babies from the three cohorts developed allergic sensitisation. 
Figure 12 Importance of variables influence on infant allergic sensitisation recorded at 12 months. 
 
 
 
 
 
CHAPTER 5: GROWTH FACTOR LEVELS AND CYTOKINES DETECTABILITY IN COLOSTRUM AND BREAST MILK OF MOTHERS FROM MOSCOW, LONDON AND VERONA 
AND INFANT HEALTH OUTCOMES 
 
177 
 
5.4.7 Cough or wheeze reported at 12 months 
The only factor shown to be important to be for cough and/or wheeze development at the age of 12 months was HGF concentration in 
breast milk (Figure 13). There is a non-significant trend for HGF to be associated with  a higher risk of cough or wheeze development,  
OR 1,89 (95% CI 0,94 - 3,78). 
Figure 13 Importance of variables influence on cough/wheeze reported at 12 months and OR of cough/wheeze development due to the most important 
factors. 
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5.4.8 Reflux and/or vomiting reported at 12 months of age 
The only factor to show importance for reflux and/or vomiting reported at one year of age was detectability of IL13 in breast milk (Figure 
14). There is a non-significant  trend for detectability of this cytokine to be associated with less reflux and/or vomiting OR 0,21  (95% CI 
0,04 - 1,04).   
Figure 14 Importance of variables influence on reflux/vomiting reported at 12 months and OR of reflux/vomiting development due to the most important 
factors. 
O
R
 (
9
5
%
 C
I)
B M  IL  1 3  d e te c ta b le
0 .0
0 .5
1 .0
1 .5
 
CHAPTER 5: GROWTH FACTOR LEVELS AND CYTOKINES DETECTABILITY IN COLOSTRUM AND BREAST 
MILK OF MOTHERS FROM MOSCOW, LONDON AND VERONA AND INFANT HEALTH OUTCOMES 
 
179 
 
5.5 Discussion 
Mothers from the three geographical regions studied have different environment, 
diets, lifestyles making it difficult to take of account all factors which potentially may 
influence breast milk composition as well as health outcomes. I attempted to assess 
factors which from the common sense point of view and according to previous 
studies may have an impact of infants’ health at first year of life. All the results were 
adjusted to the site of collection as a potential confounder.  
 
5.5.1 Eczematous rash reported by the mother, atopy and allergy 
development 
Many authors studied colostrum and breast milk composition influence on atopy 
and/or allergy development in the first years of life and existing data are very 
inconclusive and studies produced conflicting results. 
The limitation of my study is that very few babies developed eczema, according to 
UK working party criteria and recurrent rash development reported by the mother is 
not the most accurate and precise criterion to use. It has been suggested that 
mothers tend to over-report food allergy in their children but childhood eczema can 
be accurately reported by caregiver (Silverberg et al., 2015).  
My data suggest that the gender of the baby substantially increasing the risk of 
eczematous rash development, with girls at higher risk. It is in contrast with the 
known higher prevalence of eczema during the first year of life in boys.  Differences 
in perception of eczema by women living in different countries and participating in 
our study could also play some role in reporting. Some of the previous studies have 
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shown that gender long term does not seem to play a significant role in risk of 
developing atopy, eczema (Schafer et al., 1999, Chonmaitree et al., 2014) and 
allergic rhinoconjunctivitis.   
Jones et al. showed that low sCD14 levels in BM is associated with eczema 
development (Jones et al., 2002a) and Savilahti reported similar trends for colostrum 
(Savilahti et al., 2005). Later studies, however, failed to reproduce these results and 
did not report any protective effect of this soluble receptor on eczema  (Snijders et 
al., 2006, Ismail et al., 2013). 
Since it was impossible to conduct statistical analysis focused on true eczema in this 
study, due to a very small number of children with this condition the analysis focused 
on maternal reported  eczema-like rash development and reported allergic events. 
My findings suggest that TGFβ2 in mature breast milk is associated with significant 
risk of eczematous rash reported by the age of 12 months. Some studies focused on 
growth factors analysis, supporting my data,  found increased TGFβ1 and TGFβ2 in 
colostrum associated with the eczema onset in infants (Kalliomaki et al., 1999, 
Bottcher et al., 2008, Kuitunen et al., 2012). However, contrasting results of a few 
other studies do not allow  final conclusions on the influence of TGFβ on eczema 
development (Bottcher et al., 2003, Snijders et al., 2006, Ismail et al., 2013, Orivuori 
et al., 2014).  
Detectable IL13 in mature milk reduced the risk of parent reported eczematous rash 
development, whilst detectability of this cytokine in colostrum had a similar effect on 
food allergy/sensitivity/intollerance reported by the mothers at six months of age. 
This is the first study to report this association between IL13 in colostrum/breast milk 
and eczematous rash and/or food adverse events in children at 12 months of age. 
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Although maternal reported events is a subjective measure and risk of bias is 
increased, these data could be validated on a larger cohorts of high risk infants.  
It is interesting to speculate on the likely mechanisms involved, if indeed it can be 
confirmed that TGFβ2 has an adverse effect on eczema development and IL13 is 
protective. While IL13 is a promoter of IgE production this and indeed all other Th1 
and Th2 cytokines have been reported to be lower in infants who subsequently 
developed allergic problems. This may be a reflection of greater immunological 
immaturity in those destined to be allergic. Provision of IL13 in BM may militate 
against this trend. Furthermore, it is now understood that eczema is primarily not an 
allergic disease but a defect of skin epithelial barrier function where allergy is a 
secondary phenomenon occurring as a consequence of penetration of allergens 
through the skin. TGFβ is not only a regulatory cytokine reducing Th1 and 2 activity 
but also stimulates fibroblast generation of interstitial collagen. Thus increased levels 
could enhance the scarring effects of skin inflammation in an infant with an a skin 
epithelial barrier defect. 
 
Most studies agree that levels of other breast milk immune active molecules, 
cytokines in particular, are not associated with atopy and/or allergy development in 
early life (Bottcher et al., 2003, Snijders et al., 2006, Kuitunen et al., 2012, Ismail et 
al., 2013). Only 14 infants developed allergic sensitisation by 1 year and it is 
therefore not possible to provide a statistical analysis on allergy alone. 
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5.5.2 Wheeze and asthma development 
Breast milk has been shown to be beneficial for the baby, probably by providing 
oligosaccharides which facilitate colonization of a favourable micro-biome which 
protect against neonatal pneumonia (Duijts et al., 2009) but there is little evidence to 
prove a similar degree of protective effect against asthma. As discussed in detail in 
Introduction section of this thesis, Gdalevich and Mimouni provided a meta-analysis 
suggesting protective effects of exclusive breastfeeding in the first months of life on 
later asthma development (Gdalevich et al., 2001b). However, the difficulty in 
combining data is that the wheeze/asthma phenotype differs between studies. Most 
infant wheezers do not subsequently have persistent asthma. 
Bronchiolitis in early childhood is known to be associated with asthma development 
later in life (Tregoning and Schwarze, 2010, Sigurs et al., 2005, Sigurs et al., 2010). 
Data from an Australian cohort showed low levels of IL10 to be associated with an 
increased risk of subsequent bronchiolitis (Bryan et al., 2007). Oddy and co-authors 
reported increased TGF-β1 levels in breast milk to have some protective effect 
against wheeze development in infancy (Oddy et al., 2003) but this conflicts with two 
other large cohort studies (Snijders et al., 2006, Orivuori et al., 2014). Based on the 
accumulated evidence now including my observations it is unlikely that levels of 
immune active molecules in human milk have significant influence on subsequent 
cough or wheeze development up to one year of age. My data did not show any 
significant influence of colostrum and/or BM immune  active molecules association 
with parent reported cough or wheeze episodes at 12 months of age. However, there 
is a trend to report, although not significant OR 1,89 (95% CI 0,94 - 3,78), for an 
association between HGF concentration in BM and higher risk of cough or wheeze 
development. HGF is known for its ability to attenuate allergen-induced airway 
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hyper-responsiveness and reduce local IL5 and IL13 response in asthmatic mice (Ito 
et al., 2005). It is too premature to make any conclusions on why BM HGF may lead 
to an increased incidence of parental reported cough or wheeze but this finding 
requires further investigation and more studies focusing on breast milk immune 
composition and long-term health outcomes is needed.    
 
5.5.3 Runny nose or cold and fever development 
Breastfeeding provides protection against infectious diseases in early infancy and 
may reduce mortality rates due to common infections by half (Verhasselt, 2010), with 
this effect  particularly evident in the developing world. These protective capabilities 
are evident for exclusive breastfeeding, while partial breastfeeding does not seem to 
provide the same level of protection (Ladomenou et al., 2010). 
Hitherto there is little evidence on the specific breast milk immune modulators which 
influence infections rates in infancy and early childhood. Most authors suggested 
that outcomes may be explained by the "rich" immunological composition of breast 
milk (Hanson et al., 2002). Hasselbalch et al. reported that prolonged breastfeeding 
to 10 months of age was associated with increased thymic size (Hasselbalch et al., 
1999). In another study breastfeeding amplified oral polio virus vaccination antibody 
responses (Pickering et al., 1998). 
Maternal reported fever may not be a reliable indicator of infection, and fever during 
the first year of life may have other causes such as teething (Hamilton and John, 
2013). My data suggest that mothers from Moscow tend to report both, fever and 
runny nose or cold episodes significantly rarer. It raises the question of difference in 
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perception of the same term by people residing in different countries and highlights 
importance of questionnaires validation in each population.   
There was no association between breast milk composition and runny nose or cold 
reported at 6 months of age, however, when assessed at one year of age, HGF 
levels in BM  were associated with reduced incidence of runny nose or cold reported 
at 12 months of age. HGF is well known for its ability to provide protection during 
inflammatory diseases, directly targeting macrophages or lymphocytes (Nakamura 
and Mizuno, 2010). HGF may well act in a similar fashion when transferred in a high 
amounts into the infant’s gut. This finding shows that HGF as a part of BM 
composition may not only play a very important role during very first days of life, 
providing infant gut immunity development and maturation. It may also be capable to 
influence long term health outcomes. Maternal reported runny nose or cold as an 
outcome should be taken critically. Existing data suggests that  a large proportion of 
infants suffer asymptomatic infections during first year of life (Chonmaitree et al., 
2014). As our participants has not been tested for infections I realise that this is a 
limitation. 
  
5.5.4 Reflux and/or vomiting development 
Data on breast milk ability to influence reflux development in early infancy is very 
limited. It has been suggested that the protein content of human milk may influence 
acid gastro-oesophageal reflux incidence and fortification of human milk may lead to 
a more severe non acidic reflux which may be explained by high variablity of BM 
composition (Aceti et al., 2009). No studies have investigated breast milk immune 
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constituent influences on reflux development in infants. Given the association with 
food induced eosinophllic oesophagitis this may be a fruitful line of research. 
 
From my study it appears that no factors are associated with reflux and/or vomiting 
incidence reported at the age of 12 months. 
 
5.5.5 Conclusion 
The aim of the study was to investigate whether key immune factors in breast milk 
have an impact on infant health outcomes. Unfortunately, sample size do not allow 
me to dichotomise colostrum into smaller groups, according to day of collection. This 
approach would provide stronger outcomes but not meaningful statistical results. 
Despite limitations, the results suggest that variability of breast milk composition has 
an effect on maternal reported eczematous rash, food allergy, sensitivity, 
intolerance,  runny nose and cold and potentially even reflux and/or vomiting 
development in infancy. 
The results support the concept that IL13 and HGF have some protective effects and 
TGFβ2 may act as a risk factor, which may explain the diversity of results from 
epidemiological studies on the health promoting effects of breastfeeding. These 
results provide additional information which can be used in non-communicable 
diseases prevention research. Intervention trials on larger cohorts from genetically 
diverse populations are needed in order to investigate potential target cytokines 
and/or growth factors, which may benefit infants’ health both, short and long term. It 
is crucial to take into account a number of possible confounders which may influence 
human milk composition and health outcomes.
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6 Colostrum immune composition and immunological outcomes 
assessment using Principal Component analysis (PCA)  
 
6.1 Abstract  
Background: Cytokines and growth factors in colostrum and breast milk (BM) are 
likely involved in facilitating infant gut immunity maturation.  The complex 
immunological composition of human milk confers potential beneficial effects 
including protection against infections and atopy/allergy development. Environmental 
and maternal factors may influence the levels of immune active molecules in breast 
milk but there is still uncertainty which factors are responsible. I attempted to 
highlight specific groups which can be characterised by a particular compositional 
pattern which differed in outcome from the general population, using principal 
component analysis (PCA) of the data on colostrum and breast milk of women from 
three European countries. I also assessed correlations between the levels of 
immune active molecules in colostrum. 
Objectives: To examine colostrum/breast milk composition for distinct patterns and  
cluster them into specific "lactotypes". To assess if any "lactotype" was associated 
with maternal or environmental exposures and/or immunological outcomes in the 
infants at 6 and 12 months of age. 
Methods: A prospective cohort study of mother/infant pairs in London (N=105), 
Moscow (N=200) and Verona (N=80).  Participants underwent allergy testing, and 
questionnaire interview. Colostrum samples (days 0-6) and Mature Breast Milk (4-6 
weeks) were analysed in duplicate at Imperial College London using 
electrochemiluminescence (Meso Scale Discovery®) for level of TGF-β 1,2,3; HGF, 
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IL2, IL4, IL5, IL10, IL12, IL13, IFN-γ. Principal component analysis was used for data 
assessment. 
Results:  Colostrum composition could be divided into groups depending on the 
predominance of the immune active molecules profile. According to PCA analysis 
four "lactotypes", based from their coordinates on PCA, can be highlighted. They 
may be divided into two clusters, which I labelled A and B. Women having Cluster A 
"lactotype" are distinct from the cluster B "lactotype" and vice versa. Coordinates of 
the clusters at PCA: Cluster A1 (IL5 and IL10 group (r = Dim.1 from 0.503 to 0.627; 
Dim. 2 from 0.370 to 0.539)); A2 (IL12 and IL13 group (r = Dim.1 from 0.534 to 
0.574; Dim. 2 from 0.712 to 0.718)) and Cluster B1 (IL2 and IL4 group (r = Dim.1 
from 0.421 to 0.522; Dim. 2 -0.123)); and B2 (TGFβ 1,2,3 and HGF (r = Dim.1 from 
0.626 to 0.722; Dim. 2 from-0.241 to -0.510)). 
When exposures and health outcomes have been applied at PCA plot I found that 
mothers living in London significantly more often were associated with clusters B1 
and B2 (Est. Dim.1=0.432, p<0.01; Est. Dim.2=-0.253, p=0.04). Assessing outcomes 
at 6 and 12 months: cough or wheeze reported (Est.=-0.380, p<0.01), eczematous 
rash (Est.=-0.261, p=0.04) or any immunological outcomes (Est.=-0.276, p=0.03) 
were more often associated with Clusters B1 and B2. 
Conclusions: Breast milk has a very complex composition and novel approaches to 
its' assessment are needed. By applying PCA analysis to the data, it is possible to 
classify breast milk according to profile, differing from the general population. These 
"lactotypes" are characterised by predominance of a number of immune active 
molecules. The data suggests the presence of four "lactotype" groups: A1 (IL5 and 
IL10), A2 (IL12 and IL13), B1 (IL2 and IL4), B2 (TGFβ1,2,3 and HGF). The A1 and 
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A2 "lactotypes” are associated with reduced incidence of eczematous rash, cough or 
wheeze and any reported immunological outcomes (eczematous rash, cough or 
wheeze and positive atopic status of a baby combined together) at one year of age. 
Mothers from London tend to fall into cluster B "lactotype" groups significantly more 
often in comparison to women from Moscow and Verona. 
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6.2 Introduction  
Breast milk is a complicated mixture of a large variety of components (D'Alessandro 
et al., 2010) and each  may have an active role in the early stage of infant 
development. The standard approach in  breast milk research is to study one or two 
components of breast milk   but it is likely that no single immune active molecule but 
most probably a combination effect the immunological outcomes developing later in 
life. 
In this study I assessed immune active molecules levels and exposures influencing 
breast milk composition using mixed models.  This is a reliable  method to highlight 
the most important exposures influencing breast milk composition, but it does not 
provide an insight into the complexity of the breast milk and does not  highlight 
patterns or clusters of immune modulators which might affect outcomes in the 
infants. 
As a last and final step of the data analysis I classified mothers breast milk 
composition into "lactotypes", in accordance with a particular physiological patterns, 
and analyse immunological outcomes attachment to these clustered "lactotypes". 
The most suitable method to achieve this is principal component analysis (PCA) 
which allows pattern identification and  clusters data and assesses if any trends are 
present within the set of data. This method has been previously used in breast milk 
research in one previous study (Johansson et al., 2011). However, the focus of the 
study was very different (PUFA BM composition), the cohort size was limited (22 
people) and no cytokines and/or growth factors were taken into account. 
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6.3 Methods  
The main purpose of  principal component analysis is pattern identification, and  
reduces the dimensions of the dataset with a minimal loss of information available. 
For the purpose of PCA I used growth factors and cytokine concentrations as 
continuous variables rather than just detectability as it is the only way to achieve 
meaningful and well powered data for this type of analysis. Categorical variables 
have been categorised and half of the threshold used when the concentration of 
cytokines were below the lowest level of detection. 
The steps involved are listed below. 
 
6.3.1 Missing values evaluation  
In order to provide good quality information from PCA analysis it is preferable to 
analyse not less than 50% of the data. Data on immune active molecules which 
have more than 50% of missing values are excluded from the further analysis  
(Table 19). 
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Table 19 Variables and cytokines, growth factors missing data percentage 
VARIABLE NAME Missing %  CYTOKINE NAME Missing % 
Eczematous rash 58 14.65  Colostrum HGF concentration 25 6.31 
Food Allergy/Sensitivity/Intolerance 59 14.90  Colostrum IFNγ concentration 54 13.64 
Fever 58 14.65  Colostrum IL10 concentration 54 13.64 
Runny nose or cold 6 mo 60 15.15  Colostrum IL12 concentration 54 13.64 
Cough or wheeze 60 15.15  Colostrum IL13 concentration 54 13.64 
Runny nose cold 12mo 123 31.06  Colostrum IL2 concentration 54 13.64 
Stool consistency (Bristol chart) 181 45.71  Colostrum IL4 concentration 54 13.64 
Baby atopy SPT 162 40.91  Colostrum IL5 concentration 54 13.64 
Reflux/Vomiting 6 mo 120 30.30  Colostrum TGFβ1 concentration 116 29.29 
Reflux Vomiting 12mo 117 29.55  Colostrum TGFβ2 concentration 116 29.29 
Country of collection 0 0.00  Colostrum TGFβ3 concentration 116 29.29 
Labour Type 3 0.76  BM HGF concentration 187 47.22 
Sex of the baby 7 1.77  BM IFNγ concentration 206 52.02 
Gestation 31 7.83  BM IL10 concentration 206 52.02 
Exclusive BF 66 16.67  BM IL12 concentration 206 52.02 
Age of the first food intake 117 29.55  BM IL13 concentration 206 52.02 
Previous Deliveries 1 9 2.27  BM IL2 concentration 206 52.02 
Maternal Atopy 109 27.53  BM IL4 concentration 206 52.02 
    BM IL5 concentration 206 52.02 
    BM TGFβ1 concentration 237 59.85 
    BM TGFβ2 concentration 237 59.85 
    BM TGFβ3 concentration 237 59.85 
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6.3.2 Missing values imputation 
As a second step, imputation of missing values for all cytokines available has been 
performed. This is an absolute requirement as a preliminary step prior to performing 
a PCA. 
 
Regularised iterative PCA algorithm have been used, in order to avoid over-fitting 
problems and this method consists of imputing missing values with initial values such 
as the mean of the variable and then performing PCA on the completed dataset. 
These steps of estimation of the parameters via PCA and imputation of the missing 
values are iterated until convergence. 
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6.3.3 PCA with no supplementary variables – standard PCA 
This step is done in order to estimate the number of dimensions for PCA using 
different methods: 
Scree-plot: 
Table 20 Components for standard PCA 
Number of 
Eigenvaluea 
Eigenvalueb Percentage of 
Variancec 
Cumulative 
Percentage of 
Varianced 
component 1 3.865 32.212 32.212 
component 2 2.823 23.521 55.733 
component 3 1.341 11.176 66.909 
component 4 1.172 9.766 76.675 
component 5 0.801 6.675 83.350 
component 6 0.722 6.018 89.369 
component 7 0.605 5.041 94.410 
component 8 0.412 3.435 97.845 
component 9 0.185 1.538 99.383 
component 10 0.064 0.533 99.917 
component 11 0.007 0.062 99.979 
component 12 0.003 0.021 100.000 
 
a. Number of Eigenvalue - The number of eigenvalues are always equal the 
number of variables that are used in the principal components analysis. 
b. Eigenvalue - Eigenvalues are the variances of the principal components.  As PCA 
is conducted on the correlation matrix, the variables are standardized, which means 
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that each variable has a variance of 1, and the total variance is equal to the number 
of variables used in the analysis, in the case of our study, 12. 
c. Percentage of Variance - This is the proportion of the total variance that each 
factor accounts for. For example, 0.32212 = 3.865/12. 
d. Cumulative - This is the sum of the percentage column. For example, 55.733 = 
32.212+ 23.521. 
Figure 15 Scree plot (Standard PCA) 
 
 
Figure 15 shows the proportion of variance against the component number.  These 
values can be seen in the first and third column in the table above. The line drops 
rapidly and from the third component but subsequently the line  progressively 
flattens, which means that each successive component is accounting for smaller and 
smaller amounts of the total variance. 
 
Cross-validation: each cell of the data matrix is alternatively removed and predicted 
with a PCA model. The number of components which leads to the smallest mean 
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square error of prediction is retained. Specifically, the mean squared error of 
prediction (MSEP) is calculated for each number of components and 2 is the number 
of components retained for the PCA. Three components could be used for PCA 
analysis but it would lead to a significant increase in difficulty of result interpretation. 
Dimension 1 (PC1 on PCA plots) coordinates are more important than dimension 2 
(PC2 on PCA plots) as they cover more data (32,21% vs. 23,52%).
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The output of a completed dataset which is scaled to unit variance analysed in a previous step is used for an input of the PCA 
function.  
Table 21 Immune active molecules correlations for both dimensions: Dim. 1 and Dim. 2 (Standard PCA with no exposures or outcomes) 
Variables Correlation 
Dim. 1 
p.value  Variables Correlation 
Dim. 2 
p.value 
Colostrum TGFβ1 concentration 0.868 <0.001  Colostrum IL5 concentration 0.854 <0.001 
Colostrum TGFβ3 concentration 0.852 <0.001  Colostrum IL13 concentration 0.835 <0.001 
Colostrum TGFβ2 concentration 0.777 <0.001  Colostrum IL12 concentration 0.835 <0.001 
Colostrum IL2 concentration 0.756 <0.001  Colostrum IL10 concentration 0.798 <0.001 
Colostrum IL4 concentration 0.702 <0.001  Colostrum TGFβ3 concentration -0.100 0.047 
BM HGF concentration 0.519 <0.001  Colostrum TGFβ1 concentration -0.101 0.046 
Colostrum HGF concentration 0.515 <0.001  BM HGF concentration -0.137 0.006 
Colostrum IFNγ concentration 0.364 <0.001     
Colostrum IL10 concentration 0.132 0.009     
Colostrum IL5 concentration 0.131 0.009     
This table shows which variables are highly correlated to each principal component. They provide not only the correlation 
coefficients, but also tests of significance of these variables. Numbers in columns Correlation Dim. 1 and 2 provide information on 
coordinates for each variable at a particular dimension.  
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Biplot graphics use points to represent the scores of the observations on the 
principal components, and it uses vectors to represent the coefficients of the 
variables (i.e. cytokines) on the principal components. The length of the vectors 
represent the importance of a particular variable within a particular dimension, but 
not concentration. 
 
Points that are close together correspond to observations that have similar scores on 
the components displayed in the plot. These points also correspond to observations 
that have similar values on the variables. 
 
Both the direction and length of the vectors can be interpreted. Vectors point away 
from the origin in some direction. A vector points in the direction which is most like 
the variable represented by the vector. Highly correlated variables point in the same 
direction; uncorrelated variables are at right angles to each other. 
 
Coordinates of the observation can be approximated by projecting the point onto the 
variable vectors within the biplot. In order to do so, imagine the vector extension in 
both directions. The observations, whose points project furthest in the direction in 
which the vector points, are the observations that have the most of whatever the 
variable measures. Thus, vectors that point in the same direction correspond to 
variables that have similar response profiles, and can be interpreted as having 
similar meaning in the context set by the data. 
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6.3.4 PCA with the addition of supplementary individuals, supplementary 
quantitative variables and supplementary categorical variables 
(exposures and health outcomes). 
The number of dimensions for PCA has been estimated using different methods: 
 
 Scree-plot 
Table 22 Components (PCA with supplementary variables) 
Nuber of 
Eigenvalue 
Eigenvalue Percentage of 
Variance 
Cumulative 
Percentage of 
Variance 
component 1 3.635 30.289 30.289 
component 2 2.377 19.811 50.100 
component 3 1.610 13.413 63.514 
component 4 0.830 6.916 70.430 
component 5 0.765 6.372 76.802 
component 6 0.708 5.900 82.702 
component 7 0.630 5.249 87.951 
component 8 0.528 4.400 92.351 
component 9 0.380 3.167 95.518 
component 10 0.335 2.793 98.311 
component 11 0.124 1.037 99.348 
component 12 0.078 0.652 100.000 
 
Figure 16 Scree plot (PCA with supplementary variables) 
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The line drops rapidly in a similar way to PCA without supplementary variables and 
from the fourth component line is almost flat. 
As it has been done for Standard PCA analysis, cross-validation step has been 
performed: the MSEP is calculated for each number of components.  
5) The last step is PCA performance and results interpretation. The output 
(completed dataset which is scaled to unit variance) of the previous step is as input 
of the PCA function. 
The correlation coefficient between each continuous variable (e.g. HFG, IL5 etc.) 
and the dimension (PCA Dim. 1 or PCA Dim. 2) of the PCA is calculated for each 
dimension. The correlation coefficients significantly different from zero are sorted 
and returned by the software. 
 
For the categorical variables, an ANOVA model with one factor is done for each 
dimension; the coordinates of the individuals are explained by the categorical 
variable. F-test is derived to assess if variable has an influence on the dimension 
and T-tests are done category by category. It can be seen if coordinates of the 
individuals of the sub-population defined by one particular category are significantly 
different from 0. 
6.3.5 Correlation heat map 
In order to evaluate how well immune active molecules correlate one with another I 
used Spearman rank's correlation as data is not normally distributed. Concentrations 
in pg/ml have been used for growth factors and detectability for cytokines. 
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6.4 Results 
Table 23 and Table 24 show particular variables and the axes to which they are 
linked. They illustrate which continuous variables (e.g. particular immune active 
molecule) are the most correlated to each component and which categorical 
variables and categories (e.g. country of collection, health outcomes) describe each 
axis the best. Variables and categories have been sorted by p-value and only 
significant (p<0.05) results are kept and presented in the tables. 
 
6.4.1 Lactotypes 
It is evident that immune active molecules can be grouped into four clusters 
according to their location on the plot (Figure 17) determined by correlation 
coefficient (coordinates, which can be found in Table 23 and Table 24) between 
each continuous variable (immune active molecules in colostrum) and the dimension 
of the PCA (PCA Dim. 1 or PCA Dim. 2). As PCA Dim. 1 covers more data than PCA 
Dim. 2, coordinates within this dimension are relatively more important. Growth 
factors are grouped together (r = Dim.1 from 0.626 to 0.722; Dim. 2 from-0.241 to -
0.510), similar trends are seen for IL2 and IL4 (r = Dim.1 from 0.421 to 0.522; Dim. 2 
-0.123), IL5 and IL10 (r = Dim.1 from 0.503 to 0.627; Dim. 2 from 0.370 to 0.539), 
IL12 and IL13 (r = Dim.1 from 0.534 to 0.574; Dim. 2 from 0.712 to 0.718) 
respectively. 
 
6.4.2 Environmental factors and health outcomes 
The first component (PCA Dim. 1) is mainly characterized by site of collection 
(r=0.027, p<0.01), runny nose or cold reported at 12 months (r=0.019, p=0.02), reflux 
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and/or vomiting reported at 12 months (r=0.021, p<0.01) and multiparity (r=0.017, 
p=0.04). 
 
Absence of reflux and/or vomiting has a positive coordinate (Est.=0.319, p<0.01) on 
this axis, no reported runny nose or cold at 12 months of age also have a positive 
coordinate (Est.=0.273, p=0.04) same applies for the samples collected in London 
(Est.=0.432, p<0.01) whereas samples from Verona have a negative coordinate 
(Est.=-0.509, p<0.01). This gives the direction of the axis: individuals with high 
coordinates on the first component will tend not to have reflux and/or vomiting and 
runny nose or cold. 
 
The second component (PCA Dim. 2) is characterized by cough or wheeze reported 
(r=0.021, p=0.02). Individuals with low coordinates on this axis will tend to have 
cough or wheeze reported (Est.=-0.380, p<0.01), eczematous rash (Est.=-0.261, 
p=0.04) or any immunological outcomes (Est.=-0.276, p=0.03) (Figure 18Figure 
19Figure 20). 
 
6.4.3 Correlation heat map 
I assessed the correlation between different markers in colostrum and results are 
presented in (Table 25).  
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Table 23 Dimension 1 variables 
Variables Correlation 
Dim.1 
p.value  
 
Variables R2 Dim.1 p.value 
Colostrum TGFβ1 concentration 0.722 <0.001  Reflux/Vomiting at 12 months of age 0.021 0.004 
Colostrum TGFβ3 concentration 0.699 <0.001  Site of collection 0.027 0.005 
Colostrum TGFβ2 concentration 0.639 <0.001  Runny nose or cold at 12 months of 
age 
0.019 0.024 
Colostrum IL5 concentration 0.627 <0.001  Multiparity 0.017 0.037 
Colostrum HGF concentration 0.626 <0.001     
Colostrum IL12 concentration 0.574 <0.001  Category Estimate Dim.1 p.value 
Colostrum IL13 concentration 0.534 <0.001  No Reflux/Vomiting 0.319 0.004 
Colostrum IL2 concentration 0.522 <0.001  Country of collection UK 0.432 0.005 
Colostrum IL10 concentration 0.503 <0.001  No Runny nose or cold at 12 months 
of age 
0.273 0.040 
Colostrum IL4  
concentration 
0.421 <0.001  Country of collection Italy -0.509 0.001 
BM HGF concentration 0.258 <0.001     
Colostrum IFNγ concentration 0.218 <0.001     
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Table 24 Dimension 2 variables 
Variables Correlation 
Dim.2 
p.value  Variables R2 Dim.2 p.value 
Colostrum IL13 concentration 0.718 <0.001  Cough or wheeze 0.021 0.018 
Colostrum IL12 concentration 0.712 <0.001     
Colostrum IL5 concentration 0.539 <0.001  Category Estimate Dim.2 p.value 
Colostrum IL10 concentration 0.370 <0.001  Eczematous rash reported -0.261 0.045 
Exclusive breastfeeding 0.100 0.048  Country of collection UK -0.253 0.042 
Colostrum IL2 concentration -0.123 0.014  Cough or wheeze reported -0.380 0.004 
Colostrum HGF concentration -0.241 <0.001     
Colostrum TGFβ2 concentration -0.388 <0.001     
BM HGF concentration -0.440 <0.001     
Colostrum TGFβ3 concentration -0.494 <0.001     
Colostrum TGFβ1 concentration -0.510 <0.001     
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Figure 17 PCA with supplementary variables plot 
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Figure 18 PCA with Immunological outcomes plot 
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Figure 19 PCA with Cough or wheeze outcome plot 
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Figure 20 PCA with Eczematous rash reported outcome plot 
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Table 25 Correlation between breast milk composition components 
  HGF IFN-γ IL10 IL12 IL13 IL2 IL4 IL5 TGFβ1 TGFβ2 TGFβ3 Protein Na Colostrum 
collection 
time 
HGF   0,31** 0,53** 0,19** 0,20** 0,29** 0,12* 0,35** 0,58** 0,64** 0,72** 0,70** 0,66** -0,39** 
IFN-γ 0,31**   0,31** 0,31** 0,32** 0,58** 0,30** 0,28** 0,19** 0,27** 0,22** 0,24** 0,25** -0,18** 
IL10 0,53** 0,31**   0,33** 0,38** 0,30** 0,19** 0,35** 0,33** 0,44** 0,46** 0,40** 0,47** -0,25** 
IL12 0,19** 0,31** 0,33**   0,58** 0,23** 0,56** 0,41** 0,09 NS 0,12* 0,11 NS 0,09 NS 0,15* -0,09 NS 
IL13 0,20** 0,32** 0,38** 0,58**   0,20** 0,25** 0,44** 0,17** 0,23** 0,18** 0,09 NS 0,14* -0,15* 
IL2 0,29** 0,58** 0,30** 0,23** 0,20**   0,30** 0,38** 0,18** 0,25** 0,24** 0,21** 0,22** -0,11 NS 
IL4 0,12* 0,30** 0,19** 0,56** 0,25** 0,30**   0,17** -0,02 
NS 
0,05 NS 0,02 NS 0,07 NS 0,13* -0,04 NS 
IL5 0,35** 0,28** 0,35** 0,41** 0,44** 0,38** 0,17**   0,22** 0,21** 0,30** 0,27** 0,26** -0,18** 
TGFβ1 0,59** 0,19** 0,33** 0,09 NS 0,17** 0,18** -0,02 
NS 
0,22**   0,79** 0,77** 0,39** 0,44** -0,21** 
TGFβ2 0,64** 0,27** 0,44** 0,12* 0,23** 0,25** 0,05 NS 0,21** 0,79**   0,72** 0,44** 0,53** -0,16* 
TGFβ3 0,72** 0,22** 0,46** 0,11 NS 0,18** 0,24** 0,02 NS 0,30** 0,77** 0,72**   0,56** 0,58** -0,35** 
Protein 0,70** 0,24** 0,40** 0,09 NS 0,09 NS 0,21** 0,07 NS 0,27** 0,39** 0,44** 0,56**   0,72** -0,42** 
Na 0,66** 0,25** 0,47** 0,15* 0,14* 0,22** 0,13* 0,26** 0,44** 0,53** 0,58** 0,72**   -0,38** 
Colostrum 
collection 
time 
-0,39** -0,18** -0,25** -0,09 NS -0,15* -0,11 
NS 
-0,04 
NS 
-0,18** -0,21** -0,16* -0,35** -0,42** -0,38**   
* p value  <0.05; **  p value <0.01; NS - No statistical significance 
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6.5 Discussion 
Breast milk research comprises a number of studies focused on immune active 
composition with investigators usually focusing on a particular pathway of interest. In 
this study I attempted to assess data on the colostrum immunological composition using 
PCA. It is likely that a combination of factors rather than a single immune active 
molecule have a higher probability to play a major role in gut immunity maturation and 
immune modulation during first months of life. Whether women can be classified 
according to a particular breast milk immune composition pattern, remains unknown. 
This is the first attempt, to define breast milk "lactotypes".  
 
Although it is of an undoubted importance to study and analyse single factors of a 
particular interest, cluster analysis is also required. Among the large number of studies 
done in the field of breast milk research few have used PCA or similar cluster analysis 
approaches. Cabrera-Rubio et al. studied human milk microbiome, applying PCA 
analysis (Cabrera-Rubio et al., 2012) and Johansson and co-authors assessed PUFA's 
levels association with allergy in mothers, providing an intriguing insight into this topic 
(Johansson et al., 2011). 
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6.5.1 Lactotypes 
In this work I attempted to highlight groups of mothers which can be characterised by a 
certain immune profile of their breast milk. As it can be seen from the PCA plot (Figure 
18) mothers can be clustered according to the trends seen in their breast milk 
composition and following groups can be visualised (Figure 22): 
 General population group 
 IL5 and IL10 group (Cluster A1) 
 IL12 and IL13 group (Cluster A2) 
 IL2 and IL4 group (Cluster B1) 
 Growth factors group (Cluster B2) 
 
Figure 22 Lactotypes concept 
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It is very important to understand that if woman has high levels of one cytokine in her 
breast milk it does not mean that other immune active molecules in her breast milk will 
be present in lower concentrations. At the same time, women from Cluster A groups are 
not able to share high levels of immune active molecules of Cluster B groups. 
It is difficult to explain how some of the immune active molecules cluster in a particular 
way. IL5 andIL10 are clustered together, although IL10 is known to inhibit production of 
IL-5 by Th2 cells (Del Prete et al., 1993). Although IL12 and IL13 have opposite vectors 
of action they grouped together in colostrum. It is known that IL13 is a potent enhancer 
of IL12 production (D'Andrea et al., 1995). 
 
Two other clusters are more expected as IL2 and IL4 are members of a same cytokine 
family and may synergize in a certain circumstances (Steinke and Borish, 2001). All 
growth factors are grouped together which is also explainable, as TGFβ 1,2 and 3 are 
members of the same family and HGF activity is closely linked with TGFβ activity 
(Nakamura and Mizuno, 2010). 
 
The results provide a new angle on breast milk composition and suggest that it can be 
grouped according to predominance of immune active molecules. Future research 
should be focused on attempts to clarify the groups depending on their breast milk 
profile and assess any environmental and maternal factors, as well as short and long 
term health outcomes associated with these groups. 
 
6.5.2 Correlation heat map 
Knowledge on correlations can provide complimentary information to PCA analysis. As it 
can be seen from the Table 25 most of the immune active molecules in colostrum 
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correlate one with another, although the strength of these correlations varies. All 
immune active molecules are negatively correlated with the time of collection, as 
previously discussed. 
Growth factors are moderately to strongly correlated, and there is a similar pattern on 
PCA plot. It is expected, for TGFβ 1,2 and 3 as they are different isoforms of the same 
protein. HGF is also strongly correlated with TGFβ, most probably associated with 
complimentary biological activity. Growth factors do not correlate or have a very weak 
correlation with cytokines apart from IL10. Weak to moderate correlation between TGFβ 
and IL10 can be explained by their cooperation in T reg. responses (Jutel et al., 2003). 
Another significant and moderate correlation to be noted is IL4 with IL12. It is known that 
IL4 can synergise with IL12 (Bream et al., 2003) and this moderate correlation allows us 
to assume that they are involved in similar teamwork within colostrum.  IL12 is also 
moderately correlated with IL13 and to a lesser extent with IL5. Future research on 
cytokine correlations in conjunction with PCA models will allow assessment of patterns 
predominant for the general population and highlight specific groups differing from the 
reference range. 
 
6.5.3 Immunological outcomes associated with "lactotypes" 
Data analysis using PCA facilitates evaluation of health outcomes associations with 
"lactotypes". Figure 19 shows that infants with adverse immunological outcomes 
reported at one year of age are often located in the PCA Dim.2 negative coordinate and 
associated with the cluster B2 "growth factors group", especially colostrum HGF levels. 
The same applies to eczematous rash (Figure 21) and cough or wheeze (Figure 20) 
when assessed individually. At the same time it seems that colostrum with profile 
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clusters A1 and A2 have a more prominent protective effect on cough or wheeze 
development. 
These results correlate well with the data from Chapter 3, where using mixed models 
higher HGF was associated with more maternal reported eczematous rash and 
episodes of food  allergy/sensitivity/intolerance. 
Most of the studies showed some protective effect of TGFβ on immunological outcomes 
development (Oddy and Rosales, 2010), but data is far from conclusive as study design 
and outcomes assessed differ one from another. It may be explained by a certain 
difference in TGFβ isoforms function as it has been shown that TGFβ3 is different from 
TGFβ1 and 2 when reviewed as a protein structure, with a particular difference present 
in the structure of the active domain (Laverty et al., 2009). When mammary gland 
involution has been studied TGFβ3 has been found to be up-regulated by milk 
stasis, and not by circulating concentration, and induces apoptosis in mammary gland 
epithelium (Nguyen and Pollard, 2000). TGFβ1 and 2 do not seem to possess similar 
capabilities. Differences in TGFβ isoforms function have been later reported in  
cutaneous scarring experiments (Ferguson and O'Kane, 2004) in animal models 
(Whitby and Ferguson, 1991a) and in human, with TGFβ3 isoform associated with 
improvement in scarring (Ferguson et al., 2009).  
 
Potential action in breast milk leading to an increased risk of eczematous rash 
development as well as cough or wheeze may be similar to HGF function in skin 
shown in mice models (Kurz et al., 2002). HGF induced migration of Langerhans cells 
from mouse epidermis in skin biopsy assays. 
CHAPTER 6: COLOSTRUM IMMUNE COMPOSITION AND IMMUNOLOGICAL OUTCOMES ASSESSMENT 
USING PRINCIPAL COMPONENT ANALYSIS 
 
214 
 
Interestingly, samples collected in London has a tendency to fall into clusters B1 and 
B2 much more often than samples collected in Moscow and Verona. It is not clear 
what are the reasons leading to this tendency. Clusters B1 and B2 are associated 
with increased potential allergy outcomes, but it remains to be established whether 
this is a cause and effect relationship. It could equally be an epi-phenomenon as 
allergy overall is more common in UK. The gene/environment interactions which 
contribute to increased risk of allergy could in parallel also change BM cytokine 
profiles without influencing allergy outcomes. A within population intervention study 
will be required to clarify this. 
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6.6 Conclusion 
The results do not give a clear picture of breast milk composition but provide a different 
approach to breast milk analysis. Human milk has a very complex composition, full of 
wide range of immunological markers and many other important components. In this 
study I attempted to use a different approach to data analysis focusing on a combination 
of factors, rather than single factors. Lactating women can be divided into groups, 
according to specific individual characteristics of their milk. Future studies should 
address this issue on larger numbers to identify lactotypes associated with different 
immunological outcomes. 
 
Additional approaches to cluster analysis should be considered for future research in 
attempts to get the best quality of statistical analysis and potentially more  meaningful 
results.
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7 Final summary 
 
Allergic diseases such as asthma, eczema, hay-fever and food allergy are the 
commonest chronic diseases of childhood in many countries, and there is evidence that 
early life events, such as variations in breastfeeding patterns, maternal diet, 
environmental and microbial exposures may be important in their development. There 
are still a number of hurdles to overcome before we come to a clear understanding on 
how to translate these associations into clinical practice, because association is not 
synonymous with cause and effect.. There is some evidence that probiotic (Prescott et 
al., 2008, Boyle et al., 2011, Rautava et al., 2002) administration to pregnant and 
lactating women or high fish intake (Urwin et al., 2012) alters breast milk immune 
composition. Although the specific changes identified are not always correlated with 
clinical outcomes, maternal supplementation during pregnancy and lactation to enhance 
breast milk quality may have a beneficial influence on health outcomes, and modulation 
of breast milk composition is the most likely mechanism (Dotterud et al., 2010). 
The possibility that interventions which modify maternal immunity can impact infant 
immune responses by changing breast-milk composition is supported by associations 
between breast milk composition and allergic outcomes (Jones et al., 2002a, Savilahti 
et al., 2005). Variations in breast milk immune composition (and the infant’s response to 
breast milk immune constituents) may also explain some of the conflicting results of 
studies evaluating whether prolonged exclusive breast-feeding can prevent allergic 
disease (Hong et al., 2011, Kramer and Kakuma, 2012). There are over 250 proteins in 
human breast milk, including a wide variety of cytokines, inflammatory mediators, 
signaling molecules, and soluble receptors (D'Alessandro et al., 2010). Yet there is only 
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a limited literature on the relationship between maternal diet, breast milk immune 
constituents and allergy development. 
In this prospective birth cohort study mothers were recruited from three cities, in 
countries, with differing climate, genetics, and diet.  Environmental and/or maternal 
exposures were assessed in relation to colostrum and BM immune composition and in 
turn on health outcomes at 6 and 12 months of age. The sequence of investigations is 
described in Figure 23 and Figure 24. 
Figure 23 Study process 
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Figure 24 Study logics 
 
Published studies suggest that a number of exposures can influence colostrum and BM 
composition, and my data supports this concept. Among them, the most influential 
factor leading to a significant decline of immune active molecules in colostrum is time of 
collection. This finding is in agreement with many studies reporting similar patterns 
(Striker et al., 2004, Urwin et al., 2012). This factor is crucial and should be taken into 
account in interpreting results from studies. It is known that levels of cytokines in 
colostrum are higher than in BM as it has been previously reported (Ustundag et al., 
2005, Rigotti et al., 2006, Peroni et al., 2010) and confirmed by my data. 
It is unclear whether higher concentrations in colostrum are due to low volume with 
consistent absolute levels or due to differences in active transport of the immune 
modulators into colostrum. I attempted to correct for the stage of lactation, to normalise 
immune active molecules decline over time. Standardisation using the levels of total 
protein and sodium were potential correction molecules for the stage of lactation.  
However, using ratios of immune modulator to protein or sodium failed to account for 
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the stage of lactation. However, using this approach the absolute and relative declines 
of immune active molecules over a period of time varied particularly in relation to TGFβ 
isotype. As it is assumed that TGFβ has biological relevance and is active in the infant 
gut (Ogawa et al., 2004), these results suggest that infants may need relatively higher 
amounts of TGFβ 1 and 2 in the first week of life. TGFβ3 on the other hand, in relation 
to total protein, had a different pattern with increasing  ratio over time.  This may be 
explained by TGFβ3 being significantly different from TGFβ1 and 2 in its detailed 
tertiary structure of the active domain despite homology in amino acid sequence 
(Laverty et al., 2009). Existing data (Laverty et al., 2009) provides some evidence to 
suggest that TGFβ3 isoform may be distinct in its' functions to other TGFβ isoforms. 
These differences have been observed in cutaneous scarring experiments (Ferguson 
and O'Kane, 2004). Mammalian embryos heal with no scarring and full skin recovery 
(Whitby and Ferguson, 1991b) in association with expression of high levels of TGFβ3 
and low levels of TGFβ1 and 2 (Whitby and Ferguson, 1991a). Similar TGFβ3 function 
have been shown in human with this isoform associated with improvement in scarring 
(Ferguson et al., 2009). TGFβ3 have been shown to be up-regulated by milk stasis, 
 and not by circulating concentration, and induces apoptosis in mammary gland 
epithelium during involution, in contrast to TGFβ1 and 2 (Nguyen and Pollard, 2000), 
which may explain variations in TGFβ isoforms decline over time. 
 
Another exposure influencing colostrum/breast milk constituents is country of collection. 
Significant differences were apparent for TGFβ1,2 and 3 levels being highest in milk of 
mothers residing in London and HGF concentration lowest in colostrum/BM of mothers 
from Verona. The explanation for this phenomenon is not due to variations in mode of 
delivery, parity, maternal age, maternal diet, maternal atopy, smoking pet or mould 
exposure between sites. Other studies also found a significant difference of BM 
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immunological profiles between lactating mothers residing in different countries 
(Amoudruz et al., 2009, Holmlund et al., 2010, Peroni et al., 2010), but there is no clear 
understanding what caused the differences. A possible explanation is that bacterial 
exposure in the three countries is different which, in turn could lead to changes in BM 
immune composition. It may be also explained by differences in maternal diet, which 
was only assessed relatively superficially  and should be improved in future research.  
Further work is needed to understand the reasons for variations between sites in human 
milk composition. There is a trend for parity to influence colostrum/BM immune 
composition, with higher HGF and TGFβ3 levels  in primiparous mothers. Similar 
patterns have been found in a few other studies (Walter et al., 2009, Amoudruz et al., 
2009, Groer and Shelton, 2009). If parity is associated with differences in human milk 
composition it may be an additional mechanism to explain decreased allergy risk with 
an increase of birth order, but more work on a larger sample size is needed. 
An additional approach to assessing the impact of human milk constituents on 
outcomes is to consider the composition as a soup or “lacto-type” and apply Principle 
Component Analysis (PCA) to analyse the data, in order to identify any existing 
patterns. There are clusters of immune active molecules in some colostrum samples 
which differ from the general population. These lactotypes, are grouped into two 
clusters A and B, depending on their coordinates in the PCA plot and each cluster has 2 
groups within them. The final "lactotype" groups are: A1 (IL5 and IL10), A2 (IL12 and 
IL13), B1 (IL2 and IL4), B2 (TGFβ1,2,3 and HGF). Samples from London belong to 
cluster B "lactotypes" significantly more often.  These results suggest that this approach 
applied on a larger sample size will generate hypotheses around the impact on health 
outcomes of different lactotypes. Mixed models analysis suggests that increased TGFβ2 
levels in breast milk leads to a higher incidence of maternal reported recurrent 
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eczematous rash the age of 12 months. The PCA analysis identifies that lactotype B2, 
is associated with more adverse immunological outcomes in general and eczematous 
rash and cough/wheeze reported at 12 months of age. My results support the concept 
that IL13 may have some protective effects on both, eczematous rash development and 
food allergy/sensitivity/intollerance reported events and TGFβ2 may act as a risk factor, 
assessing health outcomes at one year of age. This could be a possible explanation for 
the diversity of results from epidemiological studies on the health promoting effects of 
breastfeeding.   
Overall, the data, provides intriguing insight on colostrum and mature milk immunology, 
highlighting significant differences and rapid changes during the very first days of life. 
Differences between the countries, although not fully explainable at this point, show that 
women living in different geographical locations may have distinct breast milk 
immunological profile. In some respects, results add to the confusing picture of the 
impact of breast milk immune constituents in relation to maternal and environmental 
influence and immunological outcomes in the infants. In view of the large number of 
potentially immune-active constituents in breast milk, investigation of only a limited 
range of constituents may well produce conflicting results. Future studies comparing 
breast milk composition between populations should consider strict harmonisation of 
sampling, storage and analysis protocols especially time of sampling, between sites, as 
this thesis has shown time of sampling to be a strong influence on breast milk immune 
composition. It would also be helpful to evaluate breast milk immune composition within 
a group of lactating women studied at multiple time points prospectively - such studies 
would reduce variations caused by differences between populations and between 
sampling methods, although variation in storage time of milk samples could not be 
controlled in this way. My research highlights the importance of time of colostrum 
collection and underlines the need to define colostrum based on its time of collection, 
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and its difference from transitional and/or mature milk. Data on health outcomes, 
combined with PCA results show the potential importance of breast milk composition in 
the first year of life and points to its potential to influence short term health outcomes. 
Future research needs to account for differences environmental exposures (Holmlund et 
al., 2010, Peroni et al., 2010, Tomicic et al., 2010) and  use modern systematic 
methodologies to characterize variations in breast milk composition in relation to well-
defined clinical and immune outcomes during childhood (Hunt et al., 2011). Statistical 
approaches using cluster analysis should be implemented, in order to define  patterns of 
immune active molecules, PUFA's, microbiome composition (Lacto-types). 
Understanding the relationship between breast milk composition and development of 
non communicable diseases, and particularly allergy, may allow us to establish a new 
paradigm in allergy prevention research – namely modulation of breast milk composition 
via maternal dietary and other interventions, in order to promote healthy infant immune 
development.
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8 Appendices 
8.1 Appendix A 
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8.4 Appendix D 
8.4.1 Covariates – Crosstable and groups definitions 
 Age (years):                                     
Min. 1st Qu. Median Mean 3rd Qu. Max.      
19.00    28.00 31.00 31.98 36.00 50.00 
 
Colostrum collection time (hours): 
Min. 1st Qu. Median Mean 3rd Qu. Max.      
2.0 39.0       51.0 54.2       68.0       144.0      
        
Country of collection:  
UK Russia Italy 
101 (25.4%) 221 (55.5%) 76 (19.1%) 
 
Maternal Atopy:   
No Atopy Atopic 
224 (77.8%) 64 (22.2%) 
 
Previous Deliveries: 
Primiparous Multiparous 
175 (45%) 214 (55%) 
 
Labour Type: Vaginal delivery vs. Caesarean section: 
 Vaginal C/Section 
319 (80.8%) 76 (19.2%) 
 
Antenatal Infections: 
 No Yes 
282 (72.9%) 105 (27.1%) 
 
Exposed to tobacco smoke: 
No Yes 
204 (51.9%) 189 (48.1%) 
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Pets at home or having regular contact:  
 No Yes 
218 (54.8%) 180 (45.2%)  
 
Mould/Mildew at home:  
No  Yes 
301 (77.4%) 88 (22.6%) 
 
Probiotics Prebiotics consumption during pregnancy:  
<Once a week ≥Once a week 
259 (66.8%) 129 (33.2%) 
 
Fish consumption during pregnancy two categories: 
<Once a week ≥Once a week 
170 (43.3%) 223 (56.7%) 
 
Fruits consumption during pregnancy: 
<Daily Daily 
97 (24.7%) 296 (75.3%) 
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8.4.2 Data on maternal and environmental exposures influencing Growth factors level in colostrum and breast milk                        
(Final Mixed models) 
HGF concentration 
  Value Std.Error p-value 
(Intercept) 8.81 0.20 <0.001 
Breast Milk vs. Colostrum  -1.35 0.28 <0.001 
Country of collection Russia -0.05 0.14 0.70 
Country of collection Italy -0.63 0.15 <0.001 
Multiparous vs. Primiparous -0.17 0.09 0.06 
Later colostrum collection time -0.01 0.00 <0.001 
C/Section vs. Vaginal  0.04 0.13 0.73 
Smoking vs. No smoking 0.12 0.10 0.20 
Fruits daily consumption vs. less than daily -0.22 0.13 0.10 
Probiotics/Prebiotics Once a week or more 0.14 0.10 0.16 
For BM - fruits daily consumption vs. less than daily 0.14 0.20 0.48 
For BM - Country of collection Russia -0.07 0.24 0.76 
For BM - Country of collection Italy 0.93 0.28 0.001 
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Country Time mean SE LCL UCL  Country Time difference SE *p.value 
UK Colostrum 7.978 0.108 7.766 8.189  UK - Russia Colostrum -0.010 0.132 0.997 
Russia Colostrum 7.988 0.095 7.801 8.175  UK - Italy Colostrum 0.599 0.152 <0.001 
Italy Colostrum 7.379 0.119 7.146 7.611  Russia - Italy Colostrum 0.609 0.141 <0.001 
UK BM 6.767 0.194 6.387 7.146  UK - Russia BM 0.112 0.211 0.856 
Russia BM 6.655 0.109 6.442 6.868  UK - Italy BM -0.311 0.251 0.428 
Italy BM 7.078 0.175 6.736 7.420  Russia - Italy BM -0.423 0.194 0.074 
 
Deliveries Time mean SE LCL UCL  Deliveries Time difference SE *p.value 
Primiparous Colostrum 7.869 0.083 7.706 8.031  Primiparous - Multiparous Colostrum 0.174 0.090 0.050 
Multiparous Colostrum 7.694 0.083 7.532 7.856  Primiparous - Multiparous BM 0.174 0.090 0.050 
Primiparous BM 6.920 0.112 6.701 7.140       
Multiparous BM 6.746 0.112 6.527 6.965       
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TGF-β1 concentration 
  Estimate Std.Error p-value 
(Intercept) 6.71 0.21 <0.001 
Breast Milk vs. Colostrum -0.93 0.14 <0.001 
Age influence 0.01 0.01 0.10 
Country of collection Russia -0.20 0.09 0.02 
Country of collection Italy -0.28 0.09 0.003 
Later colostrum collection time 0.00 0.00 0.01 
Fish ≥ Once a week vs. < Once a week -0.15 0.07 0.04 
C/Section vs. Vaginal -0.05 0.08 0.57 
Probiotics/Prebiotics ≥ Once a week vs. < Once a week 0.09 0.06 0.15 
For BM : Fish ≥ Once a week vs. < Once a week 0.18 0.13 0.17 
For BM : Country of collection Russia 0.59 0.15 <0.001 
For BM : Country of collection Italy 0.18 0.17 0.30 
 
Country Time mean SE LCL UCL  Country Time difference SE *p.value 
UK Colostrum 6.801 0.066 6.672 6.931  UK - Russia Colostrum 0.197 0.086 0.059 
Russia Colostrum 6.605 0.069 6.470 6.740  UK -  
Italy 
Colostrum 0.276 0.094 0.010 
Italy Colostrum 6.526 0.075 6.379 6.673  Russia - Italy Colostrum 0.079 0.098 0.701 
UK BM 5.962 0.112 5.743 6.181  UK - Russia BM -0.396 0.126 0.005 
Russia BM 6.357 0.077 6.207 6.508  UK -  
Italy 
BM 0.099 0.151 0.790 
Italy BM 5.863 0.113 5.642 6.084  Russia - Italy BM 0.495 0.128 <0.001 
Fish Time mean SE LCL UCL  Fish Time difference SE *p.value 
< Once a week Colostrum 6.720 0.062 6.598 6.842  < Once a week -  
≥ Once a week 
Colostrum 0.152 0.072 0.034 
≥ Once a week Colostrum 6.568 0.053 6.465 6.671  < Once a week -  
≥ Once a week 
BM -0.024 0.106 0.824 
< Once a week BM 6.049 0.094 5.864 6.234       
≥ Once a week BM 6.072 0.072 5.932 6.213       
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TGF-β2 concentration 
  Estimate Std.Error p-value 
(Intercept) 11.30 0.17 <0.001 
Breast Milk vs. Colostrum -1.12 0.16 <0.001 
Country of collection Russia -0.33 0.12 0.01 
Country of collection Italy -0.39 0.13 0.002 
Later colostrum collection time 0.00 0.00 0.12 
C/Section vs. Vaginal 0.02 0.14 0.86 
Fish ≥ Once a week vs. <Once a week -0.17 0.12 0.14 
Multiparous vs. Primiparous -0.10 0.10 0.31 
For BM : Fish ≥ Once a week vs. <Once a week 0.26 0.20 0.19 
    
 
Country Time mean SE LCL UCL  Country Time difference SE *p.value 
UK Colostrum 11.002 0.100 10.806 11.199  UK - Russia Colostrum 0.328 0.119 0.016 
Russia Colostrum 10.675 0.100 10.480 10.870  UK - Italy Colostrum 0.393 0.128 0.006 
Italy Colostrum 10.610 0.107 10.400 10.819  Russia - Italy Colostrum 0.065 0.118 0.845 
UK BM 10.013 0.126 9.766 10.260  UK - Russia BM 0.328 0.119 0.016 
Russia BM 9.686 0.114 9.462 9.909  UK - Italy BM 0.393 0.128 0.006 
Italy BM 9.621 0.130 9.365 9.876  Russia - Italy BM 0.065 0.118 0.845 
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TGF-β3 concentration 
  Estimate   Std.Error *p.value 
(Intercept) 8.10 0.34 <0.001 
Breast Milk vs. Colostrum -2.03 0.13 <0.001 
Age 0.01 0.01 0.18 
Country of collection Russia -0.34 0.12 0.004 
Country.of.collection Italy -0.74 0.13 <0.001 
Multiparous vs. Primiparous -0.20 0.11 0.07 
C/Section vs. Vaginal -0.12 0.13 0.39 
Later colostrum collection time -0.01 0.00 <0.001 
For BM : Multiparous vs. Primiparous 0.29 0.17 0.09 
 
Country Time mean SE LCL UCL  Country Time difference SE *p.value 
UK Colostrum 7.760 0.093 7.577 7.942  UK - Russia Colostrum 0.342 0.118 0.010 
Russia Colostrum 7.418 0.098 7.226 7.609  UK -  
Italy 
Colostrum 0.741 0.130 <0.001 
Italy Colostrum 7.019 0.111 6.802 7.237  Russia - Italy Colostrum 0.398 0.134 0.008 
UK BM 5.877 0.115 5.652 6.102  UK - Russia BM 0.342 0.118 0.010 
Russia BM 5.535 0.108 5.323 5.746  UK -  
Italy 
BM 0.741 0.130 <0.001 
Italy BM 5.136 0.128 4.885 5.387  Russia - Italy BM 0.398 0.134 0.008 
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8.4.3 Data on maternal and environmental exposures influencing Th1/Th2 cytokines detectability in colostrum and breast milk     
(Final Mixed models)  
IL2 detectability 
  Estimate SE OR 2,50% 97,50% P.value AIC BIC 
(Intercept) -0,68 0,43    0,11 298,99 321,69 
Breast Milk vs. Colostrum 0,32 0,30 1,37 0,76 2,49 0,30   
Atopic mothers vs. Non atopic -0,39 0,40 0,67 0,31 1,48 0,33   
Infections during pregnancy vs. No infections -0,46 0,35 0,63 0,32 1,25 0,19   
Later Colostrum collection time -0,02 0,01 0,98 0,97 1,00 0,02   
IL4 detectability 
  Estimate SE OR 2,50% 97,50% P.value AIC BIC 
(Intercept) -1,83 0,52 0,16 0,06 0,44 <0,001 378,81 401,587 
Breast Milk vs. Colostrum 0,72 0,34 2,05 1,05 4,00 0,04   
Atopic mothers vs. Non atopic -0,20 0,45 0,82 0,34 1,98 0,66   
Infections during pregnancy vs. No infections 0,36 0,36 1,43 0,71 2,88 0,32   
Later Colostrum collection time -0,01 0,01 0,99 0,97 1,01 0,22   
IL5 detectability 
  Estimate SE OR 2,50% 97,50% P.value AIC BIC 
(Intercept) 0,51 0,43    0,23 315,97 338,68 
Breast Milk vs. Colostrum -0,54 0,32 0,58 0,31 1,09 0,09   
Atopic mothers vs. Non atopic -0,36 0,38 0,70 0,33 1,48 0,35   
Infections during pregnancy vs. No infections -0,71 0,35 0,49 0,25 0,98 0,04   
Later Colostrum collection time -0,03 0,01 0,97 0,96 0,99 <0,001   
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IL10 detectability 
  Estimate SE OR 2,50% 97,50% P.value AIC BIC 
(Intercept) 2,08 0,44    <0,001 416,7 435,8 
Breast Milk vs. Colostrum -1,66 0,32 0,19 0,10 0,36 <0,001   
Atopic mothers vs. Non atopic -0,39 0,31 0,67 0,37 1,24 0,21   
Later Colostrum collection time -0,02 0,01 0,98 0,97 0,99 0,001   
 
IL12 detectability 
  Estimate SE OR 2,50% 97,50% P.value AIC BIC 
(Intercept) -0,90 0,50    0,07 314,90 337,61 
Breast Milk vs. Colostrum -0,11 0,32 0,89 0,47 1,69 0,73   
Atopic mothers vs. Non atopic -0,36 0,44 0,70 0,30 1,65 0,42   
Infections during pregnancy vs. No infections -0,34 0,38 0,71 0,34 1,51 0,38   
Later Colostrum collection time -0,01 0,01 0,99 0,97 1,00 0,12   
 
IL13 detectability 
  Estimate SE OR 2,50% 97,50% P.value AIC BIC 
(Intercept) -0,35 0,37    0,34 390,63 413,33 
Breast Milk vs. Colostrum 0,09 0,26 1,10 0,66 1,82 0,72   
Atopic mothers vs. Non atopic -0,46 0,33 0,63 0,33 1,22 0,17   
Infections during pregnancy vs. No infections -0,12 0,28 0,89 0,52 1,53 0,67   
Later Colostrum collection time -0,01 0,01 0,99 0,98 1,00 0,09   
 
 
APPENDIX D 
284 
 
IFNγ detectability 
  Estimate SE OR 2,50% 97,50% P.value AIC BIC 
(Intercept) -0,83 0,39    0,04 378,811 401,59 
Breast Milk vs. Colostrum 1,20 0,26 3,32 2,01 5,48 <0,001   
Atopic mothers vs. Non atopic 0,30 0,30 1,35 0,75 2,44 0,32   
Multiparous vs. Primiparous 0,01 0,26 1,01 0,61 1,66 0,98   
Later Colostrum collection time -0,01 0,01 0,99 0,98 1,00 0,04   
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8.5 Appendix E (Sheth, 2014) 
The following table is showing the dilutions necessary (in normal saline solution) to 
obtain detectable protein values in our pilot study, using the Abbott Aeroset Analyser 
Dilution  Dilution  Dilution 
1:10  1:20  1:40 
Protein g/L  Protein g/L  Protein g/L 
8.36     
9.07     
10.61     
12.87     
12.98     
15.74     
15.86     
16.53     
16.63     
18.72     
18.85     
>20.00  14.10   
>20.00  14.50   
>20.00  15.40   
>20.00  18.60   
>20.00  19.50   
>20.00  23.60   
>20.00  26.70   
>20.00  29.60   
>20.00  >39.20  37.60 
>20.00  >39.20  39.12 
>20.00  >39.20  42.96 
>20.00  >39.20  65.44 
>20.00  >39.20  >39.2 
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8.6 Appendix F (Sheth, 2014) 
 
This table shows the results of serial dilutions on two samples, enabling us to establish 
a suitable dilution factor for an appropriate protein detection range. 
 Dilution factor No 
Dilution 
1:2 1:4 1:8 1:16 1:32 
 Protein detection 
range, g\L 
0.1-2 0.2-4 0.4-8 0.8-16 1.6-32 3.2-64 
         
 Protein level g/L  5.2 2.44 1.74 0.7 0.34 
Sample 1 Concentration g/L 
(Protein x Dilution 
factor) 
12.98 10.4 9.76 13.92 11.2 10.88 
        
 Protein level g/L  >10 6.56 2.87 1.83 0.76 
Sample 2 Concentration g/L 
(Protein x Dilution 
factor) 
26.7 >20 26.24 22.96 29.28 24.32 
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8.7 Appendix G 
  
 
 
 
Corrected HGF for Na+/time of collection
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Corrected TGF2 for Na+/time of collection
Time of collection (hours)
T
G
F

2
/N
a
+
 r
a
ti
o
0 50 100 150 200
0
5000
10000
15000
20000
25000
r = 0.16
p = 0.01
Corrected TGF3 for Na+/time of collection
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